<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="review-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Vaccines (Basel)</journal-id><journal-id journal-id-type="iso-abbrev">Vaccines (Basel)</journal-id><journal-id journal-id-type="publisher-id">vaccines</journal-id><journal-title-group><journal-title>Vaccines</journal-title></journal-title-group><issn pub-type="epub">2076-393X</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC11680399</article-id><article-id pub-id-type="doi">10.3390/vaccines12121319</article-id><article-id pub-id-type="publisher-id">vaccines-12-01319</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Recombinant Live-Attenuated <italic toggle="yes">Salmonella</italic> Vaccine for Veterinary Use</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Chagas</surname><given-names>Domitila Brzoskowski</given-names></name><xref rid="af1-vaccines-12-01319" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Santos</surname><given-names>Francisco Denis Souza</given-names></name><xref rid="af1-vaccines-12-01319" ref-type="aff">1</xref><xref rid="af2-vaccines-12-01319" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>de Oliveira</surname><given-names>Natasha Rodrigues</given-names></name><xref rid="af1-vaccines-12-01319" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Bohn</surname><given-names>Tha&#x000ed;s Larr&#x000e9; Oliveira</given-names></name><xref rid="af1-vaccines-12-01319" ref-type="aff">1</xref><xref rid="fn1-vaccines-12-01319" ref-type="author-notes">&#x02020;</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-2803-4088</contrib-id><name><surname>Dellagostin</surname><given-names>Odir Ant&#x000f4;nio</given-names></name><xref rid="af1-vaccines-12-01319" ref-type="aff">1</xref><xref rid="c1-vaccines-12-01319" ref-type="corresp">*</xref><xref rid="fn1-vaccines-12-01319" ref-type="author-notes">&#x02020;</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Patil</surname><given-names>Veerupaxagouda</given-names></name><role>Academic Editor</role></contrib><contrib contrib-type="editor"><name><surname>Desai</surname><given-names>Dhruv</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-vaccines-12-01319"><label>1</label>N&#x000fa;cleo de Biotecnologia, Centro de Desenvolvimento Tecnol&#x000f3;gico, Universidade Federal de Pelotas, Pelotas 96010-610, Rio Grande do Sul, Brazil<email>thais.larre@ufpel.edu.br</email> (T.L.O.B.)</aff><aff id="af2-vaccines-12-01319"><label>2</label>Faculdade de Medicina, Universidade Federal do Rio Grande, Rio Grande 96200-400, Rio Grande do Sul, Brazil</aff><author-notes><corresp id="c1-vaccines-12-01319"><label>*</label>Correspondence: <email>odir@ufpel.edu.br</email></corresp><fn id="fn1-vaccines-12-01319"><label>&#x02020;</label><p>These authors contributed equally to this work.</p></fn></author-notes><pub-date pub-type="epub"><day>26</day><month>11</month><year>2024</year></pub-date><pub-date pub-type="collection"><month>12</month><year>2024</year></pub-date><volume>12</volume><issue>12</issue><elocation-id>1319</elocation-id><history><date date-type="received"><day>16</day><month>10</month><year>2024</year></date><date date-type="rev-recd"><day>14</day><month>11</month><year>2024</year></date><date date-type="accepted"><day>19</day><month>11</month><year>2024</year></date></history><permissions><copyright-statement>&#x000a9; 2024 by the authors.</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>Vaccination is essential for maintaining animal health, with priority placed on safety and cost effectiveness in veterinary use. The development of recombinant live-attenuated <italic toggle="yes">Salmonella</italic> vaccines (RASVs) has enabled the construction of balanced lethal systems, ensuring the stability of plasmid vectors encoding protective antigens post-immunization. These vaccines are particularly suitable for production animals, providing long-term immunity against a range of bacterial, viral, and parasitic pathogens. This review summarizes the progress made in this field, with a focus on clinical trials demonstrating the efficacy and commercial potential of RASVs in veterinary medicine.</p></abstract><kwd-group><kwd>vaccine development</kwd><kwd><italic toggle="yes">Salmonella</italic></kwd><kwd>attenuation</kwd><kwd>RASV</kwd><kwd>animal</kwd></kwd-group><funding-group><award-group><funding-source>Conselho Nacional de Desenvolvimento Cient&#x000ed;fico e Tecnol&#x000f3;gico (CNPq), Coordena&#x000e7;&#x000e3;o de Aperfei&#x000e7;oamento de Pessoal de N&#x000ed;vel Superior&#x02014;Brasil (CAPES)</funding-source><award-id>Finance Code 001</award-id></award-group><funding-statement>This research received no external funding. Scholarships were funded by Conselho Nacional de Desenvolvimento Cient&#x000ed;fico e Tecnol&#x000f3;gico (CNPq), Coordena&#x000e7;&#x000e3;o de Aperfei&#x000e7;oamento de Pessoal de N&#x000ed;vel Superior&#x02014;Brasil (CAPES) (Finance Code 001).</funding-statement></funding-group></article-meta></front><body><sec sec-type="intro" id="sec1-vaccines-12-01319"><title>1. Introduction</title><p>The growing human population has led to an increase in the demand for foods of animal origin, resulting in consequent changes in agricultural production [<xref rid="B1-vaccines-12-01319" ref-type="bibr">1</xref>]. Animals are often produced in confinement, which makes them vulnerable to the spread of various diseases [<xref rid="B2-vaccines-12-01319" ref-type="bibr">2</xref>]. Many infectious microorganisms can be zoonotic and are transmitted from animals&#x02014;whether they are food animals, companion animals, or wildlife&#x02014;to humans [<xref rid="B3-vaccines-12-01319" ref-type="bibr">3</xref>,<xref rid="B4-vaccines-12-01319" ref-type="bibr">4</xref>]. Furthermore, these diseases affect the well-being and productivity of animals, causing economic losses and impacting the food supply [<xref rid="B5-vaccines-12-01319" ref-type="bibr">5</xref>].</p><p>There are solutions that can help control diseases in production animal farms, including effective sanitation in facilities; the quarantine or slaughter of contaminated animals; the administration of treatment with antibiotics, antivirals, and antiparasitics; and vaccination [<xref rid="B2-vaccines-12-01319" ref-type="bibr">2</xref>]. However, there are growing concerns related to antibiotic resistance associated with their extensive use [<xref rid="B6-vaccines-12-01319" ref-type="bibr">6</xref>,<xref rid="B7-vaccines-12-01319" ref-type="bibr">7</xref>]. This is coupled with the high cost of developing new, effective, non-toxic drugs to treat bacterial, viral, and parasitic infections [<xref rid="B8-vaccines-12-01319" ref-type="bibr">8</xref>]. These challenges have become significant obstacles for the treating of infectious diseases.</p><p>Therefore, vaccination has emerged as an alternative that can reduce the reliance on antibiotics for treating infections [<xref rid="B1-vaccines-12-01319" ref-type="bibr">1</xref>]. While much of the current research has focused on recombinant subunit vaccines, the cost of veterinary vaccines is primarily due to the purification process required for these proteins, which makes them more expensive compared to traditional vaccines [<xref rid="B9-vaccines-12-01319" ref-type="bibr">9</xref>]. Despite their lower production costs, bacterins have been associated with variable efficacy and potential side effects, as observed in leptospirosis [<xref rid="B10-vaccines-12-01319" ref-type="bibr">10</xref>]. While each vaccination strategy has its own set of advantages and disadvantages, veterinary vaccines must prioritize safety, cost effectiveness, and the ability to provide long-lasting protective immunity against pathogenic microorganisms [<xref rid="B8-vaccines-12-01319" ref-type="bibr">8</xref>].</p><p>Among the various vaccine formulations using infectious bacterial agents as carriers of immunoprotective antigens, <italic toggle="yes">Salmonella</italic> stands out. This enteropathogenic bacterium infects both humans and animals, causing a variety of illnesses from gastroenteritis to systemic typhoid fever [<xref rid="B11-vaccines-12-01319" ref-type="bibr">11</xref>,<xref rid="B12-vaccines-12-01319" ref-type="bibr">12</xref>]. The prevalence of <italic toggle="yes">Salmonella</italic> varies geographically, with <italic toggle="yes">Salmonella enterica</italic> serovar Typhimurium (<italic toggle="yes">S.</italic> Typhimurium) being one of the most commonly isolated serovars from animals and humans worldwide. Some serovars exhibit host specificity, such as <italic toggle="yes">Salmonella enterica</italic> serovar Choleraesuis (<italic toggle="yes">S.</italic> Cholerasuis) in pigs, <italic toggle="yes">Salmonella enterica</italic> serovar Abortusovis (<italic toggle="yes">S.</italic> Abortusovis) in sheep, and <italic toggle="yes">Salmonella enterica</italic> serovar Dublin (<italic toggle="yes">S.</italic> Dublin) in cattle [<xref rid="B13-vaccines-12-01319" ref-type="bibr">13</xref>,<xref rid="B14-vaccines-12-01319" ref-type="bibr">14</xref>,<xref rid="B15-vaccines-12-01319" ref-type="bibr">15</xref>].</p><p>Despite its potential pathogenicity, <italic toggle="yes">Salmonella</italic> is easily managed and genetically manipulated, making it an ideal candidate for antigen delivery systems for several reasons [<xref rid="B16-vaccines-12-01319" ref-type="bibr">16</xref>]. The inactivation of metabolic genes in live vaccines enables the expression of essential antigens and virulence factors while constraining their ability to proliferate. Consequently, vaccine strains engineered and deleted via techniques such as site-directed mutagenesis demonstrate complete biological containment [<xref rid="B17-vaccines-12-01319" ref-type="bibr">17</xref>,<xref rid="B18-vaccines-12-01319" ref-type="bibr">18</xref>].</p><p>These attenuated strains replicate the natural infection process, possessing the ability to invade and replicate within mucosa-associated lymphatic tissues (MALT) and gut-associated lymphatic tissues (GALT), such as Peyer&#x02019;s patches, before spreading systemically via mesenteric lymph nodes [<xref rid="B18-vaccines-12-01319" ref-type="bibr">18</xref>,<xref rid="B19-vaccines-12-01319" ref-type="bibr">19</xref>]. This characteristic dissemination pattern enables <italic toggle="yes">Salmonella</italic> to evoke robust protective immunity, particularly when administered orally, which stimulates both mucosal and systemic immune responses [<xref rid="B20-vaccines-12-01319" ref-type="bibr">20</xref>,<xref rid="B21-vaccines-12-01319" ref-type="bibr">21</xref>]. Additionally, several studies have shown that administering live-attenuated <italic toggle="yes">Salmonella</italic> vaccines via intramuscular or subcutaneous routes in animals (such as mice, dogs, and goats) effectively stimulates an immune response [<xref rid="B22-vaccines-12-01319" ref-type="bibr">22</xref>,<xref rid="B23-vaccines-12-01319" ref-type="bibr">23</xref>,<xref rid="B24-vaccines-12-01319" ref-type="bibr">24</xref>].</p><p>The adoption of rationally live-attenuated <italic toggle="yes">Salmonella</italic> vaccines is already underway in farm animal vaccination programs, which aim to control infections and prevent disease spread [<xref rid="B25-vaccines-12-01319" ref-type="bibr">25</xref>,<xref rid="B26-vaccines-12-01319" ref-type="bibr">26</xref>]. Additionally, numerous studies have explored vaccine constructs based on live-attenuated <italic toggle="yes">Salmonella</italic>, primarily carrying antigens against a variety of other organisms, including bacteria, viruses, and parasites [<xref rid="B27-vaccines-12-01319" ref-type="bibr">27</xref>,<xref rid="B28-vaccines-12-01319" ref-type="bibr">28</xref>,<xref rid="B29-vaccines-12-01319" ref-type="bibr">29</xref>,<xref rid="B30-vaccines-12-01319" ref-type="bibr">30</xref>,<xref rid="B31-vaccines-12-01319" ref-type="bibr">31</xref>]. These vaccines are preferably administered orally and nasally because of their ease of delivery, allowing for needle-free administration in a straightforward and painless manner. They can be administered via spray or mixed into water, making them more suitable for widespread use in commercial animals such as poultry, swine, and fish [<xref rid="B31-vaccines-12-01319" ref-type="bibr">31</xref>,<xref rid="B32-vaccines-12-01319" ref-type="bibr">32</xref>]. However, oral administration in ruminants still poses challenges due to the process of rumination and regurgitation of food, necessitating techniques like microparticle encapsulation to enhance efficacy [<xref rid="B33-vaccines-12-01319" ref-type="bibr">33</xref>].</p><p>The significance of using live-attenuated <italic toggle="yes">Salmonella</italic> vaccines in veterinary practices is reinforced by their storage convenience [<xref rid="B16-vaccines-12-01319" ref-type="bibr">16</xref>]. They can be easily freeze-dried and maintained at room temperature, offering a notable advantage for their implementation in livestock, especially in regions lacking vaccine refrigeration facilities [<xref rid="B33-vaccines-12-01319" ref-type="bibr">33</xref>,<xref rid="B34-vaccines-12-01319" ref-type="bibr">34</xref>]. Emphasizing these diverse benefits, this review examines compelling findings from past and ongoing studies that explore the progress of recombinant live-attenuated <italic toggle="yes">Salmonella</italic> vaccines (RASVs) as a versatile delivery vector (<xref rid="vaccines-12-01319-f001" ref-type="fig">Figure 1</xref>) for the prevention of various infectious diseases.</p></sec><sec id="sec2-vaccines-12-01319"><title>2. Commercial Veterinary Vaccines Against <italic toggle="yes">Salmonella</italic> in Farm Animals</title><p>The use of vaccines to control infections caused by <italic toggle="yes">Salmonella</italic> spp. has been widely adopted in various countries [<xref rid="B35-vaccines-12-01319" ref-type="bibr">35</xref>]. However, the use of commercial bacterins poses a risk of heightened vaccine reactions at the injection site, typically following intramuscular administration, because of the presence of toxic components in bacterial cells, particularly lipopolysaccharides (LPS) and oil emulsion adjuvants [<xref rid="B36-vaccines-12-01319" ref-type="bibr">36</xref>]. Additionally, many killed whole-cell vaccines offer limited cross-protection against other antigenically related serotypes [<xref rid="B11-vaccines-12-01319" ref-type="bibr">11</xref>,<xref rid="B14-vaccines-12-01319" ref-type="bibr">14</xref>].</p><p>Live-attenuated <italic toggle="yes">Salmonella</italic> vaccines, which are designed to decrease disease prevalence and confer protection against various pathogen strains, are becoming increasingly commercially available [<xref rid="B37-vaccines-12-01319" ref-type="bibr">37</xref>,<xref rid="B38-vaccines-12-01319" ref-type="bibr">38</xref>]. These vaccines are being licensed for use in production animals across several countries [<xref rid="B39-vaccines-12-01319" ref-type="bibr">39</xref>]. Among the live-attenuated vaccines against <italic toggle="yes">Salmonella</italic> available in Europe and Australia for chicken producers are those targeting <italic toggle="yes">S</italic>. Typhimurium, <italic toggle="yes">S.</italic> Enteritidis, and <italic toggle="yes">S.</italic> Gallinarum. In a field study, Lyimu et al. [<xref rid="B25-vaccines-12-01319" ref-type="bibr">25</xref>] evaluated the effect of three commercial live-attenuated vaccine strains on cecal immune genes and compared with cytokine expression. The vaccine induced more anti-inflammatory cecal environment and Th1 responses, crucial to limiting <italic toggle="yes">Salmonella</italic> contamination in chickens. Furthermore, they reported an increase in serum IgG in the vaccine group that received the commercial vaccine against <italic toggle="yes">S.</italic> Typhimurium when compared to the control. However, they also reported that the live vaccine can modify the shape of different microbiota profiles.</p><p>Another example of commercially available vaccines for veterinary use is the live-attenuated vaccine against <italic toggle="yes">S.</italic> Typhimurium in pigs [<xref rid="B26-vaccines-12-01319" ref-type="bibr">26</xref>]. The <italic toggle="yes">Salmonella</italic> vaccine has already been evaluated in sows and piglets weaned from four, three, or twenty-four days to six or seven weeks of age [<xref rid="B40-vaccines-12-01319" ref-type="bibr">40</xref>,<xref rid="B41-vaccines-12-01319" ref-type="bibr">41</xref>] and in sows and gilts [<xref rid="B42-vaccines-12-01319" ref-type="bibr">42</xref>]. Recently, in a study using different swine production cycles, the use of the vaccine in sows, piglets, and fattening pigs resulted in control over <italic toggle="yes">S.</italic> Typhimurium infections and decreased prevalence of positive lymph nodes at slaughter [<xref rid="B26-vaccines-12-01319" ref-type="bibr">26</xref>].</p></sec><sec id="sec3-vaccines-12-01319"><title>3. Role of Attenuation in the Recombinant <italic toggle="yes">Salmonella</italic> Vaccine</title><p><italic toggle="yes">Salmonella</italic> has been used as a vector for heterologous antigens, mainly because of its ability to elicit long-lasting mucosal, systemic, and cellular immune responses [<xref rid="B17-vaccines-12-01319" ref-type="bibr">17</xref>]. It can be administered via various routes, including oral, nasal, subcutaneous, and intramuscular administration [<xref rid="B20-vaccines-12-01319" ref-type="bibr">20</xref>]. However, for the use of live recombinant <italic toggle="yes">Salmonella</italic>, the attenuation of virulence factors is mandatory in order to prevent unwanted side effects such as fever and diarrhea [<xref rid="B43-vaccines-12-01319" ref-type="bibr">43</xref>].</p><p>Several approaches have been studied for the development of live-attenuated recombinant <italic toggle="yes">Salmonella</italic> vaccines, including different mutations that guarantee the attenuation of these strains through regulated delayed attenuation, delayed antigen synthesis, and/or delayed lysis [<xref rid="B8-vaccines-12-01319" ref-type="bibr">8</xref>,<xref rid="B17-vaccines-12-01319" ref-type="bibr">17</xref>]. These strategies have enabled the construction of a balanced lethal system and the stability of plasmid vectors encoding protective antigens in vivo after immunization [<xref rid="B17-vaccines-12-01319" ref-type="bibr">17</xref>,<xref rid="B44-vaccines-12-01319" ref-type="bibr">44</xref>].</p><p>Regulation allows these vectors to present characteristics similar to those of the wild type, enabling their survival and transit through the gastrointestinal tract and the execution of the initial stages of infection before exhibiting attenuation [<xref rid="B45-vaccines-12-01319" ref-type="bibr">45</xref>]. These studies have led to advances and discoveries in biological containment and antigen delivery systems using <italic toggle="yes">Salmonella</italic> [<xref rid="B20-vaccines-12-01319" ref-type="bibr">20</xref>]. The deletion of &#x00394;pmi or &#x00394;galE genes makes the strains dependent on exogenous mannose and galactose, respectively [<xref rid="B46-vaccines-12-01319" ref-type="bibr">46</xref>]. These genes encode surface antigens, such as O antigen side chains, and cause phenotypic changes in lipopolysaccharides, which are crucial factors for host colonization [<xref rid="B18-vaccines-12-01319" ref-type="bibr">18</xref>]. Furthermore, it is possible to utilize the deletion or mutation of genes necessary for the biosynthesis of metabolically essential elements, such as aromatic amino acids and vitamins, including &#x00394;aroA, &#x00394;aroC, and &#x00394;aroD deletions [<xref rid="B47-vaccines-12-01319" ref-type="bibr">47</xref>]. An example of this type of attenuation that has been used in a study is the <italic toggle="yes">S.</italic> Typhimurium LVR01 strain, which was constructed by introducing a null deletion in the &#x00394;aroC gene of the canine parental isolate of <italic toggle="yes">S.</italic> Typhimurium, P228067 [<xref rid="B48-vaccines-12-01319" ref-type="bibr">48</xref>].</p><p>Likewise, it is possible to regulate expression at or through the promoters of the chromosomal repressor gene <italic toggle="yes">lacI</italic> in regulatory pathways with pleiotropic effects (<italic toggle="yes">cya</italic>, <italic toggle="yes">crp</italic>, <italic toggle="yes">phoP</italic>). This can include using activating or repressor protein binding sequences for genes of iron acquisition (&#x00394;<italic toggle="yes">fur</italic>), encoding the regulatory system of virulence components (&#x00394;<italic toggle="yes">phoP</italic> and &#x00394;<italic toggle="yes">phoQ</italic>), or including mutations in DNA recombination and repair genes (&#x00394;<italic toggle="yes">cya</italic>/<italic toggle="yes">crpF</italic>) or in the <italic toggle="yes">cAMP</italic> receptor protein (&#x00394;<italic toggle="yes">crp</italic>), which is regulated via an <italic toggle="yes">araC</italic> P BAD cassette [<xref rid="B47-vaccines-12-01319" ref-type="bibr">47</xref>]. Thus, the expression of these genes is regulated by arabinose or mannose supplementation, occurring only during in vitro growth [<xref rid="B17-vaccines-12-01319" ref-type="bibr">17</xref>]. Following the colonization of lymphoid tissues, synthesis of the associated proteins ceases due to the absence of mannose or arabinose in vivo [<xref rid="B28-vaccines-12-01319" ref-type="bibr">28</xref>]. Consequently, attenuation develops progressively in vivo, inhibiting the onset of disease symptoms and inducing the desired antigen-specific immune response.</p><p>Moreover, regulated delayed lysis in vivo prevents RASV persistence, aiding biocontainment by ensuring the death of the bacteria following the colonization of immune tissues [<xref rid="B17-vaccines-12-01319" ref-type="bibr">17</xref>,<xref rid="B47-vaccines-12-01319" ref-type="bibr">47</xref>]. The system regulates the expression of enzymes required for synthesizing two key components of the cell wall&#x02019;s peptidoglycan layer: diaminopimelic acid (DAP) and muramic acid. DAP synthesis is controlled by aspartate semialdehyde dehydrogenase (encoded by <italic toggle="yes">asd</italic>), while UDP-N-acetylglucosamine enolpyruvyl transferase (encoded by <italic toggle="yes">murA</italic>) regulates muramic acid production [<xref rid="B44-vaccines-12-01319" ref-type="bibr">44</xref>]. The expression of these enzymes is engineered to be regulated by exogenous arabinose; in its absence, cell lysis occurs due to an inability to synthesize the cell wall [<xref rid="B49-vaccines-12-01319" ref-type="bibr">49</xref>].</p><p>Another crucial aspect of a vaccine vector containing heterologous antigens is the stability of the plasmid [<xref rid="B8-vaccines-12-01319" ref-type="bibr">8</xref>]. Regulation of the levels and location of expression of these antigens can have a significant impact on the immunogenicity of the vaccine, potentially reducing colonization capacity and, consequently, immunological efficacy [<xref rid="B18-vaccines-12-01319" ref-type="bibr">18</xref>]. To address the problem of instability in the chromosomal integration of foreign genes, systems have been developed that include the integration of the foreign gene into the bacterial chromosome, the optimization of heterologous antigen codons [<xref rid="B50-vaccines-12-01319" ref-type="bibr">50</xref>], the use of inducible promoters in vivo [<xref rid="B49-vaccines-12-01319" ref-type="bibr">49</xref>], and those by which DNA encodes the foreign gene in a suicide vector [<xref rid="B44-vaccines-12-01319" ref-type="bibr">44</xref>].</p><p>Thus, vaccine strains generally incorporate more than one mutation or deletion in genetic constructs, making it possible to eliminate essential genes involved in virulence regulatory systems [<xref rid="B45-vaccines-12-01319" ref-type="bibr">45</xref>]. This ensures attenuation, prevents virulence reversal, and eliminates potential side effects [<xref rid="B51-vaccines-12-01319" ref-type="bibr">51</xref>]. Furthermore, these deletions increase the colonization capacity, survival in the mucosal environment, and immunogenicity of RASV vaccine constructs [<xref rid="B20-vaccines-12-01319" ref-type="bibr">20</xref>,<xref rid="B47-vaccines-12-01319" ref-type="bibr">47</xref>].</p></sec><sec id="sec4-vaccines-12-01319"><title>4. Molecular Mechanisms of Immune Stimulation by Recombinant <italic toggle="yes">Salmonella</italic></title><p>Live-attenuated <italic toggle="yes">Salmonella</italic> strains used as vaccine delivery vehicles for heterologous antigens should effectively cross the epithelial barrier, reach the underlying antigen-presenting cells in the MALT, and trigger a strong immune response [<xref rid="B51-vaccines-12-01319" ref-type="bibr">51</xref>]. These mutants establish a limited infection in the host, and during this harmless infection, they deliver a variety of in vivo synthesized antigens directly to B and T lymphocytes in the GALT [<xref rid="B52-vaccines-12-01319" ref-type="bibr">52</xref>,<xref rid="B53-vaccines-12-01319" ref-type="bibr">53</xref>].</p><p>Typically, the antigens presented by RASV colonize internal effector lymphoid tissues without compromising protective functions or integrity. The interaction between <italic toggle="yes">Salmonella</italic> and its host is initiated by various virulence factors, including type III secretion systems associated with <italic toggle="yes">Salmonella</italic> pathogenicity islands 1 and 2 (SPI-1 and SPI-2) [<xref rid="B8-vaccines-12-01319" ref-type="bibr">8</xref>,<xref rid="B52-vaccines-12-01319" ref-type="bibr">52</xref>,<xref rid="B54-vaccines-12-01319" ref-type="bibr">54</xref>]. The SPI-1-encoded system enables <italic toggle="yes">Salmonella</italic> to invade various lymphoid tissues associated with the intestinal, nasopharyngeal, and bronchial mucosa. Bacterial internalization triggers alterations in host cell signaling pathways, impacting essential cellular processes such as membrane trafficking, cell division, antigen presentation, and cytokine production [<xref rid="B51-vaccines-12-01319" ref-type="bibr">51</xref>].</p><p><italic toggle="yes">Salmonella</italic>, having adapted to the mucosal surface environment, begins the infection process, remaining in membrane-bound vacuoles, and once it reaches the mesenteric lymph nodes in antigen-presenting cells, they produce recombinant proteins [<xref rid="B51-vaccines-12-01319" ref-type="bibr">51</xref>]. Antigen delivery results in a generalized immune response that targets intestinal sensory cells, known as Peyer&#x02019;s patch M cells [<xref rid="B44-vaccines-12-01319" ref-type="bibr">44</xref>]. These cells play a key role in stimulating mucosal immune responses [<xref rid="B55-vaccines-12-01319" ref-type="bibr">55</xref>]. Furthermore, <italic toggle="yes">Salmonella</italic> spp. can be taken up by phagocytic cells and cross the reticulo-endothelial system, thereby stimulating systemic immune responses [<xref rid="B56-vaccines-12-01319" ref-type="bibr">56</xref>]. <italic toggle="yes">Salmonella</italic> efficiently targets MALT and induces local and systemic immunity [<xref rid="B12-vaccines-12-01319" ref-type="bibr">12</xref>,<xref rid="B57-vaccines-12-01319" ref-type="bibr">57</xref>]. Dendritic cells, neutrophils, and macrophages are activated in response to antigens being present in the MALT, having recognized pathogen-associated molecular patterns (PAMPs) and endogenous danger-associated molecular patterns (DAMPs), such as T3SS-1, fimbriae, and other bacterial surface adhesins [<xref rid="B56-vaccines-12-01319" ref-type="bibr">56</xref>].</p><p>Protein antigens are processed and presented through the major histocompatibility complex (MHC), stimulating T cell responses [<xref rid="B55-vaccines-12-01319" ref-type="bibr">55</xref>]. The signaling and activation of phagocytic cells initiate a critical immune response that establishes links between the innate and adaptive immune systems [<xref rid="B58-vaccines-12-01319" ref-type="bibr">58</xref>]. <italic toggle="yes">Salmonella</italic> has a preference for residing within macrophages, where the activation of these cells by interferon gamma (IFN-&#x003b3;) produced by Th1 cells significantly contributes to bacterial elimination [<xref rid="B54-vaccines-12-01319" ref-type="bibr">54</xref>]. IFN-&#x003b3;, commonly referred to as macrophage activating factor (MAF), affects the duration of macrophage activation and is crucial during infection. The secretion of IFN-&#x003b3; is dependent on IL-18, also known as the IFN-&#x003b3;-inducing factor, and is vital for establishing early host resistance to <italic toggle="yes">Salmonella</italic> infection [<xref rid="B59-vaccines-12-01319" ref-type="bibr">59</xref>]. During primary and secondary infection, <italic toggle="yes">Salmonella</italic> is dependent on IL-12, IFN-&#x003b3;, and tumor necrosis factor &#x003b1; (TNF-&#x003b1;).</p><p>Classical activation by bacterial LPS or IFN-&#x003b3; modifies the cells&#x02019; secretory profile by promoting the production of organic nitrate compounds, including nitric oxide (NO) [<xref rid="B56-vaccines-12-01319" ref-type="bibr">56</xref>]. Mucosal DC responses to inflammatory stimuli may enhance their capacity to preselect antigens expressed by recombinant <italic toggle="yes">Salmonella</italic> for targeting specific T and B cells [<xref rid="B60-vaccines-12-01319" ref-type="bibr">60</xref>]. Alternative activation by IL-4, IL-10, or IL-13 promotes the production of polyamines and proline, stimulating cell proliferation. The presence of <italic toggle="yes">Salmonella</italic> in these cells triggers cytokine secretion, leading to an inflammatory response or programmed cell death via apoptosis [<xref rid="B56-vaccines-12-01319" ref-type="bibr">56</xref>].</p><p>The RASV consistently produces recombinant protein for an appropriate duration under SPI-2-regulated conditions, after which it is translocated into the cytosol via the SPI-2 T3SS [<xref rid="B61-vaccines-12-01319" ref-type="bibr">61</xref>]. Secreted peptides are processed and presented to major histocompatibility complex (MHC) class I and II molecules to stimulate T cell responses [<xref rid="B56-vaccines-12-01319" ref-type="bibr">56</xref>]. Immunization with attenuated vaccines is a safe and effective method to induce the production of both serum and mucosal antibodies against the <italic toggle="yes">Salmonella</italic> carrier, as well as foreign antigens [<xref rid="B12-vaccines-12-01319" ref-type="bibr">12</xref>,<xref rid="B62-vaccines-12-01319" ref-type="bibr">62</xref>].</p></sec><sec id="sec5-vaccines-12-01319"><title>5. <italic toggle="yes">Salmonella</italic> as a Vaccine Vector Against Different Pathogens</title><p>Attenuated vaccines are produced using live, whole bacterial cells or viral particles that have been subjected to in vitro passages, chemical treatments, or genetic manipulation to obtain strains lacking virulence in the host. Despite the loss of virulence, these attenuated strains retain their ability to provoke a strong immune response, closely mimicking natural infection [<xref rid="B63-vaccines-12-01319" ref-type="bibr">63</xref>]. Although several conventional attenuated vaccines are available for veterinary use, concerns about the risk of residual virulence, particularly in immunocompromised hosts, and higher sensitivity to cold chain disruptions have driven the search for safer options [<xref rid="B9-vaccines-12-01319" ref-type="bibr">9</xref>,<xref rid="B63-vaccines-12-01319" ref-type="bibr">63</xref>].</p><p>Studies in mice vaccinated with a live attenuated <italic toggle="yes">Salmonella</italic> delivering <italic toggle="yes">E. coli</italic> antigens [<xref rid="B64-vaccines-12-01319" ref-type="bibr">64</xref>,<xref rid="B65-vaccines-12-01319" ref-type="bibr">65</xref>] to control post-weaning diarrhea in swine indicated that vaccine constructs were not detected in the feces of immunized animals for up to three weeks post-oral inoculation, suggesting minimal or no environmental excretion. Another study using attenuated <italic toggle="yes">S. Typhimurium</italic> carrying a DNA vaccine against <italic toggle="yes">Streptococcus agalactiae</italic> in fish showed that the bacteria were eliminated from the tissues four weeks post-immunization [<xref rid="B32-vaccines-12-01319" ref-type="bibr">32</xref>]. Conversely, Jiang et al. [<xref rid="B66-vaccines-12-01319" ref-type="bibr">66</xref>] observed that oral vaccination with strains &#x003c7;9241-tHP and &#x003c7;9352-tHP resulted in high (10<sup>4</sup> to 10<sup>7</sup> CFU/g) and moderate (10<sup>2</sup> to 10<sup>4</sup> CFU/g) levels of recombinant <italic toggle="yes">Salmonella</italic> shedding in fecal samples from chickens at 14 and 11 days of age, respectively. Similarly, rectal swabs from pigs orally vaccinated with C500 variants of <italic toggle="yes">S. Choleraesuis</italic> showed variable levels of fecal shedding [<xref rid="B67-vaccines-12-01319" ref-type="bibr">67</xref>]. These results highlight the need to test different vectors to achieve an optimal balance among immunogenicity, stability, and biocontainment.</p><p>The effective immune response and protection induced by live-attenuated recombinant <italic toggle="yes">Salmonella</italic> has been described in several studies using parasitic, bacterial, and viral antigens. The reviewed articles are compiled and presented in a detailed list including the heterologous bacterial, parasitic and viral antigens, respectively expressed in different strains of <italic toggle="yes">Salmonella</italic>, as well as the model of attenuation used, route and dose administered, immune response induced, and animal model used. This is a summary of information published to date regarding the use of recombinant attenuated <italic toggle="yes">Salmonella</italic> vaccine (RASV) as a vaccine vector. The potential of RASV is evident, and it requires further exploration.</p><sec id="sec5dot1-vaccines-12-01319"><title>5.1. RASV Administration Routes</title><p>In our review, we found that mucosal administration&#x02014;primarily via the oral route&#x02014;is more frequently explored for RASV than parenteral routes, such as intramuscular, subcutaneous, or intraperitoneal injection. A limited number of studies have used intranasal [<xref rid="B31-vaccines-12-01319" ref-type="bibr">31</xref>,<xref rid="B68-vaccines-12-01319" ref-type="bibr">68</xref>,<xref rid="B69-vaccines-12-01319" ref-type="bibr">69</xref>,<xref rid="B70-vaccines-12-01319" ref-type="bibr">70</xref>,<xref rid="B71-vaccines-12-01319" ref-type="bibr">71</xref>] and intragastric routes [<xref rid="B32-vaccines-12-01319" ref-type="bibr">32</xref>,<xref rid="B72-vaccines-12-01319" ref-type="bibr">72</xref>,<xref rid="B73-vaccines-12-01319" ref-type="bibr">73</xref>,<xref rid="B74-vaccines-12-01319" ref-type="bibr">74</xref>]. The choice of administration route can impact antigen immunogenicity, influencing immune cell priming (especially antigen-presenting cells) and promoting both local and systemic immunity [<xref rid="B75-vaccines-12-01319" ref-type="bibr">75</xref>]. Mucosal routes may be more effective, as most infectious agents enter through mucosal surfaces. Vaccination through mucosal routes can stimulate protective responses at these surfaces and systemically [<xref rid="B76-vaccines-12-01319" ref-type="bibr">76</xref>]. Conversely, subcutaneous and intramuscular vaccines form antigen depots at the injection site, attracting APCs to migrate to nearby lymph nodes, where they activate the immune response [<xref rid="B76-vaccines-12-01319" ref-type="bibr">76</xref>].</p><p>Several studies have evaluated RASV administration routes in animal models. Lalsiamthara et al. [<xref rid="B77-vaccines-12-01319" ref-type="bibr">77</xref>] examined the efficacy of an RASV containing four <italic toggle="yes">Brucella</italic> antigens administered via parenteral routes (intraperitoneal, intramuscular, and subcutaneous) in mice. The parenteral administration showed higher protection rates against <italic toggle="yes">B. abortus</italic> compared to oral administration. Another study compared intraperitoneal and oral administration of an <italic toggle="yes">S.</italic> Typhimurium vaccine expressing <italic toggle="yes">B. abortus</italic> antigens in mice. The intraperitoneal route induced stronger humoral (IgG levels) and cellular (TNF-&#x003b1; and IFN-&#x003b3;) responses, with greater protection against <italic toggle="yes">B. abortus</italic> infection post-challenge [<xref rid="B29-vaccines-12-01319" ref-type="bibr">29</xref>].</p><p>In contrast, Cong et al. [<xref rid="B73-vaccines-12-01319" ref-type="bibr">73</xref>] demonstrated the potential of mucosal routes for an RASV expressing <italic toggle="yes">T. gondii</italic> antigens. The vaccine was administered to mice orally, nasally, or intramuscularly. Mice vaccinated via mucosal routes (oral and nasal) showed higher IgG and IgA levels than those vaccinated intramuscularly. Intranasal vaccination stimulated greater CD4<sup>+</sup> and CD8<sup>+</sup> T-cell activation, with cytokine levels (IFN-&#x003b3; and IL-2) also being higher in orally and nasally vaccinated mice. Survival rates post-challenge were 60% for oral, 40% for intranasal, and 20% for intramuscular routes.</p><p>Another study by Hyoung et al. [<xref rid="B70-vaccines-12-01319" ref-type="bibr">70</xref>] evaluated an attenuated <italic toggle="yes">S.</italic> Typhimurium mutant expressing hemagglutinin from avian influenza viruses (H7N3, H7N7, and H7N9) in chickens via intramuscular, nasal, or oral routes. The RASV induced strong humoral (neutralizing antibodies) and cellular (IFN-&#x003b3;, IL-17, and IL-10) responses across all routes, with immunization conferring significant protection against a subsequent challenge with the H7N1 virus. These findings suggest that RASVs can effectively elicit immune responses across multiple administration routes, providing flexibility in tailoring vaccine strategies based on the pathogen and target population.</p></sec><sec id="sec5dot2-vaccines-12-01319"><title>5.2. Recombinant Salmonella Expressing Bacterial Antigens</title><p>Several studies were reviewed and are summarized in <xref rid="vaccines-12-01319-t001" ref-type="table">Table 1</xref>, which presents the different <italic toggle="yes">Salmonella</italic> strains, routes, doses, animal models, and the types of immune response stimulated. In one study [<xref rid="B55-vaccines-12-01319" ref-type="bibr">55</xref>], an RASV containing chromosomal fusion genes that encode the secretion signal for the SPI-2 effector protein, SspH2, and the pathogenic outer membrane lipoprotein from <italic toggle="yes">Leptospira</italic>, LipL32, was administered orally to rats. The animals received a dose of 1 &#x000d7; 10<sup>7</sup> colony forming units (CFU) per mouse of different strains of <italic toggle="yes">S</italic>. Typhimurium (ST) or saline (PBS) alone on days 0, 14, and 28. After vaccination, the group that received the RASV exhibited significantly elevated titers of total immunoglobulin G (IgG) and immunoglobulin A (IgA) specific to the rLipL32 protein, with detectable levels persisting up to 77 days post-vaccination. Notably, following the third immunization on day 28, the anti-LipL32 antibody titers in mice immunized with the RASV were significantly higher than those in mice that received only PBS (<italic toggle="yes">p</italic> &#x0003c; 0.05). Additionally, to assess the cellular immune response, there was a significant increase in the production of the LipL32-specific cytokines IFN-&#x003b3; and IL-4 in splenocytes from mice vaccinated with the RASV compared to the control group treated with PBS (<italic toggle="yes">p</italic> &#x0003c; 0.05) [<xref rid="B55-vaccines-12-01319" ref-type="bibr">55</xref>].</p><p>Another RASV using <italic toggle="yes">Salmonella</italic> Typhimurium that expresses the R2 antigen of NrdF from <italic toggle="yes">Mycoplasma hyopneumoniae</italic> was used to orally inoculate mice at a dose of 10<sup>9</sup> CFU, followed by two more boosters at the same dose. In this study, a mucosal IgA-type immune response was elicited in lung washings, but a significant level of NrdF-specific serum IgG was not detected [<xref rid="B78-vaccines-12-01319" ref-type="bibr">78</xref>]. Interestingly, Chen et al. [<xref rid="B80-vaccines-12-01319" ref-type="bibr">80</xref>] demonstrated that a DNA vaccine with a eukaryotic expression plasmid, encoding the <italic toggle="yes">M. hyopneumoniae</italic> NrdF antigen through an <italic toggle="yes">S.</italic> Typhimurium live-attenuated <italic toggle="yes">aroA</italic>, when administered orally to mice at a dose of 2 &#x000d7; 10<sup>8</sup> CFU followed by a booster dose of 3 &#x000d7; 10<sup>8</sup> CFU, induced significant NrdF-specific IFN-&#x003b3; production. However, mice orally vaccinated with <italic toggle="yes">S.</italic> Typhimurium expressing NrdF encoded by a prokaryotic expression plasmid failed to produce a serum or secretory antibody response specific to NrdF, and IFN-&#x003b3; was not produced [<xref rid="B80-vaccines-12-01319" ref-type="bibr">80</xref>]. In another study conducted by Chen and colleagues [<xref rid="B81-vaccines-12-01319" ref-type="bibr">81</xref>], a RASV of <italic toggle="yes">S</italic>. Typhimurium was used, and the gene of interest was cloned into both eukaryotic and prokaryotic expression vectors. Immunogenicity was assessed in mice orally immunized with <italic toggle="yes">M. hyopneumoniae</italic> P97R1 adhesin, which induced specific Th1 cellular immune responses in a mouse model. However, no mucosal antibody responses against P97R1 were observed.</p><p>In the delivery system of <italic toggle="yes">S.</italic> Typhimurium expressing important fimbriae of <italic toggle="yes">Escherichia coli</italic> F4 (K88), F5 (K99), F6 (987Ps), and F41 and intimin adhesin, using a murine model with a single dose or double dose of 2 &#x000d7; 10<sup>9</sup> CFU in 20 &#x000b5;L, IgG and IgA titers for individual adhesins in all immunized groups were higher in the booster dose group than in the single dose group [<xref rid="B64-vaccines-12-01319" ref-type="bibr">64</xref>]. In another study, Hur, Stein, and Lee [<xref rid="B65-vaccines-12-01319" ref-type="bibr">65</xref>] also used live-attenuated <italic toggle="yes">S.</italic> Typhimurium expressing other recombinant <italic toggle="yes">E. coli</italic> fimbrial antigens K88ab, K88ac, FedA, and FedF. The IgG2a titer was increased in the one-dose group, whereas both the IgG2a and IgG1 titers were increased in the two-dose group. Furthermore, vaccine strains were not detected in the feces excreted from immunized mice. Hur and Lee [<xref rid="B61-vaccines-12-01319" ref-type="bibr">61</xref>] evaluated the immune responses of various doses of <italic toggle="yes">Salmonella</italic> ghost (non-living, devoid of cytoplasmic content, maintaining their cellular morphology), with controlled expression of the &#x003c6;X174 E lysis gene being achieved in pigs. These bacterial ghosts carried enterotoxigenic <italic toggle="yes">E. coli</italic> fimbrial antigens (ETEC) to protect against colibacillosis in piglets. All groups were orally immunized with doses of 2 &#x000d7; 10<sup>9</sup>, 2 &#x000d7; 10<sup>10</sup>, or 2 &#x000d7; 10<sup>11</sup> CFU in 10 mL PBS and boosted at weeks 11 and 14 of pregnancy. The serum levels of immunoglobulin IgG, IgG, and IgA in the colostrum of sows in groups that received 2 &#x000d7; 10<sup>10</sup> or 2 &#x000d7; 10<sup>11</sup> CFU were significantly higher than those of sows in the control group. Notably, after a challenge with wild-type ETEC, neither piglet diarrhea nor mortality were observed.</p><p>In another study [<xref rid="B85-vaccines-12-01319" ref-type="bibr">85</xref>], live-attenuated <italic toggle="yes">S.</italic> Typhimurium JOL912, which contains the genes encoding P fimbriae (the <italic toggle="yes">pap</italic> gene cluster), the iron-regulated aerobactin receptor <italic toggle="yes">iut</italic>A, and CS31A surface antigen adhesin from avian pathogenic <italic toggle="yes">E. coli</italic> (APEC), was evaluated as the vaccine against APEC infection in chickens. The vaccine was administered orally, intramuscularly, or subcutaneously, using different doses according to three groups: a no-vaccine group, a single-vaccine-dose group, and another that received primary and booster immunizations. The birds were exposed to an intra-air sac challenge using a virulent APEC strain at a dose of 10<sup>7</sup> UFC, and the group that received two vaccine doses showed greater protection against the challenge (80%). Furthermore, this group showed significant increases in plasma IgG levels at three and for weeks old compared to birds from other groups, reinforcing the use of two vaccine doses [<xref rid="B85-vaccines-12-01319" ref-type="bibr">85</xref>]. Lee and colleagues [<xref rid="B86-vaccines-12-01319" ref-type="bibr">86</xref>] reported that, following a challenge with a virulent APEC strain, there were no deaths in the vaccinated group, whereas the control group showed a mortality rate of 15%. The administration of primary and booster doses of the <italic toggle="yes">Salmonella</italic>-delivered APEC vaccine candidate significantly enhanced the generation of antigen-specific sIgA, as well as the production of IFN-&#x003b3;, IL-6, and IL-2, thereby providing protection for chickens against colibacillosis [<xref rid="B86-vaccines-12-01319" ref-type="bibr">86</xref>]. In another study, Oh et al. [<xref rid="B88-vaccines-12-01319" ref-type="bibr">88</xref>] used the P fimbria subunit PapA from APEC, which was in live-attenuated <italic toggle="yes">S.</italic> Typhimurium. Furthermore, the study utilized the non-toxic B subunits of cholera toxin (CTB) and heat-labile toxin (LTB) as adjuvants within the vaccine formulation. Mice were inoculated with 20 &#x000b5;L containing 2 &#x000d7; 10<sup>9</sup> CFU. The findings demonstrated a significant increase in Pa-pA-specific serum IgG and mucosal IgA titers when the recombinant <italic toggle="yes">Salmonella</italic> vaccine was administered in conjunction with LTB or CTB adjuvants, highlighting the enhanced immunogenic response facilitated by these adjuvants. Rapid declines in immune responses throughout the experimental period were observed in mice immunized without an adjuvant.</p><p>The benefits of the intracellular action of <italic toggle="yes">Salmonella</italic> also correlate with natural infection in mucous membranes and in the intestinal tract, an analogous route to one of the most important infection routes of <italic toggle="yes">Brucella abortus</italic>. In a study by Kim et al. [<xref rid="B29-vaccines-12-01319" ref-type="bibr">29</xref>], live-attenuated <italic toggle="yes">S.</italic> Typhimurium was engineered to express BCSP31, Omp3b, and SOD proteins from <italic toggle="yes">B. abortus</italic>. Mice were vaccinated with a mixture of the three strains, either orally or intramuscularly [<xref rid="B29-vaccines-12-01319" ref-type="bibr">29</xref>]. The recombinant vaccine induced serum concentrations of IgG, TNF-&#x003b1;, and IFN-&#x003b3; that were higher than the control when administered via the oral route (except Omp3b) and intramuscularly. A robust IFN-&#x003b3;-mediated response helps eliminate <italic toggle="yes">Brucella</italic> infection in the host. Furthermore, it was found that after a challenge with a virulent strain of <italic toggle="yes">B. abortus</italic>, the vaccine was able to limit the colonization of the bacteria in the spleen of mice.</p><p>Another study targeting brucellosis in goats, reported by Leya and colleagues [<xref rid="B24-vaccines-12-01319" ref-type="bibr">24</xref>], developed a <italic toggle="yes">S.</italic> Typhimurium vaccine expressing four (BLS, PrpA, Omp19, and SOD) heterologous <italic toggle="yes">Brucella</italic> antigens and inoculated them subcutaneously with two doses: 5 &#x000d7; 10<sup>9</sup> CFU/mL (Group B) and 5 &#x000d7; 10<sup>10</sup> CFU/mL (Group C). The goats were challenged with a virulent <italic toggle="yes">B. abortus</italic> strain six weeks after immunization. Serum IgG titers against specific antigens in goats from Group C were significantly higher than those in non-immunized goats and the vector control group. Following antigenic stimulation, IFN-&#x003b3; levels in peripheral blood mononuclear cells were significantly elevated in Groups B and C compared to the vector control group. The immunized goats in Group C, which received the highest dose, exhibited a significantly higher level of protection (<italic toggle="yes">p</italic> &#x0003c; 0.05); however, the group with the lower dose also showed a successful reduction in microgranuloma lesions in the liver induced by <italic toggle="yes">B. abortus</italic> infection. Stabel et al. [<xref rid="B103-vaccines-12-01319" ref-type="bibr">103</xref>] reported that the use of the <italic toggle="yes">Salmonella</italic> Cholerasuis chi 3781 (SC) strain expressing the BCSP31 protein from <italic toggle="yes">B. abortus</italic>, when administered orally to pigs and mice, stimulated a strong serum IgG response to both the recombinant protein and SC in mice. In contrast, orally inoculated pigs did not develop significant serum or intestinal antibody responses.</p></sec><sec id="sec5dot3-vaccines-12-01319"><title>5.3. Recombinant Salmonella Expressing Virus Antigens</title><p>Live-attenuated strains of <italic toggle="yes">Salmonella</italic>, including <italic toggle="yes">S.</italic> Typhimurium, used in most of the studies reviewed in this article, but also <italic toggle="yes">S.</italic> Galinarium, <italic toggle="yes">S.</italic> Choleraesuis, and <italic toggle="yes">S.</italic> Pullorum, have been evaluated for use as live vaccines for the delivery of a variety of viral antigens (<xref rid="vaccines-12-01319-t002" ref-type="table">Table 2</xref>).</p><p>Among the targets studied were the hemagglutinin gene (HA1) from one of the avian influenza viruses (AIV or HPAI) of the H5N1 subtype. Liljebjelke and colleagues [<xref rid="B108-vaccines-12-01319" ref-type="bibr">108</xref>] reported the use of <italic toggle="yes">S.</italic> Typhimurium expressing AIV HA1 as an oral vaccine carrier in birds with doses of 10<sup>9</sup> CFU. Animals were challenged with homologous A/whooper swan/Mongolia/3/2005-(CQ95) or heterologous A/Chicken/Queretaro/14588-19/95-(WM05) strains of the HPAI virus. Groups that received the recombinant vaccine demonstrated a statistically significant increase in survival compared with control groups (100%) for the low-dose homologous challenge with CQ95 and partial protection against the low-dose challenge with WM05. Neither vaccine provided protection to chickens when challenged with high doses of either HPAI virus, although survival was better against the challenge with CQ95 (60%). The presence of antibodies that recognize the HA protein in serum and probe samples was assessed by hemagglutination inhibition (HI) assay and collected 2 weeks after vaccination. Furthermore, Jazayeri and collaborators [<xref rid="B110-vaccines-12-01319" ref-type="bibr">110</xref>] reported the use of glycoproteins HA, NA, and NP from AIV expressed in live-attenuated <italic toggle="yes">S.</italic> Typhimurium SV4089, administered orally to birds using the same dose as the previous study. Fluorescence in situ hybridization (FISH) was used for detection, and <italic toggle="yes">Salmonella</italic> was specifically identified using the genus-specific probe Sal3 from homogenized sections of the spleen, liver, and cecum of infected chickens, where the distinct fluorescent signal of rod-shaped bacteria could be detected. They achieved the successful elimination of <italic toggle="yes">Salmonella</italic> from the spleen and liver of infected birds, but it was still detectable in the cecum even 35 days after inoculation, demonstrating that live-attenuated <italic toggle="yes">S.</italic> Typhimurium provides an alternative in terms of in vitro stability of the transfected plasmid.</p><p>In a study using subtype H9N2 avian influenza virus, two attenuated <italic toggle="yes">S. Typhimurium</italic> strains were constructed: one with the O antigen of LPS intact (smooth strain) and the other without it (rough strain), as the removal of this antigen can increase the immunogenicity of surface proteins. This experiment, conducted in an avian model with recombinant <italic toggle="yes">Salmonella</italic> expressing H9N2 hemagglutinin (HA), evaluated whether <italic toggle="yes">Salmonella</italic> could act as a transporter to enhance immune responses to delivered antigens. Both the S-HA and R-HA strains elicited similar HA-specific immune responses, as indicated by serum IgG and HI titers, suggesting that the deletion of the O antigen does not impact the immunogenicity and delivery properties of the <italic toggle="yes">Salmonella</italic> system [<xref rid="B30-vaccines-12-01319" ref-type="bibr">30</xref>]. Additionally, Hajam et al. [<xref rid="B113-vaccines-12-01319" ref-type="bibr">113</xref>] used <italic toggle="yes">S.</italic> Gallinarum (SG) for expressing HA1, HA2, and/or the conserved ectodomain of matrix protein 2 (M2e) in the development of H9N2 vaccine strains, which were compared to a commercially available oil-adjuvanted inactivated H9N2 full-virus vaccine in a chicken model [<xref rid="B30-vaccines-12-01319" ref-type="bibr">30</xref>,<xref rid="B113-vaccines-12-01319" ref-type="bibr">113</xref>]. In search of a cheaper vaccine, and without the use of exogenous adjuvants, the experiment vaccinated chickens with a single dose, orally at a dose of 10<sup>9</sup> CFU, in groups who received either the individual H9N2 genes in SG, or as a mixture of these, while the control was vaccinated intramuscularly with the inactivated commercial H9N2 vaccine. An indirect ELISA of IgY with serum samples collected on days 14 and 28 post-vaccination showed that animals vaccinated with the RASV or a mixture of vaccine strains showed specific systemic responses to HA1 that were significantly higher (<italic toggle="yes">p</italic> &#x0003c; 0.05) than those of the control group. Cytokine gene expression revealed that IFN-&#x003b3; increased by over four times (<italic toggle="yes">p</italic> &#x0003c; 0.05) in all groups inoculated with RASV constructs compared to the PBS control group. However, the commercial vaccine induced significantly greater responses for the HA1 and HA2 genes but was not as robust for M2 when compared to the RASV. Upon challenge, chickens immunized with both vaccines exhibited comparable lung inflammation and viral loads, although both were significantly lower than those in the group vaccinated with SG alone. However, immunization with the RASV managed to efficiently inhibit the infection and spread of H9N2.</p><p>Another use of orally administered vaccines has been to combat duck enteritis virus (DEV), an acute disease that affects ducks, geese, swans, and other free-living aquatic birds, with high mortality. Yu and colleagues [<xref rid="B117-vaccines-12-01319" ref-type="bibr">117</xref>] used live-attenuated <italic toggle="yes">S.</italic> Typhimurium (SL7207) with <italic toggle="yes">E. coli</italic> LTB as an adjuvant, fused to the DEV UL24 gene in ducks. Birds were orally inoculated with SL7207 (pVAX-UL24) or SL7207 (pVAX-LTB-UL24) with 1 &#x000d7; 10<sup>10</sup> CFU. Immunization of animals with the recombinant LTB vaccine showed superior protective efficacy (60&#x02013;80%) against a lethal DEV challenge, compared to the limited survival rate (40%) of those immunized with the vaccine without the adjuvant. To support this study&#x02019;s results, Liu et al. [<xref rid="B118-vaccines-12-01319" ref-type="bibr">118</xref>] orally immunized ducks with <italic toggle="yes">S.</italic> Typhimurium S739 expressing DEV genes and adjuvants (LTB subunit and duck DuIL-2 gene). After a booster immunization, 90% of ducks immunized with recombinant <italic toggle="yes">Salmonella</italic> and the LTB adjuvant were protected during lethal challenge. IgY levels were slightly higher against the tUL24 protein in ducks vaccinated with UL24-LTB and UL24-DuIL-2 on days 10, 21, and 28 post-immunization (<italic toggle="yes">p</italic> &#x0003c; 0.05). Serum IgY and bile IgA levels in response to purified DEV were slightly lower than those for tUL24, but higher IgY titers against DEV were observed in ducks vaccinated with UL24 and tgB compared to those for tUL24 (<italic toggle="yes">p</italic> &#x0003c; 0.05). Among all groups, the highest bile IgA levels were seen in ducks receiving the attenuated <italic toggle="yes">Salmonella</italic>-DEV DNA recombinant vaccine [<xref rid="B118-vaccines-12-01319" ref-type="bibr">118</xref>]. Although the two adjuvants stimulated a high immune response in ducks, the vaccination with recombinant <italic toggle="yes">Salmonella</italic> and DuIL-2 was not capable of providing protection against homologous challenge.</p><p>Cytokines like IFN-&#x003b1; help modulate innate and adaptive immunity, providing a first line of defense against viral infections. However, their use in livestock is costly. Kim et al. [<xref rid="B122-vaccines-12-01319" ref-type="bibr">122</xref>] tested an oral vaccine using live-attenuated <italic toggle="yes">S.</italic> Typhimurium engineered to secrete porcine IFN-&#x003b1; (swIFN-&#x003b1;) to prevent clinical signs of transmissible gastroenteritis virus (TGEV), a significant economic threat in the swine industry. Administered at doses of 10<sup>9</sup> and 10<sup>11</sup> CFU per pig, the vaccine effectively reduced the severity of TGEV-induced clinical signs [<xref rid="B122-vaccines-12-01319" ref-type="bibr">122</xref>]. To assess the virus&#x02019;s spread in piglets infected with TGEV, the quantity of TGEV in fecal samples collected from the infected piglets was measured. Virus shedding was detected one day after TGEV infection and reached its peak at four days post-infection. However, piglets that received the recombinant vaccine (at doses of 10<sup>9</sup> and 10<sup>11</sup> UFC) exhibited reduced viral shedding at four days post-infection. Likewise, the amount of TGEV was lower in the intestinal tissues and mesenteric lymph nodes of piglets inoculated with the recombinant vaccine when compared to the control, helping to reduce the severity of clinical signs caused by TGEV infection.</p><p>In another study on TGEV, Zhang and collaborators [<xref rid="B123-vaccines-12-01319" ref-type="bibr">123</xref>] sought to evaluate an experimental vaccine delivered by live-attenuated <italic toggle="yes">S.</italic> Typhimurium expressing the structural protein of the virus, which is correlated with another virus that causes swine epidemic diarrhea (PEDV). These viruses are members of the Coronaviridae family, and both viruses can cause severe enteropathogenic diarrhea in pigs; therefore, the simultaneous induction of immune responses is promising for the food industry. Piglets were immunized orally with recombinant <italic toggle="yes">Salmonella</italic> at a dosage of 1.6 &#x000d7; 10<sup>11</sup> CFU per piglet and then immunized with a booster of 2 &#x000d7; 10<sup>11</sup> CFU. The RASV with two S proteins from TGEV and PEDV simultaneously stimulated immune responses against both viruses after oral immunization. Antibody levels against PEDV or TGEV in piglets immunized with the RASV of <italic toggle="yes">S</italic>. Typhimurium began to increase at 2 weeks, but the difference compared to controls was not statistically significant until the sixth week. Serum IgG levels against PEDV and TGEV were significantly higher (<italic toggle="yes">p</italic> &#x0003c; 0.01) in piglets immunized with the recombinant vaccine than with PBS or empty vector from weeks 4 to 8. Significantly elevated levels of IgG and IgA antibodies against PEDV and TGEV were induced by the RASV in week 6, though these levels were slightly lower than those induced by the monogenic vaccine and empty vector. The results showed that T lymphocyte proliferation levels increased to a statistically significant level compared to the control group in weeks 4 to 6, being higher in piglets immunized with the RASV when compared to other vaccine groups, but no significant differences were observed (<italic toggle="yes">p</italic> &#x0003e; 0.05). The results also indicated that IFN-&#x003b3; and IL-4 levels in piglets treated with the RASV were significantly higher (<italic toggle="yes">p</italic> &#x0003c; 0.01) than in control groups.</p></sec><sec id="sec5dot4-vaccines-12-01319"><title>5.4. Recombinant Salmonella Expressing Parasite Antigens</title><p>The protective mechanisms required to combat parasites differ significantly from those required for other pathogens, and parasites can actively suppress the host&#x02019;s immune response [<xref rid="B133-vaccines-12-01319" ref-type="bibr">133</xref>]. This has made it challenging to identify an effective combination of antigens, adjuvants, and routes of administration for vaccination [<xref rid="B133-vaccines-12-01319" ref-type="bibr">133</xref>,<xref rid="B134-vaccines-12-01319" ref-type="bibr">134</xref>]. However, recent years have seen notable advances in the development of vaccines utilizing recombinant antigens from these parasites, although studies in this area remain limited [<xref rid="B134-vaccines-12-01319" ref-type="bibr">134</xref>].</p><p>In this review, we compiled 14 articles (<xref rid="vaccines-12-01319-t003" ref-type="table">Table 3</xref>) that investigate the use of attenuated strains of <italic toggle="yes">Salmonella</italic> engineered to express parasite antigens. These attenuated strains are particularly attractive as live vectors because they can elicit strong mucosal immunity, which is crucial for controlling certain parasites, such as <italic toggle="yes">Trichinella spiralis</italic>, in the intestinal mucosa [<xref rid="B134-vaccines-12-01319" ref-type="bibr">134</xref>].</p><p>Pompa-Mera and collaborators [<xref rid="B31-vaccines-12-01319" ref-type="bibr">31</xref>] used <italic toggle="yes">S.</italic> Typhimurium SL3261 and inserted a fusion glycoprotein from <italic toggle="yes">T. spiralis</italic> larvae. The vaccine was administered intranasally at a dose of 1&#x000d7; 10<sup>8</sup> CFU to BALB/c mice. After challenge, mice immunized intranasally with recombinant <italic toggle="yes">Salmonella</italic> saw a reduction in the parasite load of adult <italic toggle="yes">T. spiralis</italic> by 61.83% on the eighth day post-infection, indicating a protective immune response. This immune response was characterized by the induction of antigen-specific IgG1 and IL-5 production. In another study using <italic toggle="yes">T. spiralis</italic>, the Ts87 gene was attenuated to strain <italic toggle="yes">S.</italic> Typhimurium SL7207, administered only orally to mice. They also reported a statistically significant 29.8% reduction in adult worm burden and a 34.2% reduction in larvae following <italic toggle="yes">T. Spiralis</italic> larvae challenge, compared with mice immunized with empty <italic toggle="yes">Salmonella</italic> or a PBS control. However, mice that received the recombinant <italic toggle="yes">Salmonella</italic> vaccine exhibited elevated levels of IgG2a and IgG1 subclass antibodies, with no significant difference (<italic toggle="yes">p</italic> &#x0003e; 0.05) between IgG2a and IgG1 levels, indicating a mixed Th1/Th2 immune response. Additionally, there was a notable increase (<italic toggle="yes">p</italic> &#x0003c; 0.05) in total intestinal IgA levels among mice immunized with the recombinant vaccine compared to those in the vector or PBS-only groups. Another important parasite for veterinary medicine is the cestode <italic toggle="yes">Echinococcus granulosus</italic> (EgDf1), which infects the intestines of dogs, in addition to having intermediate hosts such as herbivorous and omnivorous animals and, accidentally, humans. Chabalgoity and colleagues [<xref rid="B139-vaccines-12-01319" ref-type="bibr">139</xref>] produced a vaccine in which fatty-acid-binding proteins (FABPs) of EgDf1 fused with a C-terminal fragment of tetanus toxin (TetC) were expressed in <italic toggle="yes">S.</italic> Typhimurium LVR01. The inoculation was administered intravenously with a dose of 10<sup>6</sup> CFU, as well as via an oral dose of 4 &#x000d7; 10<sup>9</sup> CFU, in mice, eliciting an antibody response to EgDf1, the production of Th1-related antigen-specific cytokines, and significant levels of a Th2 cytokine protein in the spleen cells of orally immunized mice. Furthermore, sera from immune mice reacted strongly with fixed sections of the larval stage of the worm. Another study by the group used <italic toggle="yes">S.</italic> Typhimurium LVR01 expressing EgDf1 FABP in dogs, which were orally vaccinated at a dose of 5 &#x000d7; 10<sup>10</sup> CFU in 2 mL of PBS or given PBS alone. The dogs presented IgG antibody responses against EgDf1 when immunized with LVR01 (pTECH &#x000b1; EgDf1). All animals developed high titers of IgG antibodies against LPS in serum by week 4 after a single dose of the recombinant vaccine [<xref rid="B48-vaccines-12-01319" ref-type="bibr">48</xref>].</p><p>Cong et al. [<xref rid="B73-vaccines-12-01319" ref-type="bibr">73</xref>] tested a vaccine using live-attenuated <italic toggle="yes">S.</italic> Typhimurium as a vector for the recombinant plasmid pSAG1-2/CTA2/B, which encodes <italic toggle="yes">Toxoplasma gondii</italic> antigens SAG1 and SAG2 linked to cholera toxin subunits (CTA2/B). Orally administered in mice, this vaccine induced anti-<italic toggle="yes">T. gondii</italic> IgG antibodies, with increased IgG levels in mice that received CTA2/B as a genetic adjuvant compared to controls (<italic toggle="yes">p</italic> = 0.003, <italic toggle="yes">p</italic> = 0.004). Although both groups generated anti-<italic toggle="yes">T. gondii</italic> antibodies, mice vaccinated with CTA2/B showed a predominant Th1 response, while those without it exhibited a Th2 response. Upon challenge with virulent <italic toggle="yes">T. gondii</italic>, mice vaccinated with CTA2/B had longer survival times and a 40% survival rate (<italic toggle="yes">p</italic> = 0.003) [<xref rid="B73-vaccines-12-01319" ref-type="bibr">73</xref>].</p><p>In another study, Cong et al. [<xref rid="B22-vaccines-12-01319" ref-type="bibr">22</xref>] developed a live-attenuated <italic toggle="yes">S.</italic> Typhimurium vaccine encoding <italic toggle="yes">T. gondii</italic> epitopes (SAG1, GRA1, ROP2, GRA4, SAG2C, SAG2X) linked to CTA2/B, which was delivered to BALB/c mice via oral, nasal, or intramuscular routes. Mice immunized orally and nasally showed higher anti-<italic toggle="yes">T. gondii</italic> antibody levels than those vaccinated intramuscularly (<italic toggle="yes">p</italic> &#x0003c; 0.05). Flow cytometry revealed CD4+ and CD8+ T-cell activation, with intramuscular and intranasal immunizations inducing 28.54% and 30.01% activation, respectively. IFN-&#x003b3; and IL-2 levels were significantly higher in orally and nasally vaccinated groups than in the control (<italic toggle="yes">p</italic> = 0.02), while IL-4 and IL-5 remained low across groups. Antigen-specific lymphocyte proliferation was also higher in the oral and nasal groups. After a lethal <italic toggle="yes">T. gondii</italic> challenge, survival rates were 20% for intramuscular, 40% for intranasal, and 60% for oral immunization. These results highlight the potential of oral and nasal routes for delivering live-attenuated <italic toggle="yes">Salmonella</italic> vaccines in inducing stronger immune responses and improved protection against <italic toggle="yes">T. gondii</italic> [<xref rid="B22-vaccines-12-01319" ref-type="bibr">22</xref>].</p><p>Benitez, McNair, and Mead [<xref rid="B74-vaccines-12-01319" ref-type="bibr">74</xref>] utilized strains of live-attenuated <italic toggle="yes">S.</italic> Typhimurium expressing Cp23 and Cp40 from <italic toggle="yes">Cryptosporidium parvum</italic>, which are recognized as surface immunodominant antigens, as they are recognized by serum antibodies from humans and various animal species. In the study, mice received an oral immunization of 5 &#x000d7; 10<sup>9</sup> CFU per mouse and an intragastrical immunization of 0.2 mL of PBS for each vaccine, which included a vector with an empty plasmid, the RASV vaccine expressing the Cp23 gene, and another for the CP40 gene. Two booster doses, consisting of 100 &#x003bc;g of RASV, were injected subcutaneously on days 0 and 14, followed by oral immunization against <italic toggle="yes">Salmonella</italic>. The production of IgG and IgG1 subclasses was observed in vaccinated mice after 7 weeks of immunization. The specific serum levels of anti-Cp23 and anti-Cp40 IgG were significantly increased in mice immunized with the RASV vaccine compared to mice immunized with the control vector. IgA titers were detected in mice immunized with the RASV expressing Cp23 but not in animals immunized with the Cp40 construct (<italic toggle="yes">p</italic> &#x0003e; 0.05). Only an IgG1 antibody response was obtained, with no IgG2a response, suggesting a Th2-type response was elicited.</p><p>Chen et al. [<xref rid="B142-vaccines-12-01319" ref-type="bibr">142</xref>] studied a live-attenuated <italic toggle="yes">S.</italic> Typhimurium vaccine using active promoters (nirB, pagC, or pMohly) to express the <italic toggle="yes">Schistosoma japonicum</italic> antigen Sj23LHD-GST via the <italic toggle="yes">Salmonella</italic> type III secretion system or &#x003b1;-hemolysin. Mice were orally immunized with 0.2 mL PBS containing 10<sup>9</sup> CFUs of either recombinant <italic toggle="yes">S.</italic> Typhimurium or an empty vector, with a PBS-only group as a control. After three doses, mice vaccinated with the nirB promoter showed a moderate IgG response and the highest IgG2a ratio, indicating a strong Th1-type response. CD44 expression in splenocytes was significantly elevated in mice that received the nirB-driven antigen (25 &#x000b1; 2%) compared to other groups (<italic toggle="yes">p</italic> &#x0003c; 0.01). Following <italic toggle="yes">S. japonicum</italic> challenge, mice immunized with <italic toggle="yes">S.</italic> Typhimurium containing nirB, pagC, or pMohly1 promoters showed egg burden reductions of 57.71%, 30.07%, and 40.46%, respectively. The nirB-driven antigen delivered by type III secretion reduced parasite burden by 51.35% and egg burden by 62.59%, showing promising in vivo protective efficacy. These findings highlight the protective efficacy of antigens delivered by the <italic toggle="yes">Salmonella</italic> type III secretion system using the nirB promoter [<xref rid="B142-vaccines-12-01319" ref-type="bibr">142</xref>].</p></sec></sec><sec sec-type="conclusions" id="sec6-vaccines-12-01319"><title>6. Conclusions and Future Directions</title><p>Developing attenuated vaccines requires balancing safety and immunogenicity. Although <italic toggle="yes">Salmonella</italic> shows promise as a vaccine vector, many studies have not achieved significant protective efficacy. Over-attenuation can reduce immunogenicity and tissue colonization, while insufficient attenuation may pose biosafety risks. While safety is often evaluated based on the absence of adverse reactions and strain stability, few studies assess environmental release or potential transmission through vertical or horizontal pathways.</p><p>The development and commercialization of RASVs represents a significant advancement in veterinary medicine. These vaccines offer a safe and effective means of controlling infectious diseases in livestock, reducing the reliance on antibiotics and mitigating the risks associated with antibiotic resistance. The ability of RASVs to deliver antigens from a wide range of pathogens makes them versatile tools for disease prevention.</p><p>Looking forward, future research should focus on optimizing vaccine formulations and delivery methods, particularly for ruminants and other species where oral administration remains a challenge. Additionally, there is potential to expand the use of RASVs beyond veterinary applications, with possible implications for human medicine, particularly in the context of zoonotic diseases.</p><p>The studies reviewed here highlight the promise of RASVs as part of an integrated approach to managing infectious diseases in animal populations. Continued investment in research and development will be essential to fully realize the potential of these vaccines and to address the challenges that remain.</p></sec></body><back><fn-group><fn><p><bold>Disclaimer/Publisher&#x02019;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><notes><title>Author Contributions</title><p>Conceptualization, F.D.S.S.; methodology, D.B.C., F.D.S.S. and N.R.d.O.; validation, D.B.C.; investigation, D.B.C. and F.D.S.S.; data curation, N.R.d.O.; writing&#x02014;original draft preparation, D.B.C.; writing&#x02014;review and editing, F.D.S.S., N.R.d.O., T.L.O.B. and O.A.D.; visualization, D.B.C.; supervision, T.L.O.B. and O.A.D.; funding acquisition, O.A.D. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>Not applicable.</p></notes><notes><title>Informed Consent Statement</title><p>Not applicable.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>No new data were created or analyzed in this study. Data sharing is not applicable to this article.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest. The founding sponsors had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, and in the decision to publish the results.</p></notes><ref-list><title>References</title><ref id="B1-vaccines-12-01319"><label>1.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Roth</surname><given-names>J.</given-names></name>
<name><surname>Sandbulte</surname><given-names>M.</given-names></name>
</person-group><article-title>The Role of Veterinary Vaccines in Livestock Production, Animal Health, and Public Health</article-title><source>Veterinary Vaccines: Principles and Applications</source><person-group person-group-type="editor">
<name><surname>Metwally</surname><given-names>S.</given-names></name>
<name><surname>Idrissi</surname><given-names>A.E.</given-names></name>
<name><surname>Viljoen</surname><given-names>G.</given-names></name>
</person-group><publisher-name>Wiley</publisher-name><publisher-loc>Hudson County, NJ, USA</publisher-loc><year>2021</year><fpage>1</fpage><lpage>10</lpage><isbn>9781119506287</isbn></element-citation></ref><ref id="B2-vaccines-12-01319"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Shaji</surname><given-names>S.</given-names></name>
<name><surname>Selvaraj</surname><given-names>R.K.</given-names></name>
<name><surname>Shanmugasundaram</surname><given-names>R.</given-names></name>
</person-group><article-title><italic toggle="yes">Salmonella</italic> Infection in Poultry: A Review on the Pathogen and Control Strategies</article-title><source>Microorganisms</source><year>2023</year><volume>11</volume><elocation-id>2814</elocation-id><pub-id pub-id-type="doi">10.3390/microorganisms11112814</pub-id><pub-id pub-id-type="pmid">38004824</pub-id>
</element-citation></ref><ref id="B3-vaccines-12-01319"><label>3.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Kuria</surname><given-names>J.K.N.</given-names></name>
</person-group><article-title>Salmonellosis in Food and Companion Animals and Its Public Health Importance</article-title><source>Salmonella&#x02014;Perspectives for Low-Cost Prevention, Control and Treatment</source><publisher-name>IntechOpen</publisher-name><publisher-loc>London, UK</publisher-loc><year>2023</year></element-citation></ref><ref id="B4-vaccines-12-01319"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zanella</surname><given-names>J.R.C.</given-names></name>
</person-group><article-title>Zoonoses Emergentes e Reemergentes e Sua Import&#x000e2;ncia Para Sa&#x000fa;de e Produ&#x000e7;&#x000e3;o Animal</article-title><source>Pesqui. Agropecu&#x000e1;ria Bras.</source><year>2016</year><volume>51</volume><fpage>510</fpage><lpage>519</lpage><pub-id pub-id-type="doi">10.1590/S0100-204X2016000500011</pub-id></element-citation></ref><ref id="B5-vaccines-12-01319"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Roth</surname><given-names>J.A.</given-names></name>
</person-group><article-title>Veterinary Vaccines and Their Importance to Animal Health and Public Health</article-title><source>Procedia Vaccinol.</source><year>2011</year><volume>5</volume><fpage>127</fpage><lpage>136</lpage><pub-id pub-id-type="doi">10.1016/j.provac.2011.10.009</pub-id><pub-id pub-id-type="pmid">32288915</pub-id>
</element-citation></ref><ref id="B6-vaccines-12-01319"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Laxminarayan</surname><given-names>R.</given-names></name>
<name><surname>Duse</surname><given-names>A.</given-names></name>
<name><surname>Wattal</surname><given-names>C.</given-names></name>
<name><surname>Zaidi</surname><given-names>A.K.M.</given-names></name>
<name><surname>Wertheim</surname><given-names>H.F.L.</given-names></name>
<name><surname>Sumpradit</surname><given-names>N.</given-names></name>
<name><surname>Vlieghe</surname><given-names>E.</given-names></name>
<name><surname>Hara</surname><given-names>G.L.</given-names></name>
<name><surname>Gould</surname><given-names>I.M.</given-names></name>
<name><surname>Goossens</surname><given-names>H.</given-names></name>
<etal/>
</person-group><article-title>Antibiotic Resistance-the Need for Global Solutions</article-title><source>Lancet Infect. Dis.</source><year>2013</year><volume>13</volume><fpage>1057</fpage><lpage>1098</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(13)70318-9</pub-id><pub-id pub-id-type="pmid">24252483</pub-id>
</element-citation></ref><ref id="B7-vaccines-12-01319"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Morrison</surname><given-names>L.</given-names></name>
<name><surname>Zembower</surname><given-names>T.R.</given-names></name>
</person-group><article-title>Antimicrobial Resistance</article-title><source>Gastrointest. Endosc. Clin. N. Am.</source><year>2020</year><volume>30</volume><fpage>619</fpage><lpage>635</lpage><pub-id pub-id-type="doi">10.1016/j.giec.2020.06.004</pub-id><pub-id pub-id-type="pmid">32891221</pub-id>
</element-citation></ref><ref id="B8-vaccines-12-01319"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Clark-Curtiss</surname><given-names>J.E.</given-names></name>
<name><surname>Curtiss</surname><given-names>R.</given-names></name>
</person-group><article-title><italic toggle="yes">Salmonella</italic> Vaccines: Conduits for Protective Antigens</article-title><source>J. Immunol.</source><year>2018</year><volume>200</volume><fpage>39</fpage><lpage>48</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1600608</pub-id><pub-id pub-id-type="pmid">29255088</pub-id>
</element-citation></ref><ref id="B9-vaccines-12-01319"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jorge</surname><given-names>S.</given-names></name>
<name><surname>Dellagostin</surname><given-names>O.A.</given-names></name>
</person-group><article-title>The Development of Veterinary Vaccines: A Review of Traditional Methods and Modern Biotechnology Approaches</article-title><source>Biotechnol. Res. Innov.</source><year>2017</year><volume>1</volume><fpage>6</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1016/j.biori.2017.10.001</pub-id></element-citation></ref><ref id="B10-vaccines-12-01319"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>de Oliveira</surname><given-names>N.R.</given-names></name>
<name><surname>Santos</surname><given-names>F.D.S.</given-names></name>
<name><surname>dos Santos</surname><given-names>V.A.C.</given-names></name>
<name><surname>Maia</surname><given-names>M.A.C.</given-names></name>
<name><surname>Oliveira</surname><given-names>T.L.</given-names></name>
<name><surname>Dellagostin</surname><given-names>O.A.</given-names></name>
</person-group><article-title>Challenges and Strategies for Developing Recombinant Vaccines against Leptospirosis: Role of Expression Platforms and Adjuvants in Achieving Protective Efficacy</article-title><source>Pathogens</source><year>2023</year><volume>12</volume><elocation-id>787</elocation-id><pub-id pub-id-type="doi">10.3390/pathogens12060787</pub-id><pub-id pub-id-type="pmid">37375478</pub-id>
</element-citation></ref><ref id="B11-vaccines-12-01319"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Singh</surname><given-names>B.R.</given-names></name>
</person-group><article-title><italic toggle="yes">Salmonella</italic> Vaccines for Animals and Birds and Their Future Perspective</article-title><source>Open Vaccine J.</source><year>2009</year><volume>2</volume><fpage>100</fpage><lpage>112</lpage><pub-id pub-id-type="doi">10.2174/1875035400902010100</pub-id></element-citation></ref><ref id="B12-vaccines-12-01319"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gayet</surname><given-names>R.</given-names></name>
<name><surname>Bioley</surname><given-names>G.</given-names></name>
<name><surname>Rochereau</surname><given-names>N.</given-names></name>
<name><surname>Paul</surname><given-names>S.</given-names></name>
<name><surname>Corth&#x000e9;sy</surname><given-names>B.</given-names></name>
</person-group><article-title>Vaccination against <italic toggle="yes">Salmonella</italic> Infection: The Mucosal Way</article-title><source>Microbiol. Mol. Biol. Rev.</source><year>2017</year><volume>81</volume><fpage>e00007-17</fpage><pub-id pub-id-type="doi">10.1128/MMBR.00007-17</pub-id><pub-id pub-id-type="pmid">28615285</pub-id>
</element-citation></ref><ref id="B13-vaccines-12-01319"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Amagliani</surname><given-names>G.</given-names></name>
<name><surname>La Guardia</surname><given-names>M.E.</given-names></name>
<name><surname>Dominici</surname><given-names>S.</given-names></name>
<name><surname>Brandi</surname><given-names>G.</given-names></name>
<name><surname>Omiccioli</surname><given-names>E.</given-names></name>
</person-group><article-title><italic toggle="yes">Salmonella Abortusovis</italic>: An Epidemiologically Relevant Pathogen</article-title><source>Curr. Microbiol.</source><year>2022</year><volume>79</volume><elocation-id>3</elocation-id><pub-id pub-id-type="doi">10.1007/s00284-021-02689-1</pub-id><pub-id pub-id-type="pmid">34878615</pub-id>
</element-citation></ref><ref id="B14-vaccines-12-01319"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Soliani</surname><given-names>L.</given-names></name>
<name><surname>Rugna</surname><given-names>G.</given-names></name>
<name><surname>Prosperi</surname><given-names>A.</given-names></name>
<name><surname>Chiapponi</surname><given-names>C.</given-names></name>
<name><surname>Luppi</surname><given-names>A.</given-names></name>
</person-group><article-title><italic toggle="yes">Salmonella</italic> Infection in Pigs: Disease, Prevalence, and a Link between Swine and Human Health</article-title><source>Pathogens</source><year>2023</year><volume>12</volume><elocation-id>1267</elocation-id><pub-id pub-id-type="doi">10.3390/pathogens12101267</pub-id><pub-id pub-id-type="pmid">37887782</pub-id>
</element-citation></ref><ref id="B15-vaccines-12-01319"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Velasquez-Munoz</surname><given-names>A.</given-names></name>
<name><surname>Castro-Vargas</surname><given-names>R.</given-names></name>
<name><surname>Cullens-Nobis</surname><given-names>F.M.</given-names></name>
<name><surname>Mani</surname><given-names>R.</given-names></name>
<name><surname>Abuelo</surname><given-names>A.</given-names></name>
</person-group><article-title>Review: <italic toggle="yes">Salmonella</italic> Dublin in Dairy Cattle</article-title><source>Front. Vet. Sci.</source><year>2023</year><volume>10</volume><elocation-id>1331767</elocation-id><pub-id pub-id-type="doi">10.3389/fvets.2023.1331767</pub-id><pub-id pub-id-type="pmid">38264470</pub-id>
</element-citation></ref><ref id="B16-vaccines-12-01319"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Young</surname><given-names>M.K.</given-names></name>
<name><surname>Cox</surname><given-names>M.M.</given-names></name>
<name><surname>Calhoun</surname><given-names>L.N.</given-names></name>
</person-group><article-title><italic toggle="yes">Salmonella</italic>-Based Vaccines for Infectious Diseases</article-title><source>Expert. Rev. Vaccines</source><year>2007</year><volume>6</volume><fpage>147</fpage><lpage>152</lpage><pub-id pub-id-type="doi">10.1586/14760584.6.2.147</pub-id><pub-id pub-id-type="pmid">17408365</pub-id>
</element-citation></ref><ref id="B17-vaccines-12-01319"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wang</surname><given-names>S.</given-names></name>
<name><surname>Kong</surname><given-names>Q.</given-names></name>
<name><surname>Curtiss</surname><given-names>R.</given-names></name>
</person-group><article-title>New Technologies in Developing Recombinant Attenuated <italic toggle="yes">Salmonella</italic> Vaccine Vectors</article-title><source>Microb. Pathog.</source><year>2013</year><volume>58</volume><fpage>17</fpage><lpage>28</lpage><pub-id pub-id-type="doi">10.1016/j.micpath.2012.10.006</pub-id><pub-id pub-id-type="pmid">23142647</pub-id>
</element-citation></ref><ref id="B18-vaccines-12-01319"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Galen</surname><given-names>J.E.</given-names></name>
<name><surname>Curtiss</surname><given-names>R.</given-names></name>
</person-group><article-title>The Delicate Balance in Genetically Engineering Live Vaccines</article-title><source>Vaccine</source><year>2014</year><volume>32</volume><fpage>4376</fpage><lpage>4385</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2013.12.026</pub-id><pub-id pub-id-type="pmid">24370705</pub-id>
</element-citation></ref><ref id="B19-vaccines-12-01319"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cardenas</surname><given-names>L.</given-names></name>
<name><surname>Clements</surname><given-names>J.D.</given-names></name>
</person-group><article-title>Oral Immunization Using Live Attenuated <italic toggle="yes">Salmonella</italic> Spp. as Carriers of Foreign Antigens</article-title><source>Clin Microbiol. Rev.</source><year>1992</year><volume>5</volume><fpage>328</fpage><lpage>342</lpage><pub-id pub-id-type="doi">10.1128/CMR.5.3.328</pub-id><pub-id pub-id-type="pmid">1498769</pub-id>
</element-citation></ref><ref id="B20-vaccines-12-01319"><label>20.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Roland</surname><given-names>K.L.</given-names></name>
<name><surname>Kong</surname><given-names>Q.</given-names></name>
<name><surname>Jiang</surname><given-names>Y.</given-names></name>
</person-group><article-title>Attenuated <italic toggle="yes">Salmonella</italic> for Oral Immunization</article-title><source>Mucosal Vaccines: Innovation for Preventing Infectious Diseases</source><person-group person-group-type="editor">
<name><surname>Kiyono</surname><given-names>H.</given-names></name>
<name><surname>Pascual</surname><given-names>D.W.</given-names></name>
</person-group><publisher-name>Academic Press</publisher-name><publisher-loc>Cambridge, MA, USA</publisher-loc><year>2020</year><fpage>383</fpage><lpage>399</lpage><pub-id pub-id-type="doi">10.1016/B978-0-12-811924-2.00022-5</pub-id><isbn>9780128119242</isbn></element-citation></ref><ref id="B21-vaccines-12-01319"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Shin</surname><given-names>H.</given-names></name>
<name><surname>La</surname><given-names>T.M.</given-names></name>
<name><surname>Lee</surname><given-names>H.J.</given-names></name>
<name><surname>Kim</surname><given-names>T.</given-names></name>
<name><surname>Song</surname><given-names>S.U.U.</given-names></name>
<name><surname>Park</surname><given-names>E.</given-names></name>
<name><surname>Park</surname><given-names>G.H.</given-names></name>
<name><surname>Choi</surname><given-names>I.S.</given-names></name>
<name><surname>Park</surname><given-names>S.Y.</given-names></name>
<name><surname>Lee</surname><given-names>J.B.</given-names></name>
<etal/>
</person-group><article-title>Evaluation of Immune Responses and Protective Efficacy of a Novel Live Attenuated <italic toggle="yes">Salmonella enteritidis</italic> Vaccine Candidate in Chickens</article-title><source>Vaccines</source><year>2022</year><volume>10</volume><elocation-id>1405</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines10091405</pub-id><pub-id pub-id-type="pmid">36146484</pub-id>
</element-citation></ref><ref id="B22-vaccines-12-01319"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cong</surname><given-names>H.</given-names></name>
<name><surname>Yuan</surname><given-names>Q.</given-names></name>
<name><surname>Zhao</surname><given-names>Q.</given-names></name>
<name><surname>Zhao</surname><given-names>L.</given-names></name>
<name><surname>Yin</surname><given-names>H.</given-names></name>
<name><surname>Zhou</surname><given-names>H.</given-names></name>
<name><surname>He</surname><given-names>S.</given-names></name>
<name><surname>Wang</surname><given-names>Z.</given-names></name>
</person-group><article-title>Comparative Efficacy of a Multi-Epitope DNA Vaccine via Intranasal, Peroral, and Intramuscular Delivery against Lethal <italic toggle="yes">Toxoplasma gondii</italic> Infection in Mice</article-title><source>Parasit Vectors</source><year>2014</year><volume>7</volume><fpage>145</fpage><pub-id pub-id-type="doi">10.1186/1756-3305-7-145</pub-id><pub-id pub-id-type="pmid">24685150</pub-id>
</element-citation></ref><ref id="B23-vaccines-12-01319"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hajam</surname><given-names>I.A.</given-names></name>
<name><surname>Kim</surname><given-names>J.</given-names></name>
<name><surname>Lee</surname><given-names>J.H.</given-names></name>
</person-group><article-title>Oral Immunization with a Novel Attenuated <italic toggle="yes">Salmonella</italic> Gallinarum Encoding Infectious Bronchitis Virus Spike Protein Induces Protective Immune Responses against Fowl Typhoid and Infectious Bronchitis in Chickens</article-title><source>Vet. Res.</source><year>2018</year><volume>49</volume><fpage>91</fpage><pub-id pub-id-type="doi">10.1186/s13567-018-0588-9</pub-id><pub-id pub-id-type="pmid">30208963</pub-id>
</element-citation></ref><ref id="B24-vaccines-12-01319"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Leya</surname><given-names>M.</given-names></name>
<name><surname>Kim</surname><given-names>W.K.</given-names></name>
<name><surname>Cho</surname><given-names>J.S.</given-names></name>
<name><surname>Yu</surname><given-names>E.C.</given-names></name>
<name><surname>Kim</surname><given-names>Y.J.</given-names></name>
<name><surname>Yeo</surname><given-names>Y.</given-names></name>
<name><surname>Lyoo</surname><given-names>K.S.</given-names></name>
<name><surname>Yang</surname><given-names>M.S.</given-names></name>
<name><surname>Han</surname><given-names>S.S.</given-names></name>
<name><surname>Lee</surname><given-names>J.H.</given-names></name>
<etal/>
</person-group><article-title>Vaccination of Goats with a Combination <italic toggle="yes">Salmonella</italic> Vector Expressing Four <italic toggle="yes">Brucella</italic> Antigens (BLS, PrpA, Omp19, and SOD) Confers Protection against <italic toggle="yes">Brucella abortus</italic> Infection</article-title><source>J. Vet. Sci.</source><year>2018</year><volume>19</volume><fpage>643</fpage><lpage>652</lpage><pub-id pub-id-type="doi">10.4142/jvs.2018.19.5.643</pub-id><pub-id pub-id-type="pmid">29929362</pub-id>
</element-citation></ref><ref id="B25-vaccines-12-01319"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lyimu</surname><given-names>W.M.</given-names></name>
<name><surname>Leta</surname><given-names>S.</given-names></name>
<name><surname>Everaert</surname><given-names>N.</given-names></name>
<name><surname>Paeshuyse</surname><given-names>J.</given-names></name>
</person-group><article-title>Influence of Live Attenuated <italic toggle="yes">Salmonella</italic> Vaccines on Cecal Microbiome Composition and Microbiota Abundances in Young Broiler Chickens</article-title><source>Vaccines</source><year>2023</year><volume>11</volume><elocation-id>1116</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines11061116</pub-id><pub-id pub-id-type="pmid">37376505</pub-id>
</element-citation></ref><ref id="B26-vaccines-12-01319"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Peeters</surname><given-names>L.</given-names></name>
<name><surname>Dewulf</surname><given-names>J.</given-names></name>
<name><surname>Boyen</surname><given-names>F.</given-names></name>
<name><surname>Bross&#x000e9;</surname><given-names>C.</given-names></name>
<name><surname>Vandersmissen</surname><given-names>T.</given-names></name>
<name><surname>Rasschaert</surname><given-names>G.</given-names></name>
<name><surname>Heyndrickx</surname><given-names>M.</given-names></name>
<name><surname>Cargnel</surname><given-names>M.</given-names></name>
<name><surname>Mattheus</surname><given-names>W.</given-names></name>
<name><surname>Pasmans</surname><given-names>F.</given-names></name>
<etal/>
</person-group><article-title>Bacteriological Evaluation of Vaccination against <italic toggle="yes">Salmonella</italic> Typhimurium with an Attenuated Vaccine in Subclinically Infected Pig Herds</article-title><source>Prev. Vet. Med.</source><year>2020</year><volume>182</volume><fpage>104687</fpage><pub-id pub-id-type="doi">10.1016/j.prevetmed.2019.04.016</pub-id><pub-id pub-id-type="pmid">31126632</pub-id>
</element-citation></ref><ref id="B27-vaccines-12-01319"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Won</surname><given-names>G.</given-names></name>
<name><surname>Lee</surname><given-names>J.H.</given-names></name>
</person-group><article-title>F18+ <italic toggle="yes">Escherichia coli</italic> Flagellin Expression in <italic toggle="yes">Salmonella</italic> Has Immunoadjuvant Effects in a Ghost Vaccine Candidate Containing <italic toggle="yes">E. coli</italic> Stx2eB, FedF and FedA against Porcine Edema Disease</article-title><source>Comp. Immunol. Microbiol. Infect. Dis.</source><year>2018</year><volume>58</volume><fpage>44</fpage><lpage>51</lpage><pub-id pub-id-type="doi">10.1016/j.cimid.2018.08.003</pub-id><pub-id pub-id-type="pmid">30245050</pub-id>
</element-citation></ref><ref id="B28-vaccines-12-01319"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Li</surname><given-names>Y.A.</given-names></name>
<name><surname>Ji</surname><given-names>Z.</given-names></name>
<name><surname>Wang</surname><given-names>X.</given-names></name>
<name><surname>Wang</surname><given-names>S.</given-names></name>
<name><surname>Shi</surname><given-names>H.</given-names></name>
</person-group><article-title><italic toggle="yes">Salmonella enterica</italic> Serovar Choleraesuis Vector Delivering SaoA Antigen Confers Protection against <italic toggle="yes">Streptococcus suis</italic> Serotypes 2 and 7 in Mice and Pigs</article-title><source>Vet. Res.</source><year>2017</year><volume>48</volume><fpage>89</fpage><pub-id pub-id-type="doi">10.1186/s13567-017-0494-6</pub-id><pub-id pub-id-type="pmid">29268787</pub-id>
</element-citation></ref><ref id="B29-vaccines-12-01319"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kim</surname><given-names>W.K.</given-names></name>
<name><surname>Moon</surname><given-names>J.Y.</given-names></name>
<name><surname>Kim</surname><given-names>S.</given-names></name>
<name><surname>Hur</surname><given-names>J.</given-names></name>
</person-group><article-title>Comparison between Immunization Routes of Live Attenuated <italic toggle="yes">Salmonella</italic> Typhimurium Strains Expressing BCSP31, Omp3b, and SOD of <italic toggle="yes">Brucella abortus</italic> in Murine Model</article-title><source>Front. Microbiol.</source><year>2016</year><volume>7</volume><elocation-id>550</elocation-id><pub-id pub-id-type="doi">10.3389/fmicb.2016.00550</pub-id><pub-id pub-id-type="pmid">27148232</pub-id>
</element-citation></ref><ref id="B30-vaccines-12-01319"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hajam</surname><given-names>I.A.</given-names></name>
<name><surname>Lee</surname><given-names>J.H.</given-names></name>
</person-group><article-title>Preexisting <italic toggle="yes">Salmonella</italic>-Specific Immunity Interferes with the Subsequent Development of Immune Responses against the <italic toggle="yes">Salmonella</italic> Strains Delivering H9N2 Hemagglutinin</article-title><source>Vet. Microbiol.</source><year>2017</year><volume>205</volume><fpage>117</fpage><lpage>123</lpage><pub-id pub-id-type="doi">10.1016/j.vetmic.2017.05.021</pub-id><pub-id pub-id-type="pmid">28622853</pub-id>
</element-citation></ref><ref id="B31-vaccines-12-01319"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pompa-Mera</surname><given-names>E.N.</given-names></name>
<name><surname>Y&#x000e9;pez-Mulia</surname><given-names>L.</given-names></name>
<name><surname>Oca&#x000f1;a-Mondrag&#x000f3;n</surname><given-names>A.</given-names></name>
<name><surname>Garc&#x000ed;a-Zepeda</surname><given-names>E.A.</given-names></name>
<name><surname>Ortega-Pierres</surname><given-names>G.</given-names></name>
<name><surname>Gonz&#x000e1;lez-Bonilla</surname><given-names>C.R.</given-names></name>
</person-group><article-title><italic toggle="yes">Trichinella spiralis</italic>: Intranasal Immunization with Attenuated <italic toggle="yes">Salmonella enterica</italic> Carrying a Gp43 Antigen-Derived 30mer Epitope Elicits Protection in BALB/c Mice</article-title><source>Exp. Parasitol.</source><year>2011</year><volume>129</volume><fpage>393</fpage><lpage>401</lpage><pub-id pub-id-type="doi">10.1016/j.exppara.2011.08.013</pub-id><pub-id pub-id-type="pmid">21907709</pub-id>
</element-citation></ref><ref id="B32-vaccines-12-01319"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Huang</surname><given-names>L.Y.</given-names></name>
<name><surname>Wang</surname><given-names>K.Y.</given-names></name>
<name><surname>Xiao</surname><given-names>D.</given-names></name>
<name><surname>Chen</surname><given-names>D.F.</given-names></name>
<name><surname>Geng</surname><given-names>Y.</given-names></name>
<name><surname>Wang</surname><given-names>J.</given-names></name>
<name><surname>He</surname><given-names>Y.</given-names></name>
<name><surname>Wang</surname><given-names>E.L.</given-names></name>
<name><surname>Huang</surname><given-names>J.L.</given-names></name>
<name><surname>Xiao</surname><given-names>G.Y.</given-names></name>
</person-group><article-title>Safety and Immunogenicity of an Oral DNA Vaccine Encoding Sip of <italic toggle="yes">Streptococcus agalactiae</italic> from Nile Tilapia <italic toggle="yes">Oreochromis niloticus</italic> Delivered by Live Attenuated <italic toggle="yes">Salmonella</italic> Typhimurium</article-title><source>Fish Shellfish Immunol.</source><year>2014</year><volume>38</volume><fpage>34</fpage><lpage>41</lpage><pub-id pub-id-type="doi">10.1016/j.fsi.2014.02.017</pub-id><pub-id pub-id-type="pmid">24631734</pub-id>
</element-citation></ref><ref id="B33-vaccines-12-01319"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wang</surname><given-names>S.</given-names></name>
<name><surname>Hofacre</surname><given-names>C.L.</given-names></name>
<name><surname>Wanda</surname><given-names>S.Y.</given-names></name>
<name><surname>Zhou</surname><given-names>J.</given-names></name>
<name><surname>Callum</surname><given-names>R.A.</given-names></name>
<name><surname>Nordgren</surname><given-names>B.</given-names></name>
<name><surname>Curtiss</surname><given-names>R.</given-names></name>
</person-group><article-title>A Triple-Sugar Regulated <italic toggle="yes">Salmonella</italic> Vaccine Protects against <italic toggle="yes">Clostridium perfringens</italic>-Induced Necrotic Enteritis in Broiler Chickens</article-title><source>Poult. Sci.</source><year>2022</year><volume>101</volume><fpage>101592</fpage><pub-id pub-id-type="doi">10.1016/j.psj.2021.101592</pub-id><pub-id pub-id-type="pmid">34922043</pub-id>
</element-citation></ref><ref id="B34-vaccines-12-01319"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mizuno</surname><given-names>T.</given-names></name>
<name><surname>Mclennan</surname><given-names>M.</given-names></name>
<name><surname>Trott</surname><given-names>D.</given-names></name>
</person-group><article-title>Intramuscular Vaccination of Young Calves with a <italic toggle="yes">Salmonella</italic> Dublin Metabolic-Drift Mutant Provides Superior Protection to Oral Delivery</article-title><source>Vet. Res.</source><year>2008</year><volume>39</volume><fpage>26</fpage><pub-id pub-id-type="doi">10.1051/vetres:2008001</pub-id><pub-id pub-id-type="pmid">18275802</pub-id>
</element-citation></ref><ref id="B35-vaccines-12-01319"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Curtiss</surname><given-names>R.</given-names></name>
</person-group><article-title>Vaccines to Control <italic toggle="yes">Salmonella</italic> in Poultry</article-title><source>Avian Dis.</source><year>2023</year><volume>67</volume><fpage>427</fpage><lpage>440</lpage><pub-id pub-id-type="doi">10.1637/aviandiseases-D-23-99988</pub-id><pub-id pub-id-type="pmid">38300661</pub-id>
</element-citation></ref><ref id="B36-vaccines-12-01319"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chatfield Roberts</surname><given-names>S.M.</given-names></name>
<name><surname>Cropley</surname><given-names>I.</given-names></name>
<name><surname>Douce</surname><given-names>G.</given-names></name>
<name><surname>Dougan</surname><given-names>G.</given-names></name>
</person-group><article-title>The Development of Oral Vaccines Based on Live Attenuated <italic toggle="yes">Salmonella</italic> Strains</article-title><source>FEMS Immunol. Med. Microbiol.</source><year>1993</year><volume>7</volume><fpage>1</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1111/j.1574-695X.1993.tb00374.x</pub-id><pub-id pub-id-type="pmid">8364518</pub-id>
</element-citation></ref><ref id="B37-vaccines-12-01319"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Desin</surname><given-names>T.S.</given-names></name>
<name><surname>K&#x000f6;ster</surname><given-names>W.</given-names></name>
<name><surname>Potter</surname><given-names>A.A.</given-names></name>
</person-group><article-title><italic toggle="yes">Salmonella</italic> Vaccines in Poultry: Past, Present and Future</article-title><source>Expert. Rev. Vaccines</source><year>2013</year><volume>12</volume><fpage>87</fpage><lpage>96</lpage><pub-id pub-id-type="doi">10.1586/erv.12.138</pub-id><pub-id pub-id-type="pmid">23256741</pub-id>
</element-citation></ref><ref id="B38-vaccines-12-01319"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bearson</surname><given-names>S.M.D.</given-names></name>
</person-group><article-title><italic toggle="yes">Salmonella</italic> in Swine: Prevalence, Multidrug Resistance, and Vaccination Strategies</article-title><source>Annu. Rev. Anim. Biosci.</source><year>2021</year><volume>10</volume><fpage>373</fpage><lpage>393</lpage><pub-id pub-id-type="doi">10.1146/annurev-animal-013120-043304</pub-id><pub-id pub-id-type="pmid">34699256</pub-id>
</element-citation></ref><ref id="B39-vaccines-12-01319"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jia</surname><given-names>S.</given-names></name>
<name><surname>McWhorter</surname><given-names>A.R.</given-names></name>
<name><surname>Andrews</surname><given-names>D.M.</given-names></name>
<name><surname>Underwood</surname><given-names>G.J.</given-names></name>
<name><surname>Chousalkar</surname><given-names>K.K.</given-names></name>
</person-group><article-title>Challenges in Vaccinating Layer Hens against <italic toggle="yes">Salmonella</italic> Typhimurium</article-title><source>Vaccines</source><year>2020</year><volume>8</volume><elocation-id>696</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines8040696</pub-id><pub-id pub-id-type="pmid">33228065</pub-id>
</element-citation></ref><ref id="B40-vaccines-12-01319"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>De Ridder</surname><given-names>L.</given-names></name>
<name><surname>Maes</surname><given-names>D.</given-names></name>
<name><surname>Dewulf</surname><given-names>J.</given-names></name>
<name><surname>Butaye</surname><given-names>P.</given-names></name>
<name><surname>Pasmans</surname><given-names>F.</given-names></name>
<name><surname>Boyen</surname><given-names>F.</given-names></name>
<name><surname>Haesebrouck</surname><given-names>F.</given-names></name>
<name><surname>Van der Stede</surname><given-names>Y.</given-names></name>
</person-group><article-title>Use of a Live Attenuated <italic toggle="yes">Salmonella enterica</italic> Serovar Typhimurium Vaccine on Farrow-to-Finish Pig Farms</article-title><source>Vet. J.</source><year>2014</year><volume>202</volume><fpage>303</fpage><lpage>308</lpage><pub-id pub-id-type="doi">10.1016/j.tvjl.2014.09.012</pub-id><pub-id pub-id-type="pmid">25278382</pub-id>
</element-citation></ref><ref id="B41-vaccines-12-01319"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Theu&#x000df;</surname><given-names>T.</given-names></name>
<name><surname>Ueberham</surname><given-names>E.</given-names></name>
<name><surname>Lehmann</surname><given-names>J.</given-names></name>
<name><surname>Lindner</surname><given-names>T.</given-names></name>
<name><surname>Springer</surname><given-names>S.</given-names></name>
</person-group><article-title>Immunogenic Potential of a <italic toggle="yes">Salmonella</italic> Typhimurium Live Vaccine for Pigs against Monophasic <italic toggle="yes">Salmonella</italic> Typhimurium DT 193</article-title><source>BMC Vet. Res.</source><year>2017</year><volume>13</volume><elocation-id>343</elocation-id><pub-id pub-id-type="doi">10.1186/s12917-017-1271-5</pub-id><pub-id pub-id-type="pmid">29149900</pub-id>
</element-citation></ref><ref id="B42-vaccines-12-01319"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Smith</surname><given-names>R.P.</given-names></name>
<name><surname>Andres</surname><given-names>V.</given-names></name>
<name><surname>Martelli</surname><given-names>F.</given-names></name>
<name><surname>Gosling</surname><given-names>B.</given-names></name>
<name><surname>Marco-Jimenez</surname><given-names>F.</given-names></name>
<name><surname>Vaughan</surname><given-names>K.</given-names></name>
<name><surname>Tchorzewska</surname><given-names>M.</given-names></name>
<name><surname>Davies</surname><given-names>R.</given-names></name>
</person-group><article-title>Maternal Vaccination as a <italic toggle="yes">Salmonella</italic> Typhimurium Reduction Strategy on Pig Farms</article-title><source>J. Appl. Microbiol.</source><year>2018</year><volume>124</volume><fpage>274</fpage><lpage>285</lpage><pub-id pub-id-type="doi">10.1111/jam.13609</pub-id><pub-id pub-id-type="pmid">29024207</pub-id>
</element-citation></ref><ref id="B43-vaccines-12-01319"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hegazy</surname><given-names>W.A.H.</given-names></name>
<name><surname>Hensel</surname><given-names>M.</given-names></name>
</person-group><article-title><italic toggle="yes">Salmonella enterica</italic> as a Vaccine Carrier</article-title><source>Future Microbiol.</source><year>2012</year><volume>7</volume><fpage>111</fpage><lpage>127</lpage><pub-id pub-id-type="doi">10.2217/fmb.11.144</pub-id><pub-id pub-id-type="pmid">22191450</pub-id>
</element-citation></ref><ref id="B44-vaccines-12-01319"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nakayama</surname><given-names>K.</given-names></name>
<name><surname>Kelly</surname><given-names>S.M.</given-names></name>
<name><surname>Curtiss III</surname><given-names>R.</given-names></name>
</person-group><article-title>Construction of an ASD+ Expression-Cloning Vector: Stable Maintenance and High Level Expression of Cloned Genes in a <italic toggle="yes">Salmonella</italic> Vaccine Strain</article-title><source>Nature</source><year>1988</year><volume>6</volume><fpage>693</fpage><lpage>697</lpage><pub-id pub-id-type="doi">10.1038/nbt0688-693</pub-id></element-citation></ref><ref id="B45-vaccines-12-01319"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Roland</surname><given-names>K.L.</given-names></name>
<name><surname>Brenneman</surname><given-names>K.E.</given-names></name>
</person-group><article-title><italic toggle="yes">Salmonella</italic> as a Vaccine Delivery Vehicle</article-title><source>Expert. Rev. Vaccines</source><year>2013</year><volume>12</volume><fpage>1033</fpage><lpage>1045</lpage><pub-id pub-id-type="doi">10.1586/14760584.2013.825454</pub-id><pub-id pub-id-type="pmid">24053397</pub-id>
</element-citation></ref><ref id="B46-vaccines-12-01319"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Collins</surname><given-names>L.V.</given-names></name>
<name><surname>A1vrridge</surname><given-names>S.</given-names></name>
<name><surname>Hackettt</surname><given-names>J.</given-names></name>
</person-group><article-title>Mutations at Rfc or Pmi Attenuate <italic toggle="yes">Salmonella</italic> Typhimurium Virulence for Mice</article-title><source>Infect. Immun.</source><year>1991</year><volume>59</volume><fpage>1079</fpage><lpage>1085</lpage><pub-id pub-id-type="doi">10.1128/iai.59.3.1079-1085.1991</pub-id><pub-id pub-id-type="pmid">1997412</pub-id>
</element-citation></ref><ref id="B47-vaccines-12-01319"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Curtiss Iii</surname><given-names>R.</given-names></name>
<name><surname>Xin</surname><given-names>W.</given-names></name>
<name><surname>Li</surname><given-names>Y.</given-names></name>
<name><surname>Kong</surname><given-names>W.</given-names></name>
<name><surname>Wanda</surname><given-names>S.-Y.</given-names></name>
<name><surname>Gunn</surname><given-names>B.</given-names></name>
<name><surname>Wang</surname><given-names>S.</given-names></name>
</person-group><article-title>New Technologies in Using Recombinant Attenuated <italic toggle="yes">Salmonella</italic> Vaccine Vectors</article-title><source>Crit. Rev. Immunol.</source><year>2010</year><volume>30</volume><fpage>255</fpage><lpage>270</lpage><pub-id pub-id-type="doi">10.1615/CritRevImmunol.v30.i3.30</pub-id><pub-id pub-id-type="pmid">20370633</pub-id>
</element-citation></ref><ref id="B48-vaccines-12-01319"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chabalgoity</surname><given-names>J.A.</given-names></name>
<name><surname>Moreno</surname><given-names>M.</given-names></name>
<name><surname>Carol</surname><given-names>H.</given-names></name>
<name><surname>Dougan</surname><given-names>G.</given-names></name>
<name><surname>Hormaeche</surname><given-names>C.E.</given-names></name>
</person-group><article-title><italic toggle="yes">Salmonella</italic> Typhimurium as a Basis for a Live Oral <italic toggle="yes">Echinococcus granulosus</italic> Vaccine</article-title><source>Vaccine</source><year>2000</year><volume>19</volume><fpage>460</fpage><lpage>469</lpage><pub-id pub-id-type="doi">10.1016/S0264-410X(00)00197-3</pub-id><pub-id pub-id-type="pmid">11027809</pub-id>
</element-citation></ref><ref id="B49-vaccines-12-01319"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chatfield</surname><given-names>S.N.</given-names></name>
<name><surname>Charles</surname><given-names>I.G.</given-names></name>
<name><surname>Makoff</surname><given-names>A.J.</given-names></name>
<name><surname>Oxer</surname><given-names>M.D.</given-names></name>
<name><surname>Dougan</surname><given-names>G.</given-names></name>
<name><surname>Pickard</surname><given-names>D.</given-names></name>
<name><surname>Slater</surname><given-names>D.</given-names></name>
<name><surname>Fairweather</surname><given-names>N.F.</given-names></name>
</person-group><article-title>Use of the NirB Promoter to Direct the Stable Expression of Heterelogous Antigens in <italic toggle="yes">Salmonella</italic> Oral Vaccine Strains: Development of a Single-Dose Oral Tetanus Vaccine</article-title><source>Nature</source><year>1992</year><volume>10</volume><fpage>888</fpage><lpage>892</lpage><pub-id pub-id-type="doi">10.1038/nbt0892-888</pub-id></element-citation></ref><ref id="B50-vaccines-12-01319"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Baud</surname><given-names>D.</given-names></name>
<name><surname>Ponci</surname><given-names>F.</given-names></name>
<name><surname>Bobst</surname><given-names>M.</given-names></name>
<name><surname>De Grandi</surname><given-names>P.</given-names></name>
<name><surname>Nardelli-Haefliger</surname><given-names>D.</given-names></name>
</person-group><article-title>Improved Efficiency of a <italic toggle="yes">Salmonella</italic>-Based Vaccine against Human Papillomavirus Type 16 Virus-Like Particles Achieved by Using a Codon-Optimized Version of L1</article-title><source>J. Virol.</source><year>2004</year><volume>78</volume><fpage>12901</fpage><lpage>12909</lpage><pub-id pub-id-type="doi">10.1128/JVI.78.23.12901-12909.2004</pub-id><pub-id pub-id-type="pmid">15542642</pub-id>
</element-citation></ref><ref id="B51-vaccines-12-01319"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhou</surname><given-names>G.</given-names></name>
<name><surname>Zhao</surname><given-names>Y.</given-names></name>
<name><surname>Ma</surname><given-names>Q.</given-names></name>
<name><surname>Li</surname><given-names>Q.</given-names></name>
<name><surname>Wang</surname><given-names>S.</given-names></name>
<name><surname>Shi</surname><given-names>H.</given-names></name>
</person-group><article-title>Manipulation of Host Immune Defenses by Effector Proteins Delivered from Multiple Secretion Systems of <italic toggle="yes">Salmonella</italic> and Its Application in Vaccine Research</article-title><source>Front. Immunol.</source><year>2023</year><volume>14</volume><elocation-id>1152017</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2023.1152017</pub-id><pub-id pub-id-type="pmid">37081875</pub-id>
</element-citation></ref><ref id="B52-vaccines-12-01319"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lou</surname><given-names>L.</given-names></name>
<name><surname>Zhang</surname><given-names>P.</given-names></name>
<name><surname>Piao</surname><given-names>R.</given-names></name>
<name><surname>Wang</surname><given-names>Y.</given-names></name>
</person-group><article-title><italic toggle="yes">Salmonella</italic> Pathogenicity Island 1 (SPI-1) and Its Complex Regulatory Network</article-title><source>Front. Cell. Infect. Microbiol.</source><year>2019</year><volume>9</volume><elocation-id>270</elocation-id><pub-id pub-id-type="doi">10.3389/fcimb.2019.00270</pub-id><pub-id pub-id-type="pmid">31428589</pub-id>
</element-citation></ref><ref id="B53-vaccines-12-01319"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Malik-Kale</surname><given-names>P.</given-names></name>
<name><surname>Jolly</surname><given-names>C.E.</given-names></name>
<name><surname>Lathrop</surname><given-names>S.</given-names></name>
<name><surname>Winfree</surname><given-names>S.</given-names></name>
<name><surname>Luterbach</surname><given-names>C.</given-names></name>
<name><surname>Steele-Mortimer</surname><given-names>O.</given-names></name>
</person-group><article-title><italic toggle="yes">Salmonella</italic>- at Home in the Host Cell</article-title><source>Front. Microbiol.</source><year>2011</year><volume>2</volume><elocation-id>125</elocation-id><pub-id pub-id-type="doi">10.3389/fmicb.2011.00125</pub-id><pub-id pub-id-type="pmid">21687432</pub-id>
</element-citation></ref><ref id="B54-vaccines-12-01319"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Waterman</surname><given-names>R.</given-names></name>
<name><surname>Holden</surname><given-names>D.W.</given-names></name>
<name><surname>Waterman</surname><given-names>S.R.</given-names></name>
<name><surname>Holden</surname><given-names>D.W.</given-names></name>
</person-group><article-title>Pathogenicity Island 2 Type III Secretion SystemS Functions and Effectors of the Salmonella Pathogenicity Island 2 Type III Secretion System</article-title><source>Cell. Microbiol.</source><year>2003</year><volume>5</volume><fpage>501</fpage><lpage>511</lpage><pub-id pub-id-type="doi">10.1046/j.1462-5822.2003.00294.x</pub-id><pub-id pub-id-type="pmid">12864810</pub-id>
</element-citation></ref><ref id="B55-vaccines-12-01319"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Samakchan</surname><given-names>N.</given-names></name>
<name><surname>Thinwang</surname><given-names>P.</given-names></name>
<name><surname>Boonyom</surname><given-names>R.</given-names></name>
</person-group><article-title>Oral Immunization of Rat with Chromosomal Expression Lipl32 in Attenuated <italic toggle="yes">Salmonella</italic> Vaccine Induces Immune Respond against Pathogenic <italic toggle="yes">Leptospira</italic></article-title><source>Clin. Exp. Vaccine Res.</source><year>2021</year><volume>10</volume><fpage>217</fpage><lpage>228</lpage><pub-id pub-id-type="doi">10.7774/cevr.2021.10.3.217</pub-id><pub-id pub-id-type="pmid">34703804</pub-id>
</element-citation></ref><ref id="B56-vaccines-12-01319"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hurley</surname><given-names>D.</given-names></name>
<name><surname>McCusker</surname><given-names>M.P.</given-names></name>
<name><surname>Fanning</surname><given-names>S.</given-names></name>
<name><surname>Martins</surname><given-names>M.</given-names></name>
</person-group><article-title><italic toggle="yes">Salmonella</italic>-Host Interactions&#x02014;Modulation of the Host Innate Immune System</article-title><source>Front. Immunol.</source><year>2014</year><volume>5</volume><elocation-id>481</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2014.00481</pub-id><pub-id pub-id-type="pmid">25339955</pub-id>
</element-citation></ref><ref id="B57-vaccines-12-01319"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sirard</surname><given-names>J.-C.</given-names></name>
<name><surname>Niedergang</surname><given-names>F.</given-names></name>
<name><surname>Kraehenbuhl</surname><given-names>P.</given-names></name>
<name><surname>Sirurd</surname><given-names>J.-C.</given-names></name>
<name><surname>Kruehenbuhi</surname><given-names>J.-P.</given-names></name>
<name><surname>Sirard</surname><given-names>J.-C.</given-names></name>
</person-group><article-title>Live Attenuated <italic toggle="yes">Salmonella</italic>: A Paradigm of Mucosal Vaccines Immunological Reviews</article-title><source>Immunol. Rev.</source><year>1999</year><volume>171</volume><fpage>5</fpage><lpage>26</lpage><pub-id pub-id-type="doi">10.1111/j.1600-065X.1999.tb01340.x</pub-id><pub-id pub-id-type="pmid">10582163</pub-id>
</element-citation></ref><ref id="B58-vaccines-12-01319"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kawai</surname><given-names>T.</given-names></name>
<name><surname>Akira</surname><given-names>S.</given-names></name>
</person-group><article-title>The Role of Pattern-Recognition Receptors in Innate Immunity: Update on Toll-like Receptors</article-title><source>Nat. Immunol.</source><year>2010</year><volume>11</volume><fpage>373</fpage><lpage>384</lpage><pub-id pub-id-type="doi">10.1038/ni.1863</pub-id><pub-id pub-id-type="pmid">20404851</pub-id>
</element-citation></ref><ref id="B59-vaccines-12-01319"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Monack</surname><given-names>D.M.</given-names></name>
<name><surname>Bouley</surname><given-names>D.M.</given-names></name>
<name><surname>Falkow</surname><given-names>S.</given-names></name>
</person-group><article-title><italic toggle="yes">Salmonella</italic> Typhimurium Persists within Macrophages in the Mesenteric Lymph Nodes of Chronically Infected Nramp1+/+ Mice and Can Be Reactivated by IFN&#x003b3; Neutralization</article-title><source>J. Exp. Med.</source><year>2004</year><volume>199</volume><fpage>231</fpage><lpage>241</lpage><pub-id pub-id-type="doi">10.1084/jem.20031319</pub-id><pub-id pub-id-type="pmid">14734525</pub-id>
</element-citation></ref><ref id="B60-vaccines-12-01319"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mastroeni</surname><given-names>P.</given-names></name>
<name><surname>Chabalgoity</surname><given-names>J.A.</given-names></name>
<name><surname>Dunstan</surname><given-names>S.J.</given-names></name>
<name><surname>Maskell</surname><given-names>D.J.</given-names></name>
<name><surname>Dougan</surname><given-names>G.</given-names></name>
</person-group><article-title><italic toggle="yes">Salmonella</italic>: Immune Responses and Vaccines</article-title><source>Vet. J.</source><year>2001</year><volume>161</volume><fpage>132</fpage><lpage>164</lpage><pub-id pub-id-type="doi">10.1053/tvjl.2000.0502</pub-id><pub-id pub-id-type="pmid">11243685</pub-id>
</element-citation></ref><ref id="B61-vaccines-12-01319"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hur</surname><given-names>J.</given-names></name>
<name><surname>Lee</surname><given-names>J.H.</given-names></name>
</person-group><article-title>Protective Efficacy by Various Doses of <italic toggle="yes">Salmonella ghost</italic> Vaccine Carrying Enterotoxigenic <italic toggle="yes">Escherichia coli</italic> Fimbrial antigen against Neonatal Piglet Colibacillosis</article-title><source>Can. J. Vet. Res.</source><year>2016</year><volume>80</volume><fpage>245</fpage><lpage>249</lpage><pub-id pub-id-type="pmid">27408340</pub-id>
</element-citation></ref><ref id="B62-vaccines-12-01319"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tennant</surname><given-names>S.M.</given-names></name>
<name><surname>Levine</surname><given-names>M.M.</given-names></name>
</person-group><article-title>Live Attenuated Vaccines for Invasive <italic toggle="yes">Salmonella</italic> Infections</article-title><source>Vaccine</source><year>2015</year><volume>33</volume><fpage>36</fpage><lpage>41</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2015.04.029</pub-id></element-citation></ref><ref id="B63-vaccines-12-01319"><label>63.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Simpson</surname><given-names>L.</given-names></name>
</person-group><article-title>Vaccination</article-title><source>Primer to the Immune Response</source><publisher-name>Elsevier</publisher-name><publisher-loc>Amsterdam, The Netherlands</publisher-loc><year>2014</year><fpage>333</fpage><lpage>375</lpage><pub-id pub-id-type="doi">10.1016/B978-0-12-385245-8.00014-5</pub-id></element-citation></ref><ref id="B64-vaccines-12-01319"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hur</surname><given-names>J.</given-names></name>
<name><surname>Lee</surname><given-names>J.H.</given-names></name>
</person-group><article-title>Immune Responses to New Vaccine Candidates Constructed by a Live Attenuated <italic toggle="yes">Salmonella</italic> Typhimurium De-Livery System Expressing <italic toggle="yes">Escherichia coli</italic> F4, F5, F6, F41 and Intimin Adhesin Antigens in a Murine Model</article-title><source>J. Vet. Med. Sci</source><year>2011</year><volume>73</volume><fpage>1265</fpage><lpage>1273</lpage><pub-id pub-id-type="doi">10.1292/jvms.11-0087</pub-id><pub-id pub-id-type="pmid">21628866</pub-id>
</element-citation></ref><ref id="B65-vaccines-12-01319"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hur</surname><given-names>J.</given-names></name>
<name><surname>Stein</surname><given-names>B.D.</given-names></name>
<name><surname>Lee</surname><given-names>J.H.</given-names></name>
</person-group><article-title>A Vaccine Candidate for Post-Weaning Diarrhea in Swine Constructed with a Live Attenuated <italic toggle="yes">Salmonella</italic> Deliv-Ering <italic toggle="yes">Escherichia coli</italic> K88ab, K88ac, FedA, and FedF Fimbrial Antigens and Its Immune Responses in a Murine Model</article-title><source>Can. J. Vet. Res.</source><year>2012</year><volume>76</volume><fpage>186</fpage><lpage>194</lpage><pub-id pub-id-type="pmid">23277697</pub-id>
</element-citation></ref><ref id="B66-vaccines-12-01319"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jiang</surname><given-names>Y.</given-names></name>
<name><surname>Kulkarni</surname><given-names>R.R.</given-names></name>
<name><surname>Parreira</surname><given-names>V.R.</given-names></name>
<name><surname>Poppe</surname><given-names>C.</given-names></name>
<name><surname>Roland</surname><given-names>K.L.</given-names></name>
<name><surname>Prescott</surname><given-names>J.F.</given-names></name>
</person-group><article-title>Assessment of 2 <italic toggle="yes">Salmonella enterica</italic> Serovar Typhimurium-Based Vaccines against Necrotic Enteritis in Reducing Colonization of Chickens by <italic toggle="yes">Salmonella</italic> Serovars of Different Serogroups</article-title><source>Can. J. Vet. Res.</source><year>2010</year><volume>74</volume><fpage>264</fpage><lpage>270</lpage><pub-id pub-id-type="pmid">21197226</pub-id>
</element-citation></ref><ref id="B67-vaccines-12-01319"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Liu</surname><given-names>G.</given-names></name>
<name><surname>Li</surname><given-names>C.</given-names></name>
<name><surname>Liao</surname><given-names>S.</given-names></name>
<name><surname>Guo</surname><given-names>A.</given-names></name>
<name><surname>Wu</surname><given-names>B.</given-names></name>
<name><surname>Chen</surname><given-names>H.</given-names></name>
</person-group><article-title>C500 Variants Conveying Complete Mucosal Immunity against Fatal Infections of Pigs with <italic toggle="yes">Salmonella enterica</italic> Serovar Choleraesuis C78-1 or F18+ Shiga Toxin-Producing <italic toggle="yes">Escherichia coli</italic></article-title><source>Front. Microbiol.</source><year>2023</year><volume>14</volume><elocation-id>1210358</elocation-id><pub-id pub-id-type="doi">10.3389/fmicb.2023.1210358</pub-id><pub-id pub-id-type="pmid">37779705</pub-id>
</element-citation></ref><ref id="B68-vaccines-12-01319"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Moustafa</surname><given-names>D.A.</given-names></name>
<name><surname>Scarff</surname><given-names>J.M.</given-names></name>
<name><surname>Garcia</surname><given-names>P.P.</given-names></name>
<name><surname>Cassidy</surname><given-names>S.K.B.</given-names></name>
<name><surname>Di Giandomenico</surname><given-names>A.</given-names></name>
<name><surname>Waag</surname><given-names>D.M.</given-names></name>
<name><surname>Inzana</surname><given-names>T.J.</given-names></name>
<name><surname>Goldberg</surname><given-names>J.B.</given-names></name>
</person-group><article-title>Recombinant <italic toggle="yes">Salmonella</italic> Expressing <italic toggle="yes">Burkholderia mallei</italic> LPS o Antigen Provides Protection in a Murine Model of Melioidosis and Glanders</article-title><source>PLoS ONE</source><year>2015</year><volume>10</volume><elocation-id>e0132032</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0132032</pub-id><pub-id pub-id-type="pmid">26148026</pub-id>
</element-citation></ref><ref id="B69-vaccines-12-01319"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hur</surname><given-names>J.</given-names></name>
<name><surname>Byeon</surname><given-names>H.</given-names></name>
<name><surname>Lee</surname><given-names>H.J.</given-names></name>
</person-group><article-title>Immunologic Study and Optimization of <italic toggle="yes">Salmonella</italic> Delivery Strains Adhesin and Toxin Antigens for Protection against Progressive Rhinitis in a Murine m</article-title><source>Can. J. Vet. Res.</source><year>2014</year><volume>78</volume><fpage>297</fpage><lpage>303</lpage><pub-id pub-id-type="pmid">25355999</pub-id>
</element-citation></ref><ref id="B70-vaccines-12-01319"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hyoung</surname><given-names>K.J.</given-names></name>
<name><surname>Hajam</surname><given-names>I.A.</given-names></name>
<name><surname>Lee</surname><given-names>J.H.</given-names></name>
</person-group><article-title>A Consensus-Hemagglutinin-Based Vaccine Delivered by an Attenuated <italic toggle="yes">Salmonella</italic> Mutant Protects Chickens against Heterologous H7N1 Influenza Virus</article-title><source>Oncotarget</source><year>2017</year><volume>8</volume><fpage>38780</fpage><lpage>38792</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.16353</pub-id><pub-id pub-id-type="pmid">28418904</pub-id>
</element-citation></ref><ref id="B71-vaccines-12-01319"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jiao</surname><given-names>H.</given-names></name>
<name><surname>Pan</surname><given-names>Z.</given-names></name>
<name><surname>Yin</surname><given-names>Y.</given-names></name>
<name><surname>Geng</surname><given-names>S.</given-names></name>
<name><surname>Sun</surname><given-names>L.</given-names></name>
<name><surname>Jiao</surname><given-names>X.</given-names></name>
</person-group><article-title>Oral and Nasal DNA Vaccines Delivered by Attenuated <italic toggle="yes">Salmonella enterica</italic> Serovar Typhimurium Induce a Protective Immune Response against Infectious Bronchitis in Chickens</article-title><source>Clin. Vaccine Immunol.</source><year>2011</year><volume>18</volume><fpage>1041</fpage><lpage>1045</lpage><pub-id pub-id-type="doi">10.1128/CVI.00034-11</pub-id><pub-id pub-id-type="pmid">21593235</pub-id>
</element-citation></ref><ref id="B72-vaccines-12-01319"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yang</surname><given-names>H.</given-names></name>
<name><surname>Cao</surname><given-names>S.</given-names></name>
<name><surname>Huang</surname><given-names>X.</given-names></name>
<name><surname>Liu</surname><given-names>J.</given-names></name>
<name><surname>Tang</surname><given-names>Y.</given-names></name>
<name><surname>Wen</surname><given-names>X.</given-names></name>
</person-group><article-title>Intragastric Administration of Attenuated <italic toggle="yes">Salmonella</italic> Typhimurium Harbouring Transmissible Gastroenteritis Virus (TGEV) DNA Vaccine Induced Specific Antibody Production</article-title><source>Vaccine</source><year>2009</year><volume>27</volume><fpage>5035</fpage><lpage>5040</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2009.06.050</pub-id><pub-id pub-id-type="pmid">19573642</pub-id>
</element-citation></ref><ref id="B73-vaccines-12-01319"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cong</surname><given-names>H.</given-names></name>
<name><surname>Gu</surname><given-names>Q.M.</given-names></name>
<name><surname>Jiang</surname><given-names>Y.</given-names></name>
<name><surname>He</surname><given-names>S.Y.</given-names></name>
<name><surname>Zhou</surname><given-names>H.Y.</given-names></name>
<name><surname>Yang</surname><given-names>T.T.</given-names></name>
<name><surname>Li</surname><given-names>Y.</given-names></name>
<name><surname>Zhao</surname><given-names>Q.L.</given-names></name>
</person-group><article-title>Oral Immunization with a Live Recombinant Attenuated <italic toggle="yes">Salmonella</italic> Typhimurium Protects Mice against <italic toggle="yes">Toxoplasma gondii</italic></article-title><source>Parasite Immunol.</source><year>2005</year><volume>27</volume><fpage>29</fpage><lpage>35</lpage><pub-id pub-id-type="doi">10.1111/j.1365-3024.2005.00738.x</pub-id><pub-id pub-id-type="pmid">15813720</pub-id>
</element-citation></ref><ref id="B74-vaccines-12-01319"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Benitez</surname><given-names>A.J.</given-names></name>
<name><surname>McNair</surname><given-names>N.</given-names></name>
<name><surname>Mead</surname><given-names>J.R.</given-names></name>
</person-group><article-title>Oral Immunization with Attenuated <italic toggle="yes">Salmonella</italic> e<italic toggle="yes">nterica</italic> Serovar Typhimurium Encoding <italic toggle="yes">Cryptosporidium parvum</italic> Cp23 and Cp40 Antigens Induces a Specific Immune Response in Mice</article-title><source>Clin. Vaccine Immunol.</source><year>2009</year><volume>16</volume><fpage>1272</fpage><lpage>1278</lpage><pub-id pub-id-type="doi">10.1128/CVI.00089-09</pub-id><pub-id pub-id-type="pmid">19605593</pub-id>
</element-citation></ref><ref id="B75-vaccines-12-01319"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>M.</given-names></name>
<name><surname>Sun</surname><given-names>C.</given-names></name>
<name><surname>Gu</surname><given-names>J.</given-names></name>
<name><surname>Yan</surname><given-names>X.</given-names></name>
<name><surname>Wang</surname><given-names>B.</given-names></name>
<name><surname>Cui</surname><given-names>Z.</given-names></name>
<name><surname>Sun</surname><given-names>X.</given-names></name>
<name><surname>Tong</surname><given-names>C.</given-names></name>
<name><surname>Feng</surname><given-names>X.</given-names></name>
<name><surname>Lei</surname><given-names>L.</given-names></name>
<etal/>
</person-group><article-title><italic toggle="yes">Salmonella</italic> Typhimurium Strain Expressing OprF-OprI Protects Mice against Fatal Infection by <italic toggle="yes">Pseudomonas aeruginosa</italic></article-title><source>Microbiol. Immunol.</source><year>2015</year><volume>59</volume><fpage>533</fpage><lpage>544</lpage><pub-id pub-id-type="doi">10.1111/1348-0421.12291</pub-id><pub-id pub-id-type="pmid">26249788</pub-id>
</element-citation></ref><ref id="B76-vaccines-12-01319"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Srivastava</surname><given-names>A.</given-names></name>
<name><surname>Gowda</surname><given-names>D.V.</given-names></name>
<name><surname>Madhunapantula</surname><given-names>S.V.</given-names></name>
<name><surname>Shinde</surname><given-names>C.G.</given-names></name>
<name><surname>Iyer</surname><given-names>M.</given-names></name>
</person-group><article-title>Mucosal Vaccines: A Paradigm Shift in the Development of Mucosal Adjuvants and Delivery Vehicles</article-title><source>APMIS</source><year>2015</year><volume>123</volume><fpage>275</fpage><lpage>288</lpage><pub-id pub-id-type="doi">10.1111/apm.12351</pub-id><pub-id pub-id-type="pmid">25630573</pub-id>
</element-citation></ref><ref id="B77-vaccines-12-01319"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lalsiamthara</surname><given-names>J.</given-names></name>
<name><surname>Lee</surname><given-names>J.H.</given-names></name>
</person-group><article-title>Brucella Lipopolysaccharide Reinforced <italic toggle="yes">Salmonella</italic> Delivering <italic toggle="yes">Brucella</italic> Immunogens Protects Mice against Virulent Challenge</article-title><source>Vet. Microbiol.</source><year>2017</year><volume>205</volume><fpage>84</fpage><lpage>91</lpage><pub-id pub-id-type="doi">10.1016/j.vetmic.2017.05.012</pub-id><pub-id pub-id-type="pmid">28622869</pub-id>
</element-citation></ref><ref id="B78-vaccines-12-01319"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fagan</surname><given-names>P.K.</given-names></name>
<name><surname>Djordjevic</surname><given-names>S.P.</given-names></name>
<name><surname>Chin</surname><given-names>J.</given-names></name>
<name><surname>Eamens</surname><given-names>G.J.</given-names></name>
<name><surname>Walker</surname><given-names>M.J.</given-names></name>
</person-group><article-title>Oral Immunization of Mice with Attenuated <italic toggle="yes">Salmonella</italic> Typhimurium AroA Expressing a Recombinant <italic toggle="yes">Mycoplasma hyopneumoniae</italic> Antigen (NrdF)</article-title><source>Infect. Immun.</source><year>1997</year><volume>65</volume><fpage>2502</fpage><lpage>2507</lpage><pub-id pub-id-type="doi">10.1128/iai.65.6.2502-2507.1997</pub-id><pub-id pub-id-type="pmid">9169801</pub-id>
</element-citation></ref><ref id="B79-vaccines-12-01319"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fagan</surname><given-names>P.K.</given-names></name>
<name><surname>Walker</surname><given-names>M.J.</given-names></name>
<name><surname>Chin</surname><given-names>J.</given-names></name>
<name><surname>Eamens</surname><given-names>G.J.</given-names></name>
<name><surname>Djordjevic</surname><given-names>S.P.</given-names></name>
</person-group><article-title>Oral Immunization of Swine with Attenuated <italic toggle="yes">Salmonella</italic> Typhimurium AroA SL3261 Expressing a Recombinant Antigen of <italic toggle="yes">Mycoplasma hyopneumoniae</italic> (NrDF) Primes the Immune System for a NrDF Specific Secretory IgA Response in the Lungs</article-title><source>Microb. Pathog.</source><year>2001</year><volume>30</volume><fpage>101</fpage><lpage>110</lpage><pub-id pub-id-type="doi">10.1006/mpat.2000.0412</pub-id><pub-id pub-id-type="pmid">11162190</pub-id>
</element-citation></ref><ref id="B80-vaccines-12-01319"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chen</surname><given-names>A.Y.</given-names></name>
<name><surname>Fry</surname><given-names>S.R.</given-names></name>
<name><surname>Forbes-Faulkner</surname><given-names>J.</given-names></name>
<name><surname>Daggard</surname><given-names>G.E.</given-names></name>
<name><surname>Mukkur</surname><given-names>T.K.S.</given-names></name>
</person-group><article-title>Comparative Immunogenicity of <italic toggle="yes">M. hyopneumoniae</italic> NrdF Encoded in Different Expression Systems Delivered Orally via Attenuated <italic toggle="yes">S.</italic> Typhimurium AroA in Mice</article-title><source>Vet. Microbiol.</source><year>2006</year><volume>114</volume><fpage>252</fpage><lpage>259</lpage><pub-id pub-id-type="doi">10.1016/j.vetmic.2005.12.009</pub-id><pub-id pub-id-type="pmid">16426773</pub-id>
</element-citation></ref><ref id="B81-vaccines-12-01319"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chen</surname><given-names>A.Y.</given-names></name>
<name><surname>Fry</surname><given-names>S.R.</given-names></name>
<name><surname>Forbes-Faulkner</surname><given-names>J.</given-names></name>
<name><surname>Daggard</surname><given-names>G.</given-names></name>
<name><surname>Mukkur</surname><given-names>T.K.S.</given-names></name>
</person-group><article-title>Evaluation of the Immunogenicity of the P97R1 Adhesin of <italic toggle="yes">Mycoplasma hyopneumoniae</italic> as a Mucosal Vaccine in Mice</article-title><source>J. Med. Microbiol.</source><year>2006</year><volume>55</volume><fpage>923</fpage><lpage>929</lpage><pub-id pub-id-type="doi">10.1099/jmm.0.46088-0</pub-id><pub-id pub-id-type="pmid">16772421</pub-id>
</element-citation></ref><ref id="B82-vaccines-12-01319"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Stevenson</surname><given-names>G.</given-names></name>
<name><surname>Manning</surname><given-names>P.A.</given-names></name>
</person-group><article-title>Galactose Epimeraseless (GalE) Mutant G30 of <italic toggle="yes">Salmonella</italic> Typhimurium Is a Good Potential Live Oral Vaccine Carrier for Fimbrial Antigens</article-title><source>FEMS Microbiol. Lett.</source><year>1985</year><volume>28</volume><fpage>317</fpage><lpage>321</lpage><pub-id pub-id-type="doi">10.1111/j.1574-6968.1985.tb00813.x</pub-id></element-citation></ref><ref id="B83-vaccines-12-01319"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Won</surname><given-names>G.</given-names></name>
<name><surname>Lee</surname><given-names>J.H.</given-names></name>
</person-group><article-title>Multifaceted Immune Responses and Protective Efficacy Elicited by a Recombinant Autolyzed <italic toggle="yes">Salmonella</italic> Expressing FliC Flagellar Antigen of F18+ <italic toggle="yes">Escherichia coli</italic></article-title><source>Vaccine</source><year>2016</year><volume>34</volume><fpage>6335</fpage><lpage>6342</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2016.10.066</pub-id><pub-id pub-id-type="pmid">27817960</pub-id>
</element-citation></ref><ref id="B84-vaccines-12-01319"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Won</surname><given-names>G.</given-names></name>
<name><surname>John Hwa</surname><given-names>L.</given-names></name>
</person-group><article-title>Potent Immune Responses Induced by a Salmonella Ghost Delivery System That Expresses the Recombinant StX2eB, FedF, and FedA Proteins of the <italic toggle="yes">Escherichia coli</italic>-Producing F18 and Shiga Toxin in a Murine Model and Evaluation of Its Protective Effect as a Porcine Vaccine Candidate</article-title><source>Vet. Q.</source><year>2017</year><volume>37</volume><fpage>81</fpage><lpage>90</lpage><pub-id pub-id-type="doi">10.1080/01652176.2017.1308040</pub-id><pub-id pub-id-type="pmid">28317440</pub-id>
</element-citation></ref><ref id="B85-vaccines-12-01319"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chaudhari</surname><given-names>A.A.</given-names></name>
<name><surname>Matsuda</surname><given-names>K.</given-names></name>
<name><surname>Lee</surname><given-names>J.H.</given-names></name>
</person-group><article-title>Construction of an Attenuated <italic toggle="yes">Salmonella</italic> Delivery System Harboring Genes Encoding Various Virulence Factors of Avian Pathogenic <italic toggle="yes">Escherichia coli</italic> and Its Potential as a Candidate Vaccine for Chicken Colibacillosis</article-title><source>Avian Dis.</source><year>2013</year><volume>57</volume><fpage>88</fpage><lpage>96</lpage><pub-id pub-id-type="doi">10.1637/10277-061312-Reg.1</pub-id><pub-id pub-id-type="pmid">23678735</pub-id>
</element-citation></ref><ref id="B86-vaccines-12-01319"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lee</surname><given-names>J.H.</given-names></name>
<name><surname>Chaudhari</surname><given-names>A.A.</given-names></name>
<name><surname>Oh</surname><given-names>I.G.</given-names></name>
<name><surname>Eo</surname><given-names>S.K.</given-names></name>
<name><surname>Park</surname><given-names>S.</given-names></name>
<name><surname>Jawale</surname><given-names>C.V.</given-names></name>
</person-group><article-title>Immune Responses to Oral Vaccination with <italic toggle="yes">Salmonella</italic>-Delivered Pathogenic <italic toggle="yes">Escherichia coli</italic> Antigens and Protective efficacy against Colibacillosis</article-title><source>Can. J. Vet. Res.</source><year>2015</year><volume>79</volume><fpage>229</fpage><lpage>234</lpage><pub-id pub-id-type="pmid">26130856</pub-id>
</element-citation></ref><ref id="B87-vaccines-12-01319"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Han</surname><given-names>Y.</given-names></name>
<name><surname>Liu</surname><given-names>Q.</given-names></name>
<name><surname>Yi</surname><given-names>J.</given-names></name>
<name><surname>Liang</surname><given-names>K.</given-names></name>
<name><surname>Wei</surname><given-names>Y.</given-names></name>
<name><surname>Kong</surname><given-names>Q.</given-names></name>
</person-group><article-title>A Biologically Conjugated Polysaccharide Vaccine Delivered by Attenuated <italic toggle="yes">Salmonella</italic> Typhimurium Provides Protection against Challenge of Avian Pathogenic <italic toggle="yes">Escherichia coli</italic> O1 Infection</article-title><source>Pathog. Dis.</source><year>2017</year><volume>75</volume><fpage>ftx102</fpage><pub-id pub-id-type="doi">10.1093/femspd/ftx102</pub-id><pub-id pub-id-type="pmid">28911037</pub-id>
</element-citation></ref><ref id="B88-vaccines-12-01319"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Oh</surname><given-names>I.G.</given-names></name>
<name><surname>Jawale</surname><given-names>C.</given-names></name>
<name><surname>Lee</surname><given-names>J.</given-names></name>
</person-group><article-title>The B Subunits of Cholera and <italic toggle="yes">Escherichia coli</italic> Heat-Labile Toxins Enhance the Immune Responses in Mice Orally Immunised with a Recombinant Live P-Fimbrial Vaccine for Avian Pathogenic <italic toggle="yes">E. coli</italic></article-title><source>Acta Vet. Hung.</source><year>2014</year><volume>62</volume><fpage>293</fpage><lpage>303</lpage><pub-id pub-id-type="doi">10.1556/avet.2014.006</pub-id><pub-id pub-id-type="pmid">24659715</pub-id>
</element-citation></ref><ref id="B89-vaccines-12-01319"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Stromberg</surname><given-names>Z.R.</given-names></name>
<name><surname>Van Goor</surname><given-names>A.</given-names></name>
<name><surname>Redweik</surname><given-names>G.A.J.</given-names></name>
<name><surname>Mellata</surname><given-names>M.</given-names></name>
</person-group><article-title>Characterization of Spleen Transcriptome and Immunity against Avian Colibacillosis after Immunization with Recombinant Attenuated <italic toggle="yes">Salmonella</italic> Vaccine Strains</article-title><source>Front. Vet. Sci.</source><year>2018</year><volume>5</volume><elocation-id>198</elocation-id><pub-id pub-id-type="doi">10.3389/fvets.2018.00198</pub-id><pub-id pub-id-type="pmid">30186843</pub-id>
</element-citation></ref><ref id="B90-vaccines-12-01319"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kulkarni</surname><given-names>R.R.</given-names></name>
<name><surname>Parreira</surname><given-names>V.R.</given-names></name>
<name><surname>Jiang</surname><given-names>Y.F.</given-names></name>
<name><surname>Prescott</surname><given-names>J.F.</given-names></name>
</person-group><article-title>A Live Oral Recombinant <italic toggle="yes">Salmonella enterica</italic> Serovar Typhimurium Vaccine Expressing <italic toggle="yes">Clostridium perfringens</italic> Antigens Confers Protection against Necrotic Enteritis in Broiler Chickens</article-title><source>Clin. Vaccine Immunol.</source><year>2010</year><volume>17</volume><fpage>205</fpage><lpage>214</lpage><pub-id pub-id-type="doi">10.1128/CVI.00406-09</pub-id><pub-id pub-id-type="pmid">20007363</pub-id>
</element-citation></ref><ref id="B91-vaccines-12-01319"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wilde</surname><given-names>S.</given-names></name>
<name><surname>Jiang</surname><given-names>Y.</given-names></name>
<name><surname>Tafoya</surname><given-names>A.M.</given-names></name>
<name><surname>Horsman</surname><given-names>J.</given-names></name>
<name><surname>Yousif</surname><given-names>M.</given-names></name>
<name><surname>Vazquez</surname><given-names>L.A.</given-names></name>
<name><surname>Roland</surname><given-names>K.L.</given-names></name>
</person-group><article-title><italic toggle="yes">Salmonella</italic>-Vectored Vaccine Delivering Three <italic toggle="yes">Clostridium perfringens</italic> Antigens Protects Poultry against Necrotic Enteritis</article-title><source>PLoS ONE</source><year>2019</year><volume>14</volume><elocation-id>e0197721</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0197721</pub-id><pub-id pub-id-type="pmid">30753181</pub-id>
</element-citation></ref><ref id="B92-vaccines-12-01319"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Newton</surname><given-names>S.M.C.</given-names></name>
<name><surname>Kotb</surname><given-names>M.</given-names></name>
<name><surname>Poirier</surname><given-names>T.P.</given-names></name>
<name><surname>Stocker</surname><given-names>B.A.D.</given-names></name>
<name><surname>Beachey</surname><given-names>E.H.</given-names></name>
</person-group><article-title>Expression and Immunogenicity of a Streptococcal M Protein Epitope Inserted in <italic toggle="yes">Salmonella</italic> Flagellin</article-title><source>Infect. Immun.</source><year>1991</year><volume>59</volume><fpage>2158</fpage><lpage>2165</lpage><pub-id pub-id-type="doi">10.1128/iai.59.6.2158-2165.1991</pub-id><pub-id pub-id-type="pmid">2037377</pub-id>
</element-citation></ref><ref id="B93-vaccines-12-01319"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Park</surname><given-names>S.</given-names></name>
<name><surname>Won</surname><given-names>G.</given-names></name>
<name><surname>Lee</surname><given-names>J.H.</given-names></name>
</person-group><article-title>An Attenuated <italic toggle="yes">Salmonella</italic> Vaccine Secreting <italic toggle="yes">Lawsonia intracellularis</italic> Immunogenic Antigens Confers Dual Protection against Porcine Proliferative Enteropathy and Salmonellosis in a Murine Model</article-title><source>J. Vet. Sci.</source><year>2019</year><volume>20</volume><fpage>e24</fpage><pub-id pub-id-type="doi">10.4142/jvs.2019.20.e24</pub-id><pub-id pub-id-type="pmid">31161742</pub-id>
</element-citation></ref><ref id="B94-vaccines-12-01319"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Buckley</surname><given-names>A.M.</given-names></name>
<name><surname>Wang</surname><given-names>J.</given-names></name>
<name><surname>Hudson</surname><given-names>D.L.</given-names></name>
<name><surname>Grant</surname><given-names>A.J.</given-names></name>
<name><surname>Jones</surname><given-names>M.A.</given-names></name>
<name><surname>Maskell</surname><given-names>D.J.</given-names></name>
<name><surname>Stevens</surname><given-names>M.P.</given-names></name>
</person-group><article-title>Evaluation of Live-Attenuated <italic toggle="yes">Salmonella</italic> Vaccines Expressing <italic toggle="yes">Campylobacter</italic> Antigens for Control of <italic toggle="yes">C. jejuni</italic> in Poultry</article-title><source>Vaccine</source><year>2010</year><volume>28</volume><fpage>1094</fpage><lpage>1105</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2009.10.018</pub-id><pub-id pub-id-type="pmid">19853682</pub-id>
</element-citation></ref><ref id="B95-vaccines-12-01319"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>&#x00141;aniewski</surname><given-names>P.</given-names></name>
<name><surname>Kuczkowski</surname><given-names>M.</given-names></name>
<name><surname>Chrzastek</surname><given-names>K.</given-names></name>
<name><surname>Wo&#x0017a;niak</surname><given-names>A.</given-names></name>
<name><surname>Wyszy&#x00144;ska</surname><given-names>A.</given-names></name>
<name><surname>Wieliczko</surname><given-names>A.</given-names></name>
<name><surname>Jagusztyn-Krynicka</surname><given-names>E.K.</given-names></name>
</person-group><article-title>Evaluation of the Immunogenicity of <italic toggle="yes">Campylobacter jejuni</italic> CjaA Protein Delivered by <italic toggle="yes">Salmonella enterica</italic> Sv. Typhimurium Strain with Regulated Delayed Attenuation in Chickens</article-title><source>World J. Microbiol. Biotechnol.</source><year>2014</year><volume>30</volume><fpage>281</fpage><lpage>292</lpage><pub-id pub-id-type="doi">10.1007/s11274-013-1447-5</pub-id><pub-id pub-id-type="pmid">23913025</pub-id>
</element-citation></ref><ref id="B96-vaccines-12-01319"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Stabel</surname><given-names>T.J.</given-names></name>
<name><surname>Mayfield</surname><given-names>J.E.</given-names></name>
<name><surname>Tabatabai</surname><given-names>L.B.</given-names></name>
<name><surname>Wannemuehler1</surname><given-names>M.J.</given-names></name>
</person-group><article-title>Oral Immunization of Mice with Attenuated <italic toggle="yes">Salmonella</italic> Typhimurium Containing a Recombinant Plasmid Which Codes for Production of a 31-Kilodalton Protein of <italic toggle="yes">Brucella abortus</italic></article-title><source>Infect. Immun.</source><year>1990</year><volume>58</volume><fpage>2048</fpage><lpage>2055</lpage><pub-id pub-id-type="doi">10.1128/iai.58.7.2048-2055.1990</pub-id><pub-id pub-id-type="pmid">2114357</pub-id>
</element-citation></ref><ref id="B97-vaccines-12-01319"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Stabel</surname><given-names>T.J.</given-names></name>
<name><surname>Mayfield</surname><given-names>J.E.</given-names></name>
<name><surname>Tabatabai</surname><given-names>L.B.</given-names></name>
<name><surname>Wannemuehler1</surname><given-names>M.J.</given-names></name>
</person-group><article-title>Swine Immunity to an Attenuated <italic toggle="yes">Salmonella</italic> Typhimurium Mutant Containing a Recombinant Plasmid Which Codes for Production of a 31-Kilodalton Protein of <italic toggle="yes">Brucella abortus</italic></article-title><source>Infect. Immun.</source><year>1991</year><volume>59</volume><fpage>2941</fpage><lpage>2947</lpage><pub-id pub-id-type="doi">10.1128/iai.59.9.2941-2947.1991</pub-id><pub-id pub-id-type="pmid">1908827</pub-id>
</element-citation></ref><ref id="B98-vaccines-12-01319"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhao</surname><given-names>Z.</given-names></name>
<name><surname>Li</surname><given-names>M.</given-names></name>
<name><surname>Luo</surname><given-names>D.</given-names></name>
<name><surname>Xing</surname><given-names>L.</given-names></name>
<name><surname>Wu</surname><given-names>S.</given-names></name>
<name><surname>Duan</surname><given-names>Y.</given-names></name>
<name><surname>Yang</surname><given-names>P.</given-names></name>
<name><surname>Wang</surname><given-names>X.</given-names></name>
</person-group><article-title>Protection of Mice from <italic toggle="yes">Brucella</italic> Infection by Immunization with Attenuated <italic toggle="yes">Salmonella enterica</italic> Serovar Typhimurium Expressing A L7/L12 and BLS Fusion Antigen of <italic toggle="yes">Brucella</italic></article-title><source>Vaccine</source><year>2009</year><volume>27</volume><fpage>5214</fpage><lpage>5219</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2009.06.075</pub-id><pub-id pub-id-type="pmid">19596411</pub-id>
</element-citation></ref><ref id="B99-vaccines-12-01319"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kim</surname><given-names>W.K.</given-names></name>
<name><surname>Moon</surname><given-names>J.Y.</given-names></name>
<name><surname>Cho</surname><given-names>J.S.</given-names></name>
<name><surname>Hur</surname><given-names>J.</given-names></name>
</person-group><article-title>Protective Efficacy by Various Doses of a New Brucellosis Vaccine Candidate Based on <italic toggle="yes">Salmonella</italic> Strains Expressing <italic toggle="yes">Brucella abortus</italic> BSCP31, Omp3b and Superoxide Dismutase against Brucellosis in Murine Model</article-title><source>Pathog. Dis.</source><year>2017</year><volume>75</volume><fpage>ftx094</fpage><pub-id pub-id-type="doi">10.1093/femspd/ftx094</pub-id><pub-id pub-id-type="pmid">28873944</pub-id>
</element-citation></ref><ref id="B100-vaccines-12-01319"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kim</surname><given-names>W.K.</given-names></name>
<name><surname>Moon</surname><given-names>J.Y.</given-names></name>
<name><surname>Cho</surname><given-names>J.S.</given-names></name>
<name><surname>Park</surname><given-names>B.Y.</given-names></name>
<name><surname>Hur</surname><given-names>J.</given-names></name>
</person-group><article-title>Protective Efficacy of a Canine Brucellosis Vaccine Candidate Based on Live Attenuated <italic toggle="yes">Salmonella</italic> Expressing Recombinant <italic toggle="yes">Brucella</italic> BCSP31, Omp3b and SOD Proteins in Beagles</article-title><source>J. Vet. Med. Sci.</source><year>2018</year><volume>80</volume><fpage>1373</fpage><lpage>1379</lpage><pub-id pub-id-type="doi">10.1292/jvms.18-0136</pub-id><pub-id pub-id-type="pmid">30068897</pub-id>
</element-citation></ref><ref id="B101-vaccines-12-01319"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kim</surname><given-names>W.-K.</given-names></name>
<name><surname>Moon</surname><given-names>J.-Y.</given-names></name>
<name><surname>Cho</surname><given-names>J.-S.</given-names></name>
<name><surname>Hur</surname><given-names>J.</given-names></name>
</person-group><article-title>Protective Efficacy of a <italic toggle="yes">Brucella</italic> Vaccine Using a <italic toggle="yes">Salmonella</italic>-Based System Expressing <italic toggle="yes">Brucella</italic> Omp3b, BCSP31, and SOD proteins against Brucellosis in Korean Black Goats</article-title><source>Can. J. Vet. Res.</source><year>2019</year><volume>83</volume><fpage>261</fpage><lpage>266</lpage><pub-id pub-id-type="pmid">31571725</pub-id>
</element-citation></ref><ref id="B102-vaccines-12-01319"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Senevirathne</surname><given-names>A.</given-names></name>
<name><surname>Hewawaduge</surname><given-names>C.</given-names></name>
<name><surname>Lee</surname><given-names>J.H.</given-names></name>
</person-group><article-title>Live Vaccine Consisting of Attenuated <italic toggle="yes">Salmonella</italic> Secreting and Delivering Brucella Ribosomal Protein L7/L12 Induces Humoral and Cellular Immune Responses and Protects Mice against Virulent <italic toggle="yes">Brucella</italic> Abortus 544 Challenge</article-title><source>Vet. Res.</source><year>2020</year><volume>51</volume><fpage>6</fpage><pub-id pub-id-type="doi">10.1186/s13567-020-0735-y</pub-id><pub-id pub-id-type="pmid">31973749</pub-id>
</element-citation></ref><ref id="B103-vaccines-12-01319"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Stabel</surname><given-names>T.J.</given-names></name>
<name><surname>Mayfield</surname><given-names>J.E.</given-names></name>
<name><surname>Morfitt</surname><given-names>D.C.</given-names></name>
<name><surname>Wannemuehler</surname><given-names>M.J.</given-names></name>
</person-group><article-title>Oral Immunization of Mice and Swine with an Attenuated <italic toggle="yes">Salmonella</italic> Choleraesuis [&#x00394;cya-12 &#x00394;(Crp-Cdt)19] Mutant Containing a Recombinant Plasmid</article-title><source>Infect. Immun.</source><year>1993</year><volume>61</volume><fpage>610</fpage><lpage>618</lpage><pub-id pub-id-type="doi">10.1128/iai.61.2.610-618.1993</pub-id><pub-id pub-id-type="pmid">8423090</pub-id>
</element-citation></ref><ref id="B104-vaccines-12-01319"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ji</surname><given-names>Z.</given-names></name>
<name><surname>Shang</surname><given-names>J.</given-names></name>
<name><surname>Li</surname><given-names>Y.</given-names></name>
<name><surname>Wang</surname><given-names>S.</given-names></name>
<name><surname>Shi</surname><given-names>H.</given-names></name>
</person-group><article-title>Live Attenuated <italic toggle="yes">Salmonella enterica</italic> Serovar Choleraesuis Vaccine Vector Displaying Regulated Delayed Attenuation and Regulated Delayed Antigen Synthesis to Confer Protection against <italic toggle="yes">Streptococcus suis</italic> in Mice</article-title><source>Vaccine</source><year>2015</year><volume>33</volume><fpage>4858</fpage><lpage>4867</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2015.07.063</pub-id><pub-id pub-id-type="pmid">26238722</pub-id>
</element-citation></ref><ref id="B105-vaccines-12-01319"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Li</surname><given-names>Y.A.</given-names></name>
<name><surname>Chen</surname><given-names>Y.</given-names></name>
<name><surname>Zhao</surname><given-names>D.Y.</given-names></name>
<name><surname>Guo</surname><given-names>W.</given-names></name>
<name><surname>Chu</surname><given-names>D.</given-names></name>
<name><surname>Fan</surname><given-names>J.</given-names></name>
<name><surname>Wang</surname><given-names>X.</given-names></name>
<name><surname>Bellefleur</surname><given-names>M.</given-names></name>
<name><surname>Wang</surname><given-names>S.</given-names></name>
<name><surname>Shi</surname><given-names>H.</given-names></name>
</person-group><article-title>Live-Attenuated <italic toggle="yes">Salmonella enterica</italic> Serotype Choleraesuis Vaccine with Regulated Delayed Fur Mutation Confer Protection against <italic toggle="yes">Streptococcus suis</italic> in Mice</article-title><source>BMC Vet. Res.</source><year>2020</year><volume>16</volume><elocation-id>129</elocation-id><pub-id pub-id-type="doi">10.1186/s12917-020-02340-4</pub-id><pub-id pub-id-type="pmid">32381017</pub-id>
</element-citation></ref><ref id="B106-vaccines-12-01319"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Li</surname><given-names>Y.A.</given-names></name>
<name><surname>Sun</surname><given-names>Y.</given-names></name>
<name><surname>Fu</surname><given-names>Y.</given-names></name>
<name><surname>Zhang</surname><given-names>Y.</given-names></name>
<name><surname>Li</surname><given-names>Q.</given-names></name>
<name><surname>Wang</surname><given-names>S.</given-names></name>
<name><surname>Shi</surname><given-names>H.</given-names></name>
</person-group><article-title><italic toggle="yes">Salmonella enterica</italic> Serovar Choleraesuis Vector Delivering a Dual-Antigen Expression Cassette Provides Mouse Cross-Protection against <italic toggle="yes">Streptococcus suis</italic> Serotypes 2, 7, 9, and 1/2</article-title><source>Vet. Res.</source><year>2022</year><volume>53</volume><fpage>46</fpage><pub-id pub-id-type="doi">10.1186/s13567-022-01062-9</pub-id><pub-id pub-id-type="pmid">35733156</pub-id>
</element-citation></ref><ref id="B107-vaccines-12-01319"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhou</surname><given-names>G.</given-names></name>
<name><surname>Tian</surname><given-names>Y.</given-names></name>
<name><surname>Tian</surname><given-names>J.</given-names></name>
<name><surname>Ma</surname><given-names>Q.</given-names></name>
<name><surname>Huang</surname><given-names>S.</given-names></name>
<name><surname>Li</surname><given-names>Q.</given-names></name>
<name><surname>Wang</surname><given-names>S.</given-names></name>
<name><surname>Shi</surname><given-names>H.</given-names></name>
</person-group><article-title>Oral Immunization with Attenuated <italic toggle="yes">Salmonella</italic> Choleraesuis Expressing the P42 and P97 Antigens Protects Mice against <italic toggle="yes">Mycoplasma hyopneumoniae</italic> Challenge</article-title><source>Microbiol. Spectr.</source><year>2022</year><volume>10</volume><fpage>e02361-22</fpage><pub-id pub-id-type="doi">10.1128/spectrum.02361-22</pub-id><pub-id pub-id-type="pmid">36377878</pub-id>
</element-citation></ref><ref id="B108-vaccines-12-01319"><label>108.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Liljebjelke</surname><given-names>K.A.</given-names></name>
<name><surname>Petkov</surname><given-names>D.I.</given-names></name>
<name><surname>Kapczynski</surname><given-names>D.R.</given-names></name>
</person-group><article-title>Mucosal Vaccination with a Codon-Optimized Hemagglutinin Gene Expressed by Attenuated <italic toggle="yes">Salmonella</italic> Elicits a Protective Immune Response in Chickens against Highly Pathogenic Avian Influenza</article-title><source>Vaccine</source><year>2010</year><volume>28</volume><fpage>4430</fpage><lpage>4437</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2010.04.009</pub-id><pub-id pub-id-type="pmid">20406663</pub-id>
</element-citation></ref><ref id="B109-vaccines-12-01319"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rahman</surname><given-names>M.M.</given-names></name>
<name><surname>Uyangaa</surname><given-names>E.</given-names></name>
<name><surname>Han</surname><given-names>Y.W.</given-names></name>
<name><surname>Kim</surname><given-names>S.B.</given-names></name>
<name><surname>Kim</surname><given-names>J.H.</given-names></name>
<name><surname>Choi</surname><given-names>J.Y.</given-names></name>
<name><surname>Eo</surname><given-names>S.K.</given-names></name>
</person-group><article-title>Oral Co-Administration of Live Attenuated <italic toggle="yes">Salmonella enterica</italic> Serovar Typhimurium Expressing Chicken Interferon-&#x003b1; and Interleukin-18 Enhances the Alleviation of Clinical Signs Caused by Respiratory Infection with Avian Influenza Virus H9N2</article-title><source>Vet. Microbiol.</source><year>2012</year><volume>157</volume><fpage>448</fpage><lpage>455</lpage><pub-id pub-id-type="doi">10.1016/j.vetmic.2011.12.029</pub-id><pub-id pub-id-type="pmid">22245401</pub-id>
</element-citation></ref><ref id="B110-vaccines-12-01319"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jazayeri</surname><given-names>S.D.</given-names></name>
<name><surname>Ideris</surname><given-names>A.</given-names></name>
<name><surname>Zakaria</surname><given-names>Z.</given-names></name>
<name><surname>Omar</surname><given-names>A.R.</given-names></name>
</person-group><article-title>Attenuated <italic toggle="yes">Salmonella</italic> Typhimurium SV4089 as a Potential Carrier of Oral DNA Vaccine in Chickens</article-title><source>J. Biomed. Biotechnol.</source><year>2012</year><volume>2012</volume><elocation-id>264986</elocation-id><pub-id pub-id-type="doi">10.1155/2012/264986</pub-id><pub-id pub-id-type="pmid">22701301</pub-id>
</element-citation></ref><ref id="B111-vaccines-12-01319"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jazayeri</surname><given-names>S.D.</given-names></name>
<name><surname>Ideris</surname><given-names>A.</given-names></name>
<name><surname>Zakaria</surname><given-names>Z.</given-names></name>
<name><surname>Yeap</surname><given-names>S.K.</given-names></name>
<name><surname>Omar</surname><given-names>A.R.</given-names></name>
</person-group><article-title>Improved Immune Responses against Avian Influenza Virus Following Oral Vaccination of Chickens with HA DNA Vaccine Using Attenuated <italic toggle="yes">Salmonella</italic> Typhimurium as Carrier</article-title><source>Comp. Immunol. Microbiol. Infect. Dis.</source><year>2012</year><volume>35</volume><fpage>417</fpage><lpage>427</lpage><pub-id pub-id-type="doi">10.1016/j.cimid.2012.03.007</pub-id><pub-id pub-id-type="pmid">22512819</pub-id>
</element-citation></ref><ref id="B112-vaccines-12-01319"><label>112.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kim</surname><given-names>J.H.</given-names></name>
<name><surname>Hajam</surname><given-names>I.A.</given-names></name>
<name><surname>Lee</surname><given-names>J.H.</given-names></name>
</person-group><article-title>Oral Immunization with a Novel Attenuated <italic toggle="yes">Salmonella</italic> Typhimurium Encoding Influenza HA, M2e and NA Antigens Protects Chickens against H7N9 Infection</article-title><source>Vet. Res.</source><year>2018</year><volume>49</volume><fpage>12</fpage><pub-id pub-id-type="doi">10.1186/s13567-018-0509-y</pub-id><pub-id pub-id-type="pmid">29391053</pub-id>
</element-citation></ref><ref id="B113-vaccines-12-01319"><label>113.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hajam</surname><given-names>I.A.</given-names></name>
<name><surname>Kirthika</surname><given-names>P.</given-names></name>
<name><surname>Hewawaduge</surname><given-names>C.</given-names></name>
<name><surname>Jawalagatti</surname><given-names>V.</given-names></name>
<name><surname>Park</surname><given-names>S.W.</given-names></name>
<name><surname>Senevirathne</surname><given-names>A.</given-names></name>
<name><surname>Lee</surname><given-names>J.H.</given-names></name>
</person-group><article-title>Oral Immunization with an Attenuated <italic toggle="yes">Salmonella gallinarum</italic> Encoding the H9N2 Haemagglutinin and M2 Ectodomain Induces Protective Immune Responses against H9N2 Infection in Chickens</article-title><source>Avian Pathol.</source><year>2020</year><volume>49</volume><fpage>486</fpage><lpage>495</lpage><pub-id pub-id-type="doi">10.1080/03079457.2020.1775782</pub-id><pub-id pub-id-type="pmid">32483989</pub-id>
</element-citation></ref><ref id="B114-vaccines-12-01319"><label>114.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lee</surname><given-names>B.M.</given-names></name>
<name><surname>Han</surname><given-names>Y.W.</given-names></name>
<name><surname>Kim</surname><given-names>S.B.</given-names></name>
<name><surname>Rahman</surname><given-names>M.M.</given-names></name>
<name><surname>Uyangaa</surname><given-names>E.</given-names></name>
<name><surname>Kim</surname><given-names>J.H.</given-names></name>
<name><surname>Roh</surname><given-names>Y.S.</given-names></name>
<name><surname>Kim</surname><given-names>B.</given-names></name>
<name><surname>Han</surname><given-names>S.B.</given-names></name>
<name><surname>Hong</surname><given-names>J.T.</given-names></name>
<etal/>
</person-group><article-title>Enhanced Protection against Infection with Transmissible Gastroenteritis Virus in Piglets by Oral Co-Administration of Live Attenuated <italic toggle="yes">Salmonella enterica</italic> Serovar Typhimurium Expressing Swine Interferon-&#x003b1; and Interleukin-18</article-title><source>Comp. Immunol. Microbiol. Infect. Dis.</source><year>2011</year><volume>34</volume><fpage>369</fpage><lpage>380</lpage><pub-id pub-id-type="doi">10.1016/j.cimid.2011.05.001</pub-id><pub-id pub-id-type="pmid">21719106</pub-id>
</element-citation></ref><ref id="B115-vaccines-12-01319"><label>115.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Eo</surname><given-names>S.K.</given-names></name>
<name><surname>Yoon</surname><given-names>H.A.</given-names></name>
<name><surname>Aleyas</surname><given-names>A.G.</given-names></name>
<name><surname>Park</surname><given-names>S.O.</given-names></name>
<name><surname>Han</surname><given-names>Y.W.</given-names></name>
<name><surname>Chae</surname><given-names>J.S.</given-names></name>
<name><surname>Lee</surname><given-names>J.H.</given-names></name>
<name><surname>Song</surname><given-names>H.J.</given-names></name>
<name><surname>Cho</surname><given-names>J.G.</given-names></name>
</person-group><article-title>Systemic and Mucosal Immunity Induced by Oral Somatic Transgene Vaccination against Glycoprotein B of Pseudorabies Virus Using Live Attenuated <italic toggle="yes">Salmonella</italic> Typhimurium</article-title><source>FEMS Immunol. Med. Microbiol.</source><year>2006</year><volume>47</volume><fpage>451</fpage><lpage>461</lpage><pub-id pub-id-type="doi">10.1111/j.1574-695X.2006.00117.x</pub-id><pub-id pub-id-type="pmid">16872383</pub-id>
</element-citation></ref><ref id="B116-vaccines-12-01319"><label>116.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kim</surname><given-names>S.J.</given-names></name>
<name><surname>Bum Kim</surname><given-names>S.</given-names></name>
<name><surname>Woo Han</surname><given-names>Y.</given-names></name>
<name><surname>Uyangaa</surname><given-names>E.</given-names></name>
<name><surname>Hyoung Kim</surname><given-names>J.</given-names></name>
<name><surname>Young Choi</surname><given-names>J.</given-names></name>
<name><surname>Kim</surname><given-names>K.</given-names></name>
<name><surname>Kug Eo</surname><given-names>S.</given-names></name>
</person-group><article-title>Co-Administration of Live Attenuated <italic toggle="yes">Salmonella enterica</italic> Serovar Typhimurium Expressing Swine Interleukin-18 and Interferon-&#x003b1; Provides Enhanced Th1-Biased Protective Immunity against Inactivated Vaccine of Pseudorabies Virus</article-title><source>Microbiol. Immunol.</source><year>2012</year><volume>56</volume><fpage>529</fpage><lpage>540</lpage><pub-id pub-id-type="doi">10.1111/j.1348-0421.2012.00473.x</pub-id><pub-id pub-id-type="pmid">22551253</pub-id>
</element-citation></ref><ref id="B117-vaccines-12-01319"><label>117.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yu</surname><given-names>X.</given-names></name>
<name><surname>Jia</surname><given-names>R.</given-names></name>
<name><surname>Huang</surname><given-names>J.</given-names></name>
<name><surname>Zhu</surname><given-names>D.</given-names></name>
<name><surname>Liu</surname><given-names>Q.</given-names></name>
<name><surname>Gao</surname><given-names>X.</given-names></name>
<name><surname>Lin</surname><given-names>M.</given-names></name>
<name><surname>Yin</surname><given-names>Z.</given-names></name>
<name><surname>Wang</surname><given-names>M.</given-names></name>
<name><surname>Chen</surname><given-names>S.</given-names></name>
<etal/>
</person-group><article-title>Attenuated <italic toggle="yes">Salmonella</italic> Typhimurium Delivering DNA Vaccine Encoding Duck Enteritis Virus UL24 Induced Systemic and Mucosal Immune Responses and Conferred Good Protection against Challenge</article-title><source>Vet. Res.</source><year>2012</year><volume>43</volume><fpage>56</fpage><pub-id pub-id-type="doi">10.1186/1297-9716-43-56</pub-id><pub-id pub-id-type="pmid">22770566</pub-id>
</element-citation></ref><ref id="B118-vaccines-12-01319"><label>118.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Liu</surname><given-names>X.</given-names></name>
<name><surname>Liu</surname><given-names>Q.</given-names></name>
<name><surname>Xiao</surname><given-names>K.</given-names></name>
<name><surname>Li</surname><given-names>P.</given-names></name>
<name><surname>Liu</surname><given-names>Q.</given-names></name>
<name><surname>Zhao</surname><given-names>X.</given-names></name>
<name><surname>Kong</surname><given-names>Q.</given-names></name>
</person-group><article-title>Attenuated <italic toggle="yes">Salmonella</italic> Typhimurium Delivery of a Novel DNA Vaccine Induces Immune Responses and Provides Protection against Duck Enteritis Virus</article-title><source>Vet. Microbiol.</source><year>2016</year><volume>186</volume><fpage>189</fpage><lpage>198</lpage><pub-id pub-id-type="doi">10.1016/j.vetmic.2016.03.001</pub-id><pub-id pub-id-type="pmid">27016773</pub-id>
</element-citation></ref><ref id="B119-vaccines-12-01319"><label>119.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bhilare</surname><given-names>K.D.</given-names></name>
<name><surname>Jawalagatti</surname><given-names>V.</given-names></name>
<name><surname>Alam</surname><given-names>M.J.</given-names></name>
<name><surname>Chen</surname><given-names>B.</given-names></name>
<name><surname>Kim</surname><given-names>B.</given-names></name>
<name><surname>Lee</surname><given-names>J.H.</given-names></name>
<name><surname>Kim</surname><given-names>J.H.</given-names></name>
</person-group><article-title>Immune Response Following Safer Administration of Recombinant <italic toggle="yes">Salmonella</italic> Typhimurium Harboring ASFV Antigens in Pigs</article-title><source>Vet. Immunol. Immunopathol.</source><year>2023</year><volume>259</volume><fpage>110596</fpage><pub-id pub-id-type="doi">10.1016/j.vetimm.2023.110596</pub-id><pub-id pub-id-type="pmid">37119725</pub-id>
</element-citation></ref><ref id="B120-vaccines-12-01319"><label>120.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Li</surname><given-names>L.</given-names></name>
<name><surname>Fang</surname><given-names>W.</given-names></name>
<name><surname>Li</surname><given-names>J.</given-names></name>
<name><surname>Fang</surname><given-names>L.</given-names></name>
<name><surname>Huang</surname><given-names>Y.</given-names></name>
<name><surname>Yu</surname><given-names>L.</given-names></name>
</person-group><article-title>Oral DNA Vaccination with the Polyprotein Gene of Infectious Bursal Disease Virus (IBDV) Delivered by Attenuated <italic toggle="yes">Salmonella</italic> Elicits Protective Immune Responses in Chickens</article-title><source>Vaccine</source><year>2006</year><volume>24</volume><fpage>5919</fpage><lpage>5927</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2006.04.057</pub-id><pub-id pub-id-type="pmid">16769159</pub-id>
</element-citation></ref><ref id="B121-vaccines-12-01319"><label>121.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pan</surname><given-names>Y.</given-names></name>
<name><surname>Jia</surname><given-names>R.</given-names></name>
<name><surname>Li</surname><given-names>J.</given-names></name>
<name><surname>Wang</surname><given-names>M.</given-names></name>
<name><surname>Chen</surname><given-names>S.</given-names></name>
<name><surname>Liu</surname><given-names>M.</given-names></name>
<name><surname>Zhu</surname><given-names>D.</given-names></name>
<name><surname>Zhao</surname><given-names>X.</given-names></name>
<name><surname>Wu</surname><given-names>Y.</given-names></name>
<name><surname>Yang</surname><given-names>Q.</given-names></name>
<etal/>
</person-group><article-title>Heterologous Prime-Boost: An Important Candidate Immunization Strategy against Tembusu Virus</article-title><source>Virol. J.</source><year>2020</year><volume>17</volume><fpage>67</fpage><pub-id pub-id-type="doi">10.1186/s12985-020-01334-w</pub-id><pub-id pub-id-type="pmid">32398028</pub-id>
</element-citation></ref><ref id="B122-vaccines-12-01319"><label>122.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kim</surname><given-names>S.J.</given-names></name>
<name><surname>Han</surname><given-names>Y.W.</given-names></name>
<name><surname>Rahman</surname><given-names>M.M.</given-names></name>
<name><surname>Kim</surname><given-names>S.B.</given-names></name>
<name><surname>Uyangaa</surname><given-names>E.</given-names></name>
<name><surname>Lee</surname><given-names>B.M.</given-names></name>
<name><surname>Kim</surname><given-names>J.H.</given-names></name>
<name><surname>Roh</surname><given-names>Y.S.</given-names></name>
<name><surname>Kang</surname><given-names>S.H.</given-names></name>
<name><surname>Kim</surname><given-names>K.</given-names></name>
<etal/>
</person-group><article-title>Live Attenuated <italic toggle="yes">Salmonella enterica</italic> Serovar Typhimurium Expressing Swine Interferon-&#x003b1; Has Antiviral Activity and Alleviates Clinical Signs Induced by Infection with Transmissible Gastroenteritis Virus in Piglets</article-title><source>Vaccine</source><year>2010</year><volume>28</volume><fpage>5031</fpage><lpage>5037</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2010.05.013</pub-id><pub-id pub-id-type="pmid">20488264</pub-id>
</element-citation></ref><ref id="B123-vaccines-12-01319"><label>123.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>Y.</given-names></name>
<name><surname>Zhang</surname><given-names>X.</given-names></name>
<name><surname>Liao</surname><given-names>X.</given-names></name>
<name><surname>Huang</surname><given-names>X.</given-names></name>
<name><surname>Cao</surname><given-names>S.</given-names></name>
<name><surname>Wen</surname><given-names>X.</given-names></name>
<name><surname>Wen</surname><given-names>Y.</given-names></name>
<name><surname>Wu</surname><given-names>R.</given-names></name>
<name><surname>Liu</surname><given-names>W.</given-names></name>
</person-group><article-title>Construction of a Bivalent DNA Vaccine Co-Expressing S Genes of Transmissible Gastroenteritis Virus and Porcine Epidemic Diarrhea Virus Delivered by Attenuated <italic toggle="yes">Salmonella</italic> Typhimurium</article-title><source>Virus Genes</source><year>2016</year><volume>52</volume><fpage>354</fpage><lpage>364</lpage><pub-id pub-id-type="doi">10.1007/s11262-016-1316-z</pub-id><pub-id pub-id-type="pmid">26980672</pub-id>
</element-citation></ref><ref id="B124-vaccines-12-01319"><label>124.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>D.</given-names></name>
<name><surname>Huang</surname><given-names>X.</given-names></name>
<name><surname>Zhang</surname><given-names>X.</given-names></name>
<name><surname>Cao</surname><given-names>S.</given-names></name>
<name><surname>Wen</surname><given-names>X.</given-names></name>
<name><surname>Wen</surname><given-names>Y.</given-names></name>
<name><surname>Wu</surname><given-names>R.</given-names></name>
<name><surname>Liang</surname><given-names>E.</given-names></name>
</person-group><article-title>Construction of an Oral Vaccine for Transmissible Gastroenteritis Virus Based on the TGEV N Gene Expressed in an Attenuated <italic toggle="yes">Salmonella</italic> Typhimurium Vector</article-title><source>J. Virol. Methods</source><year>2016</year><volume>227</volume><fpage>6</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1016/j.jviromet.2015.08.011</pub-id><pub-id pub-id-type="pmid">26297958</pub-id>
</element-citation></ref><ref id="B125-vaccines-12-01319"><label>125.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Qing</surname><given-names>Y.</given-names></name>
<name><surname>Liu</surname><given-names>J.</given-names></name>
<name><surname>Huang</surname><given-names>X.</given-names></name>
<name><surname>Li</surname><given-names>Y.</given-names></name>
<name><surname>Zhang</surname><given-names>Y.</given-names></name>
<name><surname>Chen</surname><given-names>J.</given-names></name>
<name><surname>Wen</surname><given-names>X.</given-names></name>
<name><surname>Cao</surname><given-names>S.</given-names></name>
<name><surname>Wen</surname><given-names>Y.</given-names></name>
<name><surname>Wu</surname><given-names>R.</given-names></name>
<etal/>
</person-group><article-title>Immunogenicity of Transmissible Gastroenteritis Virus (TGEV) M Gene Delivered by Attenuated <italic toggle="yes">Salmonella</italic> Typhimurium in Mice</article-title><source>Virus Genes</source><year>2016</year><volume>52</volume><fpage>218</fpage><lpage>227</lpage><pub-id pub-id-type="doi">10.1007/s11262-016-1296-z</pub-id><pub-id pub-id-type="pmid">26837896</pub-id>
</element-citation></ref><ref id="B126-vaccines-12-01319"><label>126.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Xiong</surname><given-names>D.</given-names></name>
<name><surname>Song</surname><given-names>L.</given-names></name>
<name><surname>Zhai</surname><given-names>X.</given-names></name>
<name><surname>Geng</surname><given-names>S.</given-names></name>
<name><surname>Pan</surname><given-names>Z.</given-names></name>
<name><surname>Jiao</surname><given-names>X.</given-names></name>
</person-group><article-title>A Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) Vaccine Candidate Based on the Fusion Protein of PRRSV Glycoprotein 5 and the Toll-like Receptor-5 Agonist <italic toggle="yes">Salmonella</italic> Typhimurium FljB</article-title><source>BMC Vet. Res.</source><year>2015</year><volume>11</volume><elocation-id>121</elocation-id><pub-id pub-id-type="doi">10.1186/s12917-015-0439-0</pub-id><pub-id pub-id-type="pmid">26001608</pub-id>
</element-citation></ref><ref id="B127-vaccines-12-01319"><label>127.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhi</surname><given-names>Y.</given-names></name>
<name><surname>Ji</surname><given-names>H.J.</given-names></name>
<name><surname>Guo</surname><given-names>H.</given-names></name>
<name><surname>Lim</surname><given-names>J.H.</given-names></name>
<name><surname>Byun</surname><given-names>E.B.</given-names></name>
<name><surname>Kim</surname><given-names>W.S.</given-names></name>
<name><surname>Seo</surname><given-names>H.S.</given-names></name>
</person-group><article-title><italic toggle="yes">Salmonella</italic> Vaccine Vector System for Foot-and-Mouth Disease Virus and Evaluation of Its Efficacy with Virus-like Particles</article-title><source>Vaccines</source><year>2021</year><volume>9</volume><elocation-id>22</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines9010022</pub-id><pub-id pub-id-type="pmid">33466461</pub-id>
</element-citation></ref><ref id="B128-vaccines-12-01319"><label>128.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Steger</surname><given-names>K.K.</given-names></name>
<name><surname>Valentine</surname><given-names>P.J.</given-names></name>
<name><surname>Heffron</surname><given-names>F.</given-names></name>
<name><surname>So</surname><given-names>M.</given-names></name>
<name><surname>Pauza</surname><given-names>C.D.</given-names></name>
</person-group><article-title>Recombinant, Attenuated <italic toggle="yes">Salmonella</italic> Typhimurium Stimulate Lymphoproliferative Responses to SIV Capsid Antigen in Rhesus Macaques</article-title><source>Vaccine</source><year>1999</year><volume>17</volume><fpage>923</fpage><lpage>932</lpage><pub-id pub-id-type="doi">10.1016/S0264-410X(98)00278-3</pub-id><pub-id pub-id-type="pmid">10067699</pub-id>
</element-citation></ref><ref id="B129-vaccines-12-01319"><label>129.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wang</surname><given-names>X.</given-names></name>
<name><surname>Liu</surname><given-names>J.</given-names></name>
<name><surname>Wu</surname><given-names>X.</given-names></name>
<name><surname>Yu</surname><given-names>L.</given-names></name>
<name><surname>Chen</surname><given-names>H.</given-names></name>
<name><surname>Guo</surname><given-names>H.</given-names></name>
<name><surname>Zhang</surname><given-names>M.</given-names></name>
<name><surname>Li</surname><given-names>H.</given-names></name>
<name><surname>Liu</surname><given-names>X.</given-names></name>
<name><surname>Sun</surname><given-names>S.</given-names></name>
<etal/>
</person-group><article-title>Oral Immunisation of Mice with a Recombinant Rabies Virus Vaccine Incorporating the Heat-Labile Enterotoxin B Subunit of <italic toggle="yes">Escherichia coli</italic> in an Attenuated <italic toggle="yes">Salmonella</italic> Strain</article-title><source>Res. Vet. Sci.</source><year>2012</year><volume>93</volume><fpage>675</fpage><lpage>681</lpage><pub-id pub-id-type="doi">10.1016/j.rvsc.2011.09.015</pub-id><pub-id pub-id-type="pmid">22019192</pub-id>
</element-citation></ref><ref id="B130-vaccines-12-01319"><label>130.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ong</surname><given-names>W.C.</given-names></name>
<name><surname>Jin</surname><given-names>H.</given-names></name>
<name><surname>Jiang</surname><given-names>C.</given-names></name>
<name><surname>Yan</surname><given-names>W.</given-names></name>
<name><surname>Liu</surname><given-names>M.</given-names></name>
<name><surname>Chen</surname><given-names>J.</given-names></name>
<name><surname>Zuo</surname><given-names>X.</given-names></name>
<name><surname>Zheng</surname><given-names>Z.</given-names></name>
</person-group><article-title>Attenuated <italic toggle="yes">Salmonella</italic> Choleraesuis-Mediated RNAi Targeted to Conserved Regions against Foot-and-Mouth Disease Virus in Guinea Pigs and Swine</article-title><source>Vet. Res.</source><year>2010</year><volume>41</volume><fpage>30</fpage><pub-id pub-id-type="doi">10.1051/vetres/2010002</pub-id><pub-id pub-id-type="pmid">20167192</pub-id>
</element-citation></ref><ref id="B131-vaccines-12-01319"><label>131.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ding</surname><given-names>K.</given-names></name>
<name><surname>Shang</surname><given-names>K.</given-names></name>
<name><surname>Yu</surname><given-names>Z.H.</given-names></name>
<name><surname>Yu</surname><given-names>C.</given-names></name>
<name><surname>Jia</surname><given-names>Y.Y.</given-names></name>
<name><surname>He</surname><given-names>L.</given-names></name>
<name><surname>Liao</surname><given-names>C.S.</given-names></name>
<name><surname>Li</surname><given-names>J.</given-names></name>
<name><surname>Zhang</surname><given-names>C.J.</given-names></name>
<name><surname>Li</surname><given-names>Y.J.</given-names></name>
<etal/>
</person-group><article-title>Recombinant-Attenuated <italic toggle="yes">Salmonella</italic> Pullorum Strain Expressing the Hemagglutinin-Neuraminidase Protein of Newcastle Disease Virus (NDV) Protects Chickens against NDV and Salmonella Pullorum Challenge</article-title><source>J. Vet. Sci.</source><year>2018</year><volume>19</volume><fpage>232</fpage><lpage>241</lpage><pub-id pub-id-type="doi">10.4142/jvs.2018.19.2.232</pub-id><pub-id pub-id-type="pmid">29032660</pub-id>
</element-citation></ref><ref id="B132-vaccines-12-01319"><label>132.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Layton</surname><given-names>S.L.</given-names></name>
<name><surname>Kapczynski</surname><given-names>D.R.</given-names></name>
<name><surname>Higgins</surname><given-names>S.</given-names></name>
<name><surname>Higgins</surname><given-names>J.</given-names></name>
<name><surname>Wolfenden</surname><given-names>A.D.</given-names></name>
<name><surname>Liljebjelke</surname><given-names>K.A.</given-names></name>
<name><surname>Bottje</surname><given-names>W.G.</given-names></name>
<name><surname>Swayne</surname><given-names>D.</given-names></name>
<name><surname>Berghman</surname><given-names>L.R.</given-names></name>
<name><surname>Kwon</surname><given-names>Y.M.</given-names></name>
<etal/>
</person-group><article-title>Vaccination of Chickens with Recombinant <italic toggle="yes">Salmonella</italic> Expressing M2e and CD154 Epitopes Increases Protection and Decreases Viral Shedding after Low Pathogenic Avian Influenza Challenge</article-title><source>Poult. Sci.</source><year>2009</year><volume>88</volume><fpage>2244</fpage><lpage>2252</lpage><pub-id pub-id-type="doi">10.3382/ps.2009-00251</pub-id><pub-id pub-id-type="pmid">19834072</pub-id>
</element-citation></ref><ref id="B133-vaccines-12-01319"><label>133.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tang</surname><given-names>B.</given-names></name>
<name><surname>Li</surname><given-names>J.</given-names></name>
<name><surname>Li</surname><given-names>T.</given-names></name>
<name><surname>Xie</surname><given-names>Y.</given-names></name>
<name><surname>Guan</surname><given-names>W.</given-names></name>
<name><surname>Zhao</surname><given-names>Y.</given-names></name>
<name><surname>Yang</surname><given-names>S.</given-names></name>
<name><surname>Liu</surname><given-names>M.</given-names></name>
<name><surname>Xu</surname><given-names>D.</given-names></name>
</person-group><article-title>Vaccines as a Strategy to Control Trichinellosis</article-title><source>Front. Microbiol.</source><year>2022</year><volume>13</volume><elocation-id>857786</elocation-id><pub-id pub-id-type="doi">10.3389/fmicb.2022.857786</pub-id><pub-id pub-id-type="pmid">35401479</pub-id>
</element-citation></ref><ref id="B134-vaccines-12-01319"><label>134.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hewitson</surname><given-names>J.P.</given-names></name>
<name><surname>Maizels</surname><given-names>R.M.</given-names></name>
</person-group><article-title>Vaccination against Helminth Parasite Infections</article-title><source>Expert. Rev. Vaccines</source><year>2014</year><volume>13</volume><fpage>473</fpage><lpage>487</lpage><pub-id pub-id-type="doi">10.1586/14760584.2014.893195</pub-id><pub-id pub-id-type="pmid">24606541</pub-id>
</element-citation></ref><ref id="B135-vaccines-12-01319"><label>135.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yang</surname><given-names>Y.</given-names></name>
<name><surname>Zhang</surname><given-names>Z.</given-names></name>
<name><surname>Yang</surname><given-names>J.</given-names></name>
<name><surname>Chen</surname><given-names>X.</given-names></name>
<name><surname>Cui</surname><given-names>S.</given-names></name>
<name><surname>Zhu</surname><given-names>X.</given-names></name>
</person-group><article-title>Oral Vaccination with Ts87 DNA Vaccine Delivered by Attenuated <italic toggle="yes">Salmonella</italic> Typhimurium Elicits a Protective Immune Response against <italic toggle="yes">Trichinella spiralis</italic> Larval Challenge</article-title><source>Vaccine</source><year>2010</year><volume>28</volume><fpage>2735</fpage><lpage>2742</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2010.01.026</pub-id><pub-id pub-id-type="pmid">20105428</pub-id>
</element-citation></ref><ref id="B136-vaccines-12-01319"><label>136.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Liu</surname><given-names>P.</given-names></name>
<name><surname>Wang</surname><given-names>Z.Q.</given-names></name>
<name><surname>Liu</surname><given-names>R.D.</given-names></name>
<name><surname>Jiang</surname><given-names>P.</given-names></name>
<name><surname>Long</surname><given-names>S.R.</given-names></name>
<name><surname>Liu</surname><given-names>L.N.</given-names></name>
<name><surname>Zhang</surname><given-names>X.Z.</given-names></name>
<name><surname>Cheng</surname><given-names>X.C.</given-names></name>
<name><surname>Yu</surname><given-names>C.</given-names></name>
<name><surname>Ren</surname><given-names>H.J.</given-names></name>
<etal/>
</person-group><article-title>Oral Vaccination of Mice with <italic toggle="yes">Trichinella spiralis</italic> Nudix Hydrolase DNA Vaccine Delivered by Attenuated <italic toggle="yes">Salmonella</italic> Elicited Protective Immunity</article-title><source>Exp. Parasitol.</source><year>2015</year><volume>153</volume><fpage>29</fpage><lpage>38</lpage><pub-id pub-id-type="doi">10.1016/j.exppara.2015.02.008</pub-id><pub-id pub-id-type="pmid">25733024</pub-id>
</element-citation></ref><ref id="B137-vaccines-12-01319"><label>137.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Qi</surname><given-names>X.</given-names></name>
<name><surname>Han</surname><given-names>Y.</given-names></name>
<name><surname>Jiang</surname><given-names>P.</given-names></name>
<name><surname>Yue</surname><given-names>X.</given-names></name>
<name><surname>Ren</surname><given-names>H.N.</given-names></name>
<name><surname>Sun</surname><given-names>G.G.</given-names></name>
<name><surname>Long</surname><given-names>S.R.</given-names></name>
<name><surname>Yu</surname><given-names>C.</given-names></name>
<name><surname>Cheng</surname><given-names>X.C.</given-names></name>
<name><surname>Cui</surname><given-names>J.</given-names></name>
<etal/>
</person-group><article-title>Oral Vaccination with <italic toggle="yes">Trichinella spiralis</italic> DNase II DNA Vaccine Delivered by Attenuated <italic toggle="yes">Salmonella</italic> Induces a Protective Immunity in BALB/c Mice</article-title><source>Vet. Res.</source><year>2018</year><volume>49</volume><fpage>119</fpage><pub-id pub-id-type="doi">10.1186/s13567-018-0614-y</pub-id><pub-id pub-id-type="pmid">30518422</pub-id>
</element-citation></ref><ref id="B138-vaccines-12-01319"><label>138.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Li</surname><given-names>J.F.</given-names></name>
<name><surname>Guo</surname><given-names>K.X.</given-names></name>
<name><surname>Qi</surname><given-names>X.</given-names></name>
<name><surname>Lei</surname><given-names>J.J.</given-names></name>
<name><surname>Han</surname><given-names>Y.</given-names></name>
<name><surname>Yan</surname><given-names>S.W.</given-names></name>
<name><surname>Jiang</surname><given-names>P.</given-names></name>
<name><surname>Yu</surname><given-names>C.</given-names></name>
<name><surname>Cheng</surname><given-names>X.C.</given-names></name>
<name><surname>Wang</surname><given-names>Z.Q.</given-names></name>
<etal/>
</person-group><article-title>Protective Immunity against <italic toggle="yes">Trichinella spiralis</italic> in Mice Elicited by Oral Vaccination with Attenuated <italic toggle="yes">Salmonella</italic>-Delivered TsSP1.2 DNA</article-title><source>Vet. Res.</source><year>2018</year><volume>49</volume><fpage>87</fpage><pub-id pub-id-type="doi">10.1186/s13567-018-0582-2</pub-id><pub-id pub-id-type="pmid">30189894</pub-id>
</element-citation></ref><ref id="B139-vaccines-12-01319"><label>139.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chabalgoity</surname><given-names>J.A.</given-names></name>
<name><surname>Harrison</surname><given-names>J.A.</given-names></name>
<name><surname>Esteves</surname><given-names>A.</given-names></name>
<name><surname>Demarco De Hormaeche</surname><given-names>R.</given-names></name>
<name><surname>Ehrlich</surname><given-names>R.</given-names></name>
<name><surname>Anjam Khan</surname><given-names>C.M.</given-names></name>
<name><surname>Hormaeche</surname><given-names>C.E.</given-names></name>
</person-group><article-title>Expression and Immunogenicity of an <italic toggle="yes">Echinococcus granulosus</italic> Fatty Acid-Binding Protein in Live Attenuated <italic toggle="yes">Salmonella</italic> Vaccine Strains</article-title><source>Infect. Immun.</source><year>1997</year><volume>65</volume><fpage>2402</fpage><lpage>2412</lpage><pub-id pub-id-type="doi">10.1128/iai.65.6.2402-2412.1997</pub-id><pub-id pub-id-type="pmid">9169781</pub-id>
</element-citation></ref><ref id="B140-vaccines-12-01319"><label>140.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>M&#x000fc;ller-Schollenberger</surname><given-names>V.</given-names></name>
<name><surname>Beyer</surname><given-names>W.</given-names></name>
<name><surname>Schnitzler</surname><given-names>P.</given-names></name>
<name><surname>Merckelbach</surname><given-names>A.</given-names></name>
<name><surname>Roth</surname><given-names>S.</given-names></name>
<name><surname>Kalinna</surname><given-names>B.H.</given-names></name>
<name><surname>Lucius</surname><given-names>R.</given-names></name>
</person-group><article-title>Immunisation with <italic toggle="yes">Salmonella</italic> Typhimurium-Delivered Glyceraldehyde-3-Phosphate Dehydrogenase Protects Mice against Challenge Infection with <italic toggle="yes">Echinococcus multilocularis</italic> Eggs</article-title><source>Int. J. Parasitol.</source><year>2001</year><volume>31</volume><fpage>1441</fpage><lpage>1449</lpage><pub-id pub-id-type="doi">10.1016/S0020-7519(01)00244-2</pub-id><pub-id pub-id-type="pmid">11595231</pub-id>
</element-citation></ref><ref id="B141-vaccines-12-01319"><label>141.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Xu</surname><given-names>D.</given-names></name>
<name><surname>Mcsorley</surname><given-names>S.J.</given-names></name>
<name><surname>Chatfield</surname><given-names>S.N.</given-names></name>
<name><surname>Dougant</surname><given-names>G.</given-names></name>
<name><surname>Liew</surname><given-names>F.Y.</given-names></name>
</person-group><article-title>Protection against <italic toggle="yes">Leishmania major</italic> Infection in Genetically Susceptible BALB/c Mice by GP63 Delivered Orally in Attenuated <italic toggle="yes">Salmonella</italic> Typhimurium (AroA-AroD-)</article-title><source>Immunology</source><year>1995</year><volume>85</volume><fpage>1</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">7635511</pub-id>
</element-citation></ref><ref id="B142-vaccines-12-01319"><label>142.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chen</surname><given-names>G.</given-names></name>
<name><surname>Dai</surname><given-names>Y.</given-names></name>
<name><surname>Chen</surname><given-names>J.</given-names></name>
<name><surname>Wang</surname><given-names>X.</given-names></name>
<name><surname>Tang</surname><given-names>B.</given-names></name>
<name><surname>Zhu</surname><given-names>Y.</given-names></name>
<name><surname>Hua</surname><given-names>Z.</given-names></name>
</person-group><article-title>Oral Delivery of the Sj23LHD-GST Antigen by <italic toggle="yes">Salmonella</italic> Typhimurium Type III Secretion System Protects against <italic toggle="yes">Schistosoma japonicum</italic> Infection in Mice</article-title><source>PLoS Negl. Trop. Dis.</source><year>2011</year><volume>5</volume><elocation-id>e1313</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pntd.0001313</pub-id><pub-id pub-id-type="pmid">21909450</pub-id>
</element-citation></ref><ref id="B143-vaccines-12-01319"><label>143.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lattemann</surname><given-names>C.T.</given-names></name>
<name><surname>Yan</surname><given-names>Z.-X.</given-names></name>
<name><surname>Matzen</surname><given-names>A.</given-names></name>
<name><surname>Meyer</surname><given-names>T.F.</given-names></name>
<name><surname>Apfel</surname><given-names>H.</given-names></name>
</person-group><article-title>Immunogenicity of the Extracellular Copper/Zinc Superoxide Dismutase of the Filarial Parasite <italic toggle="yes">Acanthocheilonema viteae</italic> Delivered by a Two-Phase Vaccine Strain of <italic toggle="yes">Salmonella</italic> Typhimurium</article-title><source>Parasite Immunol.</source><year>1999</year><volume>21</volume><fpage>219</fpage><lpage>224</lpage><pub-id pub-id-type="doi">10.1046/j.1365-3024.1999.00207.x</pub-id><pub-id pub-id-type="pmid">10320619</pub-id>
</element-citation></ref></ref-list></back><floats-group><fig position="float" id="vaccines-12-01319-f001"><label>Figure 1</label><caption><p>Recombinant live-attenuated <italic toggle="yes">Salmonella</italic> vaccines (RASV): main characteristics and applications as veterinary vaccines for bacterial, viral, and parasitic antigens. AIV, avian influenza viruses; LPAI, low pathogenic avian influenza; TGEV, transmissible gastroenteritis virus; ASFV, African swine fever virus; DEV, duck enteritis virus; IBV, infectious bronchitis virus; PCV2, porcine circovirus type 2.</p></caption><graphic xlink:href="vaccines-12-01319-g001" position="float"/></fig><table-wrap position="float" id="vaccines-12-01319-t001"><object-id pub-id-type="pii">vaccines-12-01319-t001_Table 1</object-id><label>Table 1</label><caption><p>Bacterial antigens expressed in <italic toggle="yes">Salmonella</italic>.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Antigen (Organism)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">Salmonella</italic><break/>Strain or Plasmid</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Attenuation</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Route/Dose<break/>(CFU)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Model</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Immunity</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Reference</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SspH2, LipL32 (<italic toggle="yes">Leptospira</italic> spp.)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">S.</italic> Typhimurium SL3261</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x00394;<italic toggle="yes">aroA</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">O/1 &#x000d7; 10<sup>7</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Rat</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HI, MI, CI</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B55-vaccines-12-01319" ref-type="bibr">55</xref>]</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">NrdF (<italic toggle="yes">M. hyopneumoniae</italic>)</td><td align="center" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">S.</italic> Typhimurium SL3261</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x00394;<italic toggle="yes">aroA</italic></td><td align="center" valign="middle" rowspan="1" colspan="1">O/10<sup>9</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">Mice</td><td align="center" valign="middle" rowspan="1" colspan="1">HI, MI</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B78-vaccines-12-01319" ref-type="bibr">78</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">S.</italic> Typhimurium SL3261</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x00394;<italic toggle="yes">aroA</italic></td><td align="center" valign="middle" rowspan="1" colspan="1">O/1 &#x000d7; 10<sup>9</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">Swine</td><td align="center" valign="middle" rowspan="1" colspan="1">HI, MI, CI</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B79-vaccines-12-01319" ref-type="bibr">79</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">S.</italic> Typhimurium CS332 </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x00394;<italic toggle="yes">aroA</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">O/2 &#x000d7; 10<sup>8</sup>; 2nd dose 3 &#x000d7; 10<sup>8</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mice</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HI, MI, CI</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B80-vaccines-12-01319" ref-type="bibr">80</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">P97R1 (<italic toggle="yes">M. hyopneumoniae</italic>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">S.</italic> Typhimurium CS332 </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x00394;<italic toggle="yes">aroA</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">O/2 &#x000d7; 10<sup>8</sup>; 2nd dose 3 &#x000d7; 10<sup>8</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mice</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HI, MI, CI</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B81-vaccines-12-01319" ref-type="bibr">81</xref>]</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-top:solid thin" colspan="1">K88ab (<italic toggle="yes">Escherichia coli</italic>)</td><td align="center" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">S.</italic> Typhimurium G30/pFM205</td><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">galE</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">O, IP/1 &#x000d7; 10<sup>8</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">Mice</td><td align="center" valign="middle" rowspan="1" colspan="1">HI</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B82-vaccines-12-01319" ref-type="bibr">82</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">S.</italic> Typhimurium</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x00394;<italic toggle="yes">lon</italic> &#x00394;<italic toggle="yes">cpxR</italic> &#x00394;<italic toggle="yes">asd</italic></td><td align="center" valign="middle" rowspan="1" colspan="1">O/1 &#x000d7; 10<sup>8</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">Mice</td><td align="center" valign="middle" rowspan="1" colspan="1">HI, MI</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B65-vaccines-12-01319" ref-type="bibr">65</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">S.</italic> Typhimurium</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x00394;<italic toggle="yes">lon</italic> &#x00394;<italic toggle="yes">cpxR</italic> &#x00394;<italic toggle="yes">asd</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">O/2 &#x000d7; 10<sup>10</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pregnant sows and piglets</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HI, MI</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B64-vaccines-12-01319" ref-type="bibr">64</xref>]</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-top:solid thin" colspan="1">K88ab, K88ac, K99, FasA, F41 (<italic toggle="yes">E. coli</italic>)</td><td align="center" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">S.</italic> ghost-controlled expression of &#x003c6;X174 lysis gene E</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">O/primed and boosted 2 &#x000d7; 10<sup>9</sup>, 2 &#x000d7; 10<sup>10</sup>, and 2 &#x000d7; 10<sup>11</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">Pregnant sows and piglets</td><td align="center" valign="middle" rowspan="1" colspan="1">HI, MI</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B61-vaccines-12-01319" ref-type="bibr">61</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">S.</italic> Typhimurium JOL912</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x00394;<italic toggle="yes">lon</italic>, &#x00394;<italic toggle="yes">cpxR</italic>, &#x00394;<italic toggle="yes">asd</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IM/1 &#x000d7; 10<sup>8</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mice</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HI, CI, MI</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B83-vaccines-12-01319" ref-type="bibr">83</xref>]</td></tr><tr><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Stx2eB, FedF, FedA F18+ Shiga toxin (<italic toggle="yes">E. coli</italic>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">S.</italic> Typhimurium JOL1311 and JOL912 </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x00394;<italic toggle="yes">asd</italic>, &#x00394;<italic toggle="yes">lon</italic>, &#x00394;<italic toggle="yes">cpxR</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IM/9 &#x000d7; 10<sup>7</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mice</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HI, CI, MI</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B84-vaccines-12-01319" ref-type="bibr">84</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">fliC F18+ Shiga toxin (<italic toggle="yes">E. coli</italic>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">S.</italic> Typhimurium JOL1454,<break/>JOL1460, JOL1464</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x00394;<italic toggle="yes">lon</italic>, &#x00394;<italic toggle="yes">cpxR</italic>, &#x00394;<italic toggle="yes">asd</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SC/3 &#x000d7; 10<sup>7</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mice</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HI, CI, MI</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B27-vaccines-12-01319" ref-type="bibr">27</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">APEC papA, papG, iutA, and clpG (<italic toggle="yes">E. coli</italic>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">S.</italic> Typhimurium JOL912</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x00394;<italic toggle="yes">lon</italic>, &#x00394;<italic toggle="yes">cpxR</italic>, &#x00394;<italic toggle="yes">asdA16</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">O/1 &#x000d7; 10<sup>7</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Chicken</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HI, CI, MI</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B85-vaccines-12-01319" ref-type="bibr">85</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">APEC papA, papG, iutA, and clpG (<italic toggle="yes">E. coli</italic>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">S.</italic> Typhimurium JOL912</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x00394;<italic toggle="yes">lon</italic>, &#x00394;<italic toggle="yes">cpxR</italic>, &#x00394;<italic toggle="yes">asdA16</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">O/1 x 10<sup>7</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Chicken</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HI, CI, MI</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B86-vaccines-12-01319" ref-type="bibr">86</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">APEC O-antigen (<italic toggle="yes">E. coli</italic>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">S.</italic> Typhimurium S100</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x00394;<italic toggle="yes">asd</italic>, &#x00394;<italic toggle="yes">crp</italic>, &#x00394;<italic toggle="yes">cya</italic>, &#x00394;<italic toggle="yes">rfbP</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">O/&#x000d7; 10<sup>9</sup>, IM/5.0 &#x000d7; 10<sup>7</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Chicken</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HI, MI</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B87-vaccines-12-01319" ref-type="bibr">87</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">APEC PapA, CTB and LTB (<italic toggle="yes">E. coli</italic>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">S.</italic> Typhimurium <italic toggle="yes">&#x003c7;</italic>8501</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">hisG</italic>, &#x00394;<italic toggle="yes">crp-28</italic>, &#x00394;<italic toggle="yes">asdA16</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">O/2 &#x000d7; 10<sup>9</sup>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mice</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HI, MI</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B88-vaccines-12-01319" ref-type="bibr">88</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">APEC (<italic toggle="yes">E. coli</italic>) </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">S.</italic> Typhimurium <italic toggle="yes">&#x003c7;</italic>8025</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x00394;<italic toggle="yes">asd</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">O/1 &#x000d7; 10<sup>8</sup>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Chicken</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MI</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B89-vaccines-12-01319" ref-type="bibr">89</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">tHP (<italic toggle="yes">Clostridium perfringens</italic>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">S.</italic> Typhimurium</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x00394;<italic toggle="yes">asd</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">O/1 &#x000d7; 10<sup>9</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Chicken</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Intestinal colonization, BSG</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B66-vaccines-12-01319" ref-type="bibr">66</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">tHP (<italic toggle="yes">C. perfringens</italic>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">S.</italic> Typhimurium <italic toggle="yes">&#x003c7;</italic>9352</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x00394;<italic toggle="yes">asd</italic>, <italic toggle="yes">lacI</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">O/1.2 &#x000d7; 10<sup>9</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Chicken</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MI</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B90-vaccines-12-01319" ref-type="bibr">90</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x003b1;-toxin, NetB toxin, Fba (<italic toggle="yes">C. perfringens</italic>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">S.</italic> Typhimurium <italic toggle="yes">&#x003c7;</italic>11802</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x00394;<italic toggle="yes">asd</italic>, <italic toggle="yes">lacI</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">O/1 &#x000d7; 10<sup>8</sup> or 1 &#x000d7; 10<sup>9</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Chicken</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CI, MI</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B91-vaccines-12-01319" ref-type="bibr">91</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PLcC, GST-NetB (<italic toggle="yes">C. perfringens</italic>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">Salmonella</italic> vaccine <italic toggle="yes">(PIESV) &#x003c7;</italic>11802 and <italic toggle="yes">&#x003c7;</italic>12341</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">asdA</italic>, <italic toggle="yes">murA</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">O/~5 &#x000d7; 10<sup>8</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Chicken</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NE Intestinal Lesion Scoring</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B33-vaccines-12-01319" ref-type="bibr">33</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">O antigen (<italic toggle="yes">Burkholderia mallei</italic>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">S.</italic> Typhimurium SL326</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x00394;<italic toggle="yes">aroA</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IN/1 &#x000d7; 10<sup>7</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mice</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HI, MI</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B68-vaccines-12-01319" ref-type="bibr">68</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">M protein (<italic toggle="yes">Streptococcus pyogenes</italic>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">S.</italic> Typhimurium <italic toggle="yes">LB5000</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">-</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SC/Rabbit: 10<sup>8</sup> heat-killed bacteria or purified flagella; IP/Mice: 1 &#x000d7; 10<sup>6</sup> to 2 &#x000d7; 10<sup>6</sup> live vaccine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mice and Rabbit</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HI</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B92-vaccines-12-01319" ref-type="bibr">92</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">optA, optB, LfliC, Lhly (<italic toggle="yes">Lawsonia intracellularis</italic>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">S.</italic> Typhimurium JOL912</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x00394;<italic toggle="yes">asd</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">O/1 &#x000d7; 10<sup>7</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mice</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HI, MI</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B93-vaccines-12-01319" ref-type="bibr">93</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sip (<italic toggle="yes">Streptococcus agalactiae</italic>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">S.</italic> Typhimurium SL7207</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x00394;<italic toggle="yes">aroA</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IG/10<sup>7</sup>, 10<sup>8</sup> and 10<sup>9</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Fish</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HI</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B32-vaccines-12-01319" ref-type="bibr">32</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">F1, I2 (<italic toggle="yes">Pseudomonas aeruginosa</italic>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">S.</italic> Typhimurium LH430</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">phoP/phoQ</italic>,&#x00394;<italic toggle="yes">asd</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">O and SC/2.0&#x02009;&#x000d7;&#x02009;10<sup>8</sup> to 2.0 &#x000d7; 10<sup>10</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mice</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HI, CI, MI</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B75-vaccines-12-01319" ref-type="bibr">75</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CP39, FimA, PtfA, ToxA (<italic toggle="yes">Pasteurella multocida</italic>) F1P2 (<italic toggle="yes">Bordetella bronchiseptica</italic>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">S.</italic> Typhimurium JOL912</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x00394;<italic toggle="yes">lon</italic>, &#x00394;<italic toggle="yes">cpxR</italic>, &#x00394;<italic toggle="yes">asd</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IN/1 &#x000d7; 10<sup>5</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mice</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HI, MI</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B69-vaccines-12-01319" ref-type="bibr">69</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CjaA (<italic toggle="yes">Campylobacter jejuni</italic>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">S.</italic> Typhimurium LB5010</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x00394;<italic toggle="yes">aroA</italic>, <italic toggle="yes">fliM</italic>, <italic toggle="yes">spaS</italic>, <italic toggle="yes">ssaU</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">O/1 &#x000d7; 10<sup>8</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Chicken</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HI, MI</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B94-vaccines-12-01319" ref-type="bibr">94</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CjaA (<italic toggle="yes">C. jejuni</italic>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">S.</italic> Typhimurium <italic toggle="yes">&#x003c7;</italic>9718</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x00394;<italic toggle="yes">asd</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">O/1 &#x000d7; 10<sup>8</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Chicken</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MI</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B95-vaccines-12-01319" ref-type="bibr">95</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BCSP31 (<italic toggle="yes">Brucella abortus</italic>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">S.</italic> Typhimurium chi 4064</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x00394;<italic toggle="yes">cya</italic>, &#x00394;<italic toggle="yes">crp</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">O/2 &#x000d7; 10<sup>8</sup> to 4 &#x000d7; 10<sup>8</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mice</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HI, MI, Blatogenisis </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B96-vaccines-12-01319" ref-type="bibr">96</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BCSP31 (<italic toggle="yes">B. abortus</italic>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">S.</italic> Typhimurium chi 4064</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x00394;<italic toggle="yes">cya</italic>, &#x00394;<italic toggle="yes">crp</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">O/1 &#x000d7; 10<sup>10</sup> to 2 &#x000d7; 10<sup>10</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Crossbred swine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HI, MI, Blatogenisis </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B97-vaccines-12-01319" ref-type="bibr">97</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">L7/L12, BLS (<italic toggle="yes">B. abortus</italic>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">S.</italic> Typhimurium X4072</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x00394;<italic toggle="yes">asd</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">O/1 &#x000d7; 10<sup>9</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mice</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HI, CI, MI</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B98-vaccines-12-01319" ref-type="bibr">98</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BCSP31, Omp3b, SOD (<italic toggle="yes">B. abortus</italic>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">S.</italic> Typhimurium JOL912</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x00394;<italic toggle="yes">lon</italic>, &#x00394;<italic toggle="yes">cpxR</italic>, &#x00394;<italic toggle="yes">asd</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IP/1.2 &#x000d7; 10<sup>6</sup>; O/1.2 &#x000d7; 10<sup>9</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mice</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HI, CI</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B29-vaccines-12-01319" ref-type="bibr">29</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SOD, BLS, PrpA, Omp19 (<italic toggle="yes">B. abortus</italic>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">S.</italic> Typhimurium JOL912 and JOL1800</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x00394;<italic toggle="yes">lon</italic>, &#x00394;<italic toggle="yes">cpxR</italic>, &#x00394;<italic toggle="yes">asd</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">O and IP/2 &#x000d7; 10<sup>7</sup>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mice</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CI, MI</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B77-vaccines-12-01319" ref-type="bibr">77</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BCSP31, Omp3b, SOD (<italic toggle="yes">B. abortus</italic>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">S.</italic> Typhimurium JOL911 and JOL912</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x00394;<italic toggle="yes">lon</italic>, &#x00394;<italic toggle="yes">cpxR</italic>, &#x00394;<italic toggle="yes">asd</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IP/1.2 &#x000d7; 10<sup>4</sup>, 1.2 &#x000d7; 10<sup>5</sup> and 1.2 &#x000d7; 10<sup>6</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mice</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HI, CI</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B99-vaccines-12-01319" ref-type="bibr">99</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BCSP31, Omp3b, and SOD (<italic toggle="yes">B. abortus</italic>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">S.</italic> Typhimurium pMMP65</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x00394;<italic toggle="yes">lon</italic>, &#x00394;<italic toggle="yes">cpxR</italic>, &#x00394;<italic toggle="yes">asd</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SC/3 &#x000d7; 10<sup>9</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Dog</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HI, CI</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B100-vaccines-12-01319" ref-type="bibr">100</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PrpA (<italic toggle="yes">B. abortus</italic>)<break/></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">S.</italic> Typhimurium JOL1818 and JOL1881</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x00394;<italic toggle="yes">lon</italic>, &#x00394;<italic toggle="yes">cpxR</italic>, &#x00394;<italic toggle="yes">asd</italic>, &#x00394;<italic toggle="yes">rfaL</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IP/1 &#x000d7; 10<sup>7</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mice</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HI, CI</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B77-vaccines-12-01319" ref-type="bibr">77</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SOD, BLS, PrpA, Omp19 (<italic toggle="yes">B. abortus</italic>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">S.</italic> Typhimurium JOL1800</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02206;<italic toggle="yes">lon</italic>, &#x02206;<italic toggle="yes">cpxR</italic>, &#x02206;<italic toggle="yes">asd</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SC/5 &#x000d7; 10<sup>9</sup> and 5 &#x000d7; 10<sup>10</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Goat</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HI, CI</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B24-vaccines-12-01319" ref-type="bibr">24</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BCSP31, Omp3b, and SOD (<italic toggle="yes">B. abortus</italic>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">S.</italic> Typhimurium JOL912</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x00394;<italic toggle="yes">lon</italic>, &#x00394;<italic toggle="yes">cpxR</italic>, &#x00394;<italic toggle="yes">asd</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SC/3 &#x000d7; 10<sup>9</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Goat</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HI, CI</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B101-vaccines-12-01319" ref-type="bibr">101</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">L7/L12 (<italic toggle="yes">B. abortus</italic>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">S.</italic> Typhimurium JOL1800</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02206;<italic toggle="yes">lon</italic>, &#x02206;<italic toggle="yes">cpxR</italic>, &#x02206;<italic toggle="yes">asd</italic>, &#x02206;<italic toggle="yes">rfaL</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IM/10<sup>7</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mice</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HI, MI</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B102-vaccines-12-01319" ref-type="bibr">102</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BCSP31<break/>(<italic toggle="yes">B. abortus</italic>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">S.</italic> Choleraesuis chi 3781</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02206;<italic toggle="yes">cpxR</italic>, &#x02206;<italic toggle="yes">cya</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">O/Mice: 4 &#x000d7;10<sup>10</sup>; Swine: 4 &#x000d7; 10<sup>8</sup> to 6 &#x000d7; 10<sup>8</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mice and crossbred swine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HI, MI,</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B103-vaccines-12-01319" ref-type="bibr">103</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6-PGD (<italic toggle="yes">Streptococcus sui</italic>s)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">S.</italic> Choleraesuis rSC0011</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x00394;<italic toggle="yes">asd</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">O/1 &#x000b1; 0.3 &#x000d7; 10<sup>9</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mice</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HI, MI</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B104-vaccines-12-01319" ref-type="bibr">104</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Serotypes 2 and 7 (<italic toggle="yes">S. sui</italic>s)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">S.</italic> Choleraesuis rSC0016 </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x00394;<italic toggle="yes">sopB</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">O/Suis: 1 &#x000b1; 0.3 &#x000d7; 10<sup>9</sup>; Mice: 1 &#x000b1; 0.3 &#x000d7; 10<sup>9</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mice and Swine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HI, MI</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B28-vaccines-12-01319" ref-type="bibr">28</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SaoA (<italic toggle="yes">S. sui</italic>s)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">S.</italic> Choleraesuis<break/>rSC0012</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x00394;<italic toggle="yes">fur</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">O/1 &#x000b1; 0.2 &#x000d7; 10<sup>9</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mice</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HI, MI, CI</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B105-vaccines-12-01319" ref-type="bibr">105</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Serotypes 1/2, 2, 3, 7, 9 (<italic toggle="yes">S. sui</italic>s)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">S.</italic> Choleraesuis rSC0016</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x00394;<italic toggle="yes">sopB</italic>, &#x00394;<italic toggle="yes">asd, lacl</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">O/1 &#x000b1; 0.2 &#x000d7; 10<sup>9</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mice</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HI, CI</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B106-vaccines-12-01319" ref-type="bibr">106</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">P42, P97 (<italic toggle="yes">M. hyopneumoniae</italic>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">S.</italic> Choleraesuis rSC0016</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x00394;<italic toggle="yes">asd</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">O/10<sup>9</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mice</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HI, MI, CI</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B107-vaccines-12-01319" ref-type="bibr">107</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">F18+ Shiga toxin (<italic toggle="yes">E. coli</italic>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">S.</italic> Choleraesuis C520</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">crp,</italic> &#x00394;<italic toggle="yes">asd</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">O/2 &#x000d7; 10<sup>9</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Swine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HI, MI, CI</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B67-vaccines-12-01319" ref-type="bibr">67</xref>]</td></tr></tbody></table><table-wrap-foot><fn><p>IG, intragastric; IM, intramuscular; IN, intranasal; IP, intraperitoneal; O, oral; SC, subcutaneous; CFU, colony-forming unit; HI, humoral immunity; CI, cellular immunity; MI, mucosal immunity.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="vaccines-12-01319-t002"><object-id pub-id-type="pii">vaccines-12-01319-t002_Table 2</object-id><label>Table 2</label><caption><p>Viral antigens expressed in <italic toggle="yes">Salmonella</italic>.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Antigen (Organism)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">Salmonella</italic><break/>Strain or Plasmid</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Attenuation</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Route/Dose<break/>(CFU)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Model</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Immunity</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Reference</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HA (AIV H5N1)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">S.</italic> Typhimurium BRD509 </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x00394;<italic toggle="yes">aroA</italic>, &#x00394;<italic toggle="yes">aroD</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">O/10<sup>9</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Chicken</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hemagglutination inhibition</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B108-vaccines-12-01319" ref-type="bibr">108</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">chIFN-a, chIL-18 (AIV H9N2)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">S.</italic> Typhimurium <italic toggle="yes">&#x003c7;</italic>8501</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">hisG</italic>, &#x00394;<italic toggle="yes">crp-28</italic>, &#x00394;<italic toggle="yes">asdA16</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">O/10<sup>9</sup> and 10<sup>11</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Chicken</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CI, hemagglutination inhibition, PCR</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B109-vaccines-12-01319" ref-type="bibr">109</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HA, NA, NP<break/>(AIV H5N1)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">S.</italic> Typhimurium SV4089</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">Dam</italic>, &#x00394;<italic toggle="yes">PhoP</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">O/10<sup>9</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Chicken</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PCR, FISH, and culturing on XLT4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B110-vaccines-12-01319" ref-type="bibr">110</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HA (AIV H5N1)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">S.</italic> Typhimurium SV4089</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">Dam</italic>, &#x00394;<italic toggle="yes">PhoP</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">O, IM/10<sup>9</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Chicken</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CI, hemagglutination inhibition, PCR</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B111-vaccines-12-01319" ref-type="bibr">111</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HA (AIV H9N2)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">S. Typhimurium</italic> JOL912, JOL1800</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x00394;<italic toggle="yes">lon</italic>, &#x00394;<italic toggle="yes">cpxR</italic>, &#x00394;<italic toggle="yes">asd</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">O/10<sup>8</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Chicken</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HI, hemagglutination inhibition</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B30-vaccines-12-01319" ref-type="bibr">30</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HA (AIV H7N1)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">S.</italic> Typhimurium JOL1863</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x00394;<italic toggle="yes">lon</italic>, &#x00394;<italic toggle="yes">cpxR</italic>, &#x00394;<italic toggle="yes">asd</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">O, IN, IM/10<sup>9</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Chicken</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HI, MI, Hemagglutination inhibition</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B70-vaccines-12-01319" ref-type="bibr">70</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HA, M2, NA (LPAI H7N9)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">S.</italic> Typhimurium JOL1800</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">O antigen deficient</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">O/10<sup>9</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Chicken</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HI, CI, MI</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B112-vaccines-12-01319" ref-type="bibr">112</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">H9N2 haemagglutinin, M2 (AIV H9N2)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">S.</italic> Gallinarum JOL967</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x00394;<italic toggle="yes">lon</italic>, &#x00394;<italic toggle="yes">cpxR</italic>, &#x00394;<italic toggle="yes">asd</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">O, IM/10<sup>9</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Chicken</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HI, CI, MI</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B113-vaccines-12-01319" ref-type="bibr">113</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">swIFN-&#x003b1;, swIL-18 (TGEV)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">S.</italic> Typhimurium 8501</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">hisG</italic>, &#x00394;<italic toggle="yes">crp-28</italic>, &#x00394;<italic toggle="yes">asdA16</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">O/10<sup>11</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Swine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Gross lesion, histopathology, qRT-PCR</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B114-vaccines-12-01319" ref-type="bibr">114</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Glycoprotein B (PrV)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">S.</italic> Typhimurium SL7207 </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x00394;<italic toggle="yes">aroA</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">O/5 to 10 10<sup>7</sup>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mice</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HI, MI</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B115-vaccines-12-01319" ref-type="bibr">115</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">swIL-18, swIFN-&#x003b1; (PrV)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">S.</italic> Typhimurium <italic toggle="yes">&#x003c7;</italic>8501</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">hisG</italic>, &#x00394;<italic toggle="yes">crp-28</italic>, &#x00394;<italic toggle="yes">asdA16</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">O/10<sup>11</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Swine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HI, CI</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B116-vaccines-12-01319" ref-type="bibr">116</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">UL24 (DEV)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">S.</italic> Typhimurium SL7207</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">hisG46</italic>, <italic toggle="yes">DEL407</italic>, &#x00394;<italic toggle="yes">aroA</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">O/10<sup>11</sup>, 10<sup>10</sup> or 10<sup>9</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Duck</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HI, CI, MI</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B117-vaccines-12-01319" ref-type="bibr">117</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">tgB, UL24 (DEV)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">S.</italic> Typhimurium <italic toggle="yes">S</italic>739</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x00394;<italic toggle="yes">asd-66</italic>, &#x00394;<italic toggle="yes">crp-24</italic>, &#x00394;<italic toggle="yes">cya-25</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">O/10<sup>10</sup>; 10<sup>11</sup> or 10<sup>12</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Duck</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MI</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B118-vaccines-12-01319" ref-type="bibr">118</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CD2v/CTL/9GL, p54/p12/p72(ASFV)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">S.</italic> Typhimurium JOL912</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x00394;<italic toggle="yes">lon</italic>, &#x00394;<italic toggle="yes">cpxR</italic>, &#x00394;<italic toggle="yes">asd</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IM/10<sup>8</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Swine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HI, CI, MI</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B119-vaccines-12-01319" ref-type="bibr">119</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">S1, N (IBV)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">S.</italic> Typhimurium SL7207</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x00394;<italic toggle="yes">aroA</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">O, IN/1 &#x000d7; 10<sup>9</sup>, 5 &#x000d7; 10<sup>9</sup> or 1 &#x000d7; 10<sup>10</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Chicken</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HI, MI</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B71-vaccines-12-01319" ref-type="bibr">71</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">VP2/4/3 (IBVD)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">S.</italic> Typhimurium </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">Dam</italic>, <italic toggle="yes">Phop</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">O/10<sup>9</sup>, 10<sup>8</sup> or 10<sup>7</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Chicken</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HI</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B120-vaccines-12-01319" ref-type="bibr">120</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">prM-E (TMUV)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">S.</italic> Typhimurium <italic toggle="yes">SL7207 + adenovirus adjuvant with duck IL-2</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x00394;<italic toggle="yes">aroA</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">O, IM/10<sup>7</sup>, 10<sup>10</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Duck</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HI, CI</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B121-vaccines-12-01319" ref-type="bibr">121</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N (TGEV)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">S.</italic> Typhimurium SL7207</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x00394;<italic toggle="yes">aroA</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IG/10<sup>7</sup>, 10<sup>8</sup> or 10<sup>9</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mice</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HI, MI</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B72-vaccines-12-01319" ref-type="bibr">72</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">swIFN-&#x003b1; (TGEV)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">S.</italic> Typhimurium <italic toggle="yes">&#x003c7;</italic>8501</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">hisG</italic>, &#x00394;<italic toggle="yes">crp-28</italic>, &#x00394;<italic toggle="yes">asdA16</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">O/10<sup>9</sup> or 10<sup>11</sup>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Swine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">qRT-PCR</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B122-vaccines-12-01319" ref-type="bibr">122</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">S (TGEV, PEDV)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">S.</italic> Typhimurium SL7207</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x00394;<italic toggle="yes">aroA</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">O/1.6 &#x000d7; 10<sup>11</sup>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Swine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HI, CI, MI</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B123-vaccines-12-01319" ref-type="bibr">123</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N (TGEV)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">S.</italic> Typhimurium SL7207</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x00394;<italic toggle="yes">aroA</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">O/10<sup>12</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Swine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HI, CI, MI</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B124-vaccines-12-01319" ref-type="bibr">124</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">M (TGEV)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">S.</italic> Typhimurium <italic toggle="yes">m</italic> SL7207</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x00394;<italic toggle="yes">aroA</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IG/10<sup>9</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mice</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HI, CI, MI</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B125-vaccines-12-01319" ref-type="bibr">125</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Glycoprotein 5, TLR-5 (PRRSV)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">S.</italic> Typhimurium SL7207, FljB</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IP/50 &#x003bc;g</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mice</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HI</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B126-vaccines-12-01319" ref-type="bibr">126</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">VP1 (FMDV)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">S.</italic> Typhimurium KST0666</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">Irradiated</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IP/1 &#x000d7; 10<sup>4</sup> to 3 &#x000d7; 10<sup>8</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mice</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HI, CI, MI, VN</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B127-vaccines-12-01319" ref-type="bibr">127</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">p27 capsid (SIV)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">S.</italic> Typhimurium PV4570</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x00394;<italic toggle="yes">aroA</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IM, IG/10<sup>10</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Rhesus macaques</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HI, CI, MI</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B128-vaccines-12-01319" ref-type="bibr">128</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Glycoprotein (RV), LTB (<italic toggle="yes">E. coli</italic>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">S.</italic> Typhimurium LH430</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">phoP</italic>, <italic toggle="yes">phoQ</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">O/5 &#x000d7; 10<sup>10</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mice</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HI, CI</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B129-vaccines-12-01319" ref-type="bibr">129</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">siRNA expressing 3D, VP4 and 2B (FMDV)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">S.</italic> Choleraesuis<break/>C500</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IM/Guinea pigs: 1.0 &#x000d7; 10<sup>9</sup>; Swines: 5 &#x000d7; 10<sup>9</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Guinea Pigs, Swine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SPB-ELISA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B130-vaccines-12-01319" ref-type="bibr">130</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cap (PCV2)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">S.</italic> Choleraesuis<break/>rSC0016</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x00394;<italic toggle="yes">sopB</italic>, &#x00394;<italic toggle="yes">asdA</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">O/10<sup>9</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mice</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HI, CI, MI, qPCR, VN</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B28-vaccines-12-01319" ref-type="bibr">28</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HN (NDV)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">S.</italic> Pullorum C79-13</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x00394;<italic toggle="yes">crp</italic>, &#x00394;<italic toggle="yes">asd</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">O/10<sup>9</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Chicken</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HI, MI, hemagglutination inhibition</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B131-vaccines-12-01319" ref-type="bibr">131</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">S1 (IBV)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">S.</italic> Gallinarum JOL2068, JOL2077</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x00394;<italic toggle="yes">lon</italic>, &#x00394;<italic toggle="yes">cpxR</italic>, &#x00394;<italic toggle="yes">asd</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">O/10<sup>9</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Chicken</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HI, MI</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B23-vaccines-12-01319" ref-type="bibr">23</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">M2e, CD154 (AIV H5N1)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">Salmonella enteritidis</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x00394;<italic toggle="yes">aroA</italic>, &#x00394;<italic toggle="yes">htrA</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">O/10<sup>6</sup> to 10<sup>8</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Chicken</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MI, hemagglutination inhibition</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B132-vaccines-12-01319" ref-type="bibr">132</xref>]</td></tr></tbody></table><table-wrap-foot><fn><p>IG, intragastric; IM, intramuscular; IN, intranasal; IP, intraperitoneal; O, oral; CFU, colony-forming unit; HI, humoral immunity; CI, cellular immunity; MI, mucosal immunity; VN, virus neutralization assays; AIV, avian influenza viruses; ASFV, African swine fever virus; DEV, duck enteritis virus; FMDV, foot-and-mouth disease virus; IBV, infectious bronchitis virus; IBVD, infectious bursal disease virus; LTB, heat-labile enterotoxin B; NDV, Newcastle disease virus; PCV2, porcine circovirus type 2; PRRSV, porcine reproductive and respiratory syndrome; PrV, pseudorabies virus; p3D-NT56, siRNA directed against the polymerase gene 3D of FMDV; SIV, simian immunodeficiency virus; TGEV, porcine transmissible gastroenteritis virus; TLR-5, toll-like receptor 5 TMUV, Tembusu virus; VLP, virus-like particles.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="vaccines-12-01319-t003"><object-id pub-id-type="pii">vaccines-12-01319-t003_Table 3</object-id><label>Table 3</label><caption><p>Parasitic antigens expressed in <italic toggle="yes">Salmonella</italic>.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Antigen (Organism)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">Salmonella</italic><break/>Strain or Plasmid</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Attenuation</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Route/Dose<break/>(CFU)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Model</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Immunity</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Reference</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ts87 (<italic toggle="yes">Trichinella spiralis</italic>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">S.</italic> Typhimurium SL7207</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x00394;<italic toggle="yes">aroA</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">O/10<sup>8</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mice</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HI, CI, MI</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B135-vaccines-12-01319" ref-type="bibr">135</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ag30 (<italic toggle="yes">T. spiralis</italic>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">S.</italic> Typhimurium SL3261</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x00394;<italic toggle="yes">aroA</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IN/10<sup>9</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mice</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HI, CI, MI</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B31-vaccines-12-01319" ref-type="bibr">31</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TsNd (<italic toggle="yes">T. spiralis</italic>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">S.</italic> Typhimurium SL1344</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x00394;<italic toggle="yes">cya</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">O/10<sup>8</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mice</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HI, CI, MI</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B136-vaccines-12-01319" ref-type="bibr">136</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DNase II (<italic toggle="yes">T. spiralis</italic>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">S.</italic> Typhimurium SL1344</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x00394;<italic toggle="yes">cya</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">O/10<sup>8</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mice</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HI, CI, MI</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B137-vaccines-12-01319" ref-type="bibr">137</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">rTsSP1.2 (<italic toggle="yes">T. spiralis</italic>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">S.</italic> Typhimurium SL1344</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x00394;<italic toggle="yes">cya</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">O/10<sup>8</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mice</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HI, CI, MI</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B138-vaccines-12-01319" ref-type="bibr">138</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">FABP (<italic toggle="yes">Echinococcus granulosus</italic>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">S.</italic> Typhimurium SL3261</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x00394;<italic toggle="yes">aroA</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IV/10<sup>6</sup>, O/4 &#x000d7; 10<sup>9</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mice</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HI, CI, MI</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B139-vaccines-12-01319" ref-type="bibr">139</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">FABP (<italic toggle="yes">E. granulosus</italic>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">S.</italic> Typhimurium LVR01</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x00394;<italic toggle="yes">aroC</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">O/5 &#x000d7; 10<sup>10</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Dog</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HI, CI, MI</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B48-vaccines-12-01319" ref-type="bibr">48</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">EmGAPDH (<italic toggle="yes">Echinococcus multilocularis</italic>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">S.</italic> Typhimurium</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">O/2 &#x000d7; 10<sup>10</sup> or IP: 5 &#x000d7; 10<sup>5</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mice</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Western blotting</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B140-vaccines-12-01319" ref-type="bibr">140</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">gp63 (<italic toggle="yes">Leishmania major</italic>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">S.</italic> Typhimurium BRD509</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x00394;<italic toggle="yes">aroA</italic>, &#x00394;<italic toggle="yes">aroD</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">O/1 &#x000d7; 10<sup>10</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mice</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HI, CI</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B141-vaccines-12-01319" ref-type="bibr">141</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SAG, SAG2 (<italic toggle="yes">Toxoplasma gondii</italic>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">S.</italic> Typhimurium BRD509</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x00394;<italic toggle="yes">aroA</italic>, &#x00394;<italic toggle="yes">aroD</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IG/10<sup>9</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mice</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HI, CI</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B73-vaccines-12-01319" ref-type="bibr">73</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Tachyzoite and bradyzoite proteins (<italic toggle="yes">T. gondii</italic>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">S.</italic> Typhimurium BRD509</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x00394;<italic toggle="yes">aroA</italic>, &#x00394;<italic toggle="yes">aroD</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">O, IN, IM/1 to 5 &#x000d7; 10<sup>9</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mice</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HI, CI, MI</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B22-vaccines-12-01319" ref-type="bibr">22</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cp23, Cp40<break/>(<italic toggle="yes">Cryptosporidium parvum</italic>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">S.</italic> Typhimurium SL3261 and LB5010</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x00394;<italic toggle="yes">aroA</italic>, <italic toggle="yes">galE</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IG/5 &#x000d7; 10<sup>9</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mice</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HI, MI</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B74-vaccines-12-01319" ref-type="bibr">74</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sj23LHD-GST (<italic toggle="yes">Schistosoma japonicum</italic>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">S.</italic> Typhimurium VNP20009</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">purI</italic>, <italic toggle="yes">msbB</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">O/10<sup>9</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mice</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HI, CI</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B142-vaccines-12-01319" ref-type="bibr">142</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">EC-SOD (<italic toggle="yes">Acanthocheilonema viteae</italic>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">S.</italic> Typhimurium SL3261</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x00394;<italic toggle="yes">aroA</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">O/5 &#x000d7; 10<sup>8</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Jird</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HI</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B143-vaccines-12-01319" ref-type="bibr">143</xref>]</td></tr></tbody></table><table-wrap-foot><fn><p>IG, intragastric; IM, intramuscular; IN, intranasal; IP, intraperitoneal; IV, intravenous; O, oral; CFU, colony-forming unit; HI, humoral immunity; CI, cellular immunity; MI, mucosal; EmGAPDH, immunityglyceraldehyde-3-phosphate dehydrogenase.</p></fn></table-wrap-foot></table-wrap></floats-group></article>